"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_SANGERARDO",2000,82,7.58536585365854,2.84146341463415,0.634146341463415,0.353658536585366,0.682926829268293,1.2258064516129,1.23809523809524,1.07407407407407,1.19148936170213,0.231707317073171,4,36,18,6,19,0.44,0.22,0.07,0.23,34.21,0.754612383597203,NA,0.219512195121951,0.658536585365854,0.434,0.333,0.246,0.321,"PAOLO LISSONI;L VIGORÈ;LUCA FUMAGALLI;C UDERZO;ETTORE BEGHI;ANTONIO PESENTI;FRANCO ROVELLI;R. FERRANTE;MARIO MANDALÁ;LUCA FUMAGALLI;F BRIVIO;ROBERTO FUMAGALLI;FABIO MALUGANI;C. MANGIONI;PATRIZIA VERGANI;GIUSEPPE CITERIO;PIETRO PIOLTELLI;JOHN C. PEZZULLO;ELOISA MARIANI;COSTANTINO MANGIONI","11;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","PAOLO LISSONI;PAOLO LISSONI;GUIDO GRASSI;ANTONIO PESENTI;ROBERTO SEGA;MARIO COLOMBO;MASSIMO BORELLI;ETTORE BEGHI;DEBORAH M. ANCONA;DANIEL CASSUTO;G EMANUELLI;GIUSEPPE MANCIA;FRANCO ROVELLI;L VIGORÈ;LUCA FUMAGALLI;C. MANGIONI;ROBERTO FUMAGALLI;GIUSEPPE CITERIO;G GRASSI;PIETRO PIOLTELLI","1.49;1.33;1.14;1.04;1;1;0.7;0.68;0.67;0.67;0.67;0.64;0.58;0.56;0.56;0.55;0.54;0.53;0.5;0.49","PAOLO LISSONI;L VIGORÈ;C UDERZO;ETTORE BEGHI;ANTONIO PESENTI;FRANCO ROVELLI;R. FERRANTE;F BRIVIO;ROBERTO FUMAGALLI;FABIO MALUGANI;C. MANGIONI;PATRIZIA VERGANI;GIUSEPPE CITERIO;PIETRO PIOLTELLI;ELOISA MARIANI;COSTANTINO MANGIONI;GABRIELE TANCINI;BENEDETTA NICOLINI;DANIELA LONGONI;TIZIANA QUIRINO","11;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2","PAOLO LISSONI;PAOLO LISSONI;GUIDO GRASSI;ANTONIO PESENTI;ROBERTO SEGA;MARIO COLOMBO;MASSIMO BORELLI;ETTORE BEGHI;DEBORAH M. ANCONA;DANIEL CASSUTO;G EMANUELLI;GIUSEPPE MANCIA;FRANCO ROVELLI;L VIGORÈ;C. MANGIONI;ROBERTO FUMAGALLI;GIUSEPPE CITERIO;PIETRO PIOLTELLI;ELOISA MARIANI;MARIO MANDAL AGRAVE","1.49;1.33;1.14;1.04;1;1;0.7;0.68;0.67;0.67;0.67;0.64;0.58;0.56;0.55;0.54;0.53;0.49;0.49;0.48","PAOLO LISSONI;COSTANTINO MANGIONI;C. MANGIONI;ANDREA GABBUTI;CANIO MARTINELLI;E. DI CINTIO;FABIO PARAZZINI;FEDERICA ALESSI;GIANCARLO GHISELLI;IVANO FAGGION;LAURA VALSECCHI;LIA TIMILLERO;LUIGI PUSTERLA;PAOLO BONFANTI;PAOLO FORTUNA;SILVIA CARRADORI;SIMONA LANDONIO;TIZIANA QUIRINO;FRANCO ROVELLI;FERNANDO BRIVIO","439;232;221;209;209;209;209;209;209;209;209;209;209;209;209;209;209;209;189;178","COSTANTINO MANGIONI;PAOLO LISSONI;GAIA KULMAN;C. MANGIONI;ANNA FAGOTTI;CINZIA LAVARINO;FRANCESCA VECCHIONE;FRANCO ZUNINO;GABRIELLA FERRANDINA;GIANLUIGI BRESCIANI;GIORGIO BOLIS;GIOVANNA SCARFONE;GIOVANNI SCAMBIA;LAURA GATTI;MARCO A. PIEROTTI;MARIA OGGIONNI;PAOLA PEREGO;SILVANA PILOTTI;VALERIA LUCCHINI;DOMENICO VITOBELLO","232;220;163;160;146;146;146;146;146;146;146;146;146;146;146;146;146;146;146;144","PAOLO LISSONI;C UDERZO;COSTANTINO MANGIONI;ANTONIO PESENTI;ETTORE BEGHI;F BRIVIO;GIUSEPPE CITERIO;GIUSEPPE MANCIA;ANNA CAPPELLINI;C. MANGIONI;DANIEL CASSUTO;DEBORAH M. ANCONA;FABIO MALUGANI;FRANCO ROVELLI;G EMANUELLI;G. BOGLIUN;GABRIELE TANCINI;GUIDO CAVALETTI;GUIDO GRASSI;L VIGORÈ","9;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;SOCIOLOGY;ECONOMICS;HISTORY;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE","78;21;11;5;4;3;3;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;ANESTHESIA;ENDOCRINOLOGY;ONCOLOGY;PATHOLOGY;PSYCHIATRY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;OPTICS;INTENSIVE CARE MEDICINE;PEDIATRICS;CARDIOLOGY;PHARMACOLOGY;CANCER RESEARCH;GYNECOLOGY;NURSING;OBSTETRICS","62;32;18;17;11;10;10;9;9;9;8;7;7;6;6;5;5;4;4;4;4","CANCER;GENE;IMMUNE SYSTEM;BLOOD PRESSURE;DISEASE;POPULATION;CHEMOTHERAPY;PREGNANCY;INCIDENCE (GEOMETRY);LEUKEMIA;MELATONIN;ADVERSE EFFECT;ANTIGEN;CIRRHOSIS;IMMUNOSUPPRESSION;LYMPHOCYTE;PLATELET;PROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;ANTIBODY;BONE MARROW;CARCINOMA;HORMONE;LYMPHOMA;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;REGIMEN;RESPIRATORY DISTRESS;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION","19;10;8;7;7;7;6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;DENDRITIC CELL;GESTATION;HEART RATE;IMMUNOTHERAPY;BONE MARROW TRANSPLANTATION;CHROMOSOME;GESTATIONAL AGE;LYMPHOBLASTIC LEUKEMIA;PINEAL GLAND;ACUTE RESPIRATORY DISTRESS;ANTIHYPERTENSIVE DRUG;CISPLATIN;COLORECTAL CANCER;CYTOTOXIC T CELL;ENDOCRINE SYSTEM;FETUS;GENOTYPE;HEPATITIS C VIRUS;IMMUNOGENICITY;INTERLEUKIN-3 RECEPTOR;LYMPHOCYTOPENIA;MYELIN;NEURORADIOLOGY;NEUTROPENIA;OBSTETRICS AND GYNAECOLOGY;OVARIAN CANCER;PACLITAXEL;PARACENTESIS;PHENOTYPE;PLACEBO;POTASSIUM TITANYL PHOSPHATE;PROGRESSIVE DISEASE;PROLACTIN;PROSTATE;PROSTATE CANCER;ULCERATIVE COLITIS;VIRAL DISEASE;VIRAL LOAD","5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","METASTATIC BREAST CANCER;ANEUPLOIDY;ANTIRETROVIRAL THERAPY;CD11C;OVARIAN CARCINOMA;SIDA;ANGIOTENSIN RECEPTOR BLOCKERS;ANTENATAL STEROID;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ANTIGEN-PRESENTING CELL;APGAR SCORE;ASPARAGINASE;AUTONOMIC NERVOUS SYSTEM;BAROREFLEX;BONE MARROW TRANSPLANT;BREAKPOINT;BROMOCRIPTINE;CANCER IMMUNOTHERAPY;CCL2;CD40;CHEMOKINE RECEPTOR;CHILDHOOD LEUKEMIA;CHORIOAMNIONITIS;CIRCULATING TUMOR CELL;COLONOSCOPY;DEFIBROTIDE;DYSKINESIA;EPITHELIAL OVARIAN CANCER;ESTROGEN RECEPTOR;FLUORESCENCE IN SITU HYBRIDIZATION;GESTATIONAL DIABETES;HAEMODYNAMIC RESPONSE;HBSAG;HEART RATE VARIABILITY;HEPACIVIRUS;HISTOCOMPATIBILITY;IFOSFAMIDE;INFLAMMATORY BOWEL DISEASES;INTERFACE (MATTER);INTERLEUKIN 12;INTRAVENTRICULAR HEMORRHAGE;MASKED HYPERTENSION;MEAN ARTERIAL PRESSURE;MICROSATELLITE;OESTROGEN RECEPTOR;PLATELETPHERESIS;PRAZOSIN;PRENATAL DIAGNOSIS;PROCTITIS;SENTINEL LYMPH NODE;SENTINEL NODE;THYMIDYLATE SYNTHASE;URAPIDIL;VINCRISTINE;WHITE COAT HYPERTENSION;X-INACTIVATION;XQ28","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;;AGED;ADOLESCENT;INTERLEUKIN-2;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASMS;SUBARACHNOID HEMORRHAGE;TREATMENT OUTCOME;DENDRITIC CELLS;HYPERTENSION;RETROSPECTIVE STUDIES;CARCINOMA;MELATONIN;OVARIAN NEOPLASMS;CHILD","57;44;38;32;32;23;20;14;13;11;11;10;10;9;9;9;8;8;8;7","IMMUNOBIOLOGY OF DENDRITIC CELLS;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPILEPSY AND SEIZURES;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;HEMATOPOIETIC STEM CELL BIOLOGY;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;LYMPHOID NEOPLASMS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;PRENATAL ANEUPLOIDY DIAGNOSIS AND SCREENING TECHNIQUES;ROLE OF CHEMOKINE RECEPTORS IN CANCER METASTASIS;SKIN SCARRING AND REMODELING MECHANISMS;;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ATOPIC DERMATITIS AND SKIN MICROBIOME","5;5;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","MELATONIN;IMMUNOSUPPRESSION;ASCITES;CANCER IMMUNOEDITING;DENDRITIC CELLS;PRENATAL DIAGNOSIS;REGIMEN;ANTIHYPERTENSIVE DRUG;ANTIRETROVIRAL THERAPY;BLOOD PRESSURE;BOLUS (DIGESTION);CANCER THERAPY;CD11C;CERVICAL CANCER;CHEMOKINE RECEPTORS;CONCOMITANT;DISCONTINUATION;EPILEPSY;FACIAL REJUVENATION;FETAL DNA ANALYSIS","5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CANCER PATIENTS;DENDRITIC CELLS;BONE MARROW;MARROW TRANSPLANTATION;CIRCULATING DENDRITIC;OVARIAN CARCINOMA;ACUTE LYMPHOBLASTIC;ACUTE RESPIRATORY;ADVANCED CANCER;ADVERSE REACTIONS;ALLERGIC NEURITIS;ARTERIAL HYPERTENSION;CELL CANCER;CIRCULATING IMMATURE;CLINICAL RESPONSE;CLINICOPATHOLOGICAL NEUROPHYSIOLOGICAL;COHORT STUDY;DIODE-PUMPED NDYAG;DISTRESS SYNDROME;EXPERIMENTAL ALLERGIC;FACIAL TELANGIECTASIAS;HIV PATIENTS;II STUDY;IMMUNOLOGICAL STUDY;LEUKEMIA RECEIVING;LYMPHOBLASTIC LEUKEMIA;MATURE DENDRITIC;METASTATIC BREAST;NDYAG LASER;NEURITIS CLINICOPATHOLOGICAL","5;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CANCER PATIENTS;RENAL FUNCTION;BLOOD PRESSURE;ADVERSE REACTIONS;OFFICE BP;PI THERAPY;SAQUINAVIR HGC;MATURE DC;VULVAR CANCER;ADVERSE EVENTS;AGE SEX;ALBUMIN INFUSION;ASCITES RELAPSED;ASCITESCIRRHOTIC PATIENTS;BILIRUBIN MGLDL;CHILD-PUGH SCORE;CIRRHOSIS PUGH;CIRRHOTIC PATIENTS;COMPLICATIONS DEVELOPEDPATIENTS;DEVELOPED RENAL;DIFFUSE HCC;FOLLOW UPTHE;GRAMSL LITER;HCC BILIRUBIN;HEPATORENAL SYNDROME;INFUSION GRAMSL;LARGE-VOLUME PARACENTESIS;LV ALBUMIN;PARACENTESIS COMBINED;PATIENTS RECEIVING","8;8;7;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",11,0.13,5,2,0,0,0,0,7,0,1,2,0,0,1,0,2,0,0,1,0,0,0,41.5,41.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,6.67,1353.67,1.79,0,0,32,0,0,2,0,0,0,0,1,0,3,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","2;2;2;1;1","CLINICAL RESEARCH;CANCER;HEMATOLOGY;RARE DISEASES;STEM CELL RESEARCH;TRANSPLANTATION;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;ORPHAN DRUG;PREVENTION;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN","3;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION","2;2;1","BLOOD CANCER;LEUKEMIA / LEUKAEMIA","2;2","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",1,307151,15357.55,2,20,9,1,1,7678.775,10.6787866554236,"AZIENDA OSPEDALIERA SAN GERARDO;BAYER (GERMANY);ERASMUS MC;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;HOSPITAL OF LITHUANIAN UNIVERSITY OF HEALTH SCIENCES KAUNAS CLINICS;HOSPITAL UNIVERSITARIO 12 DE OCTUBRE;HUMBOLDT-UNIVERSITÄT ZU BERLIN;INSTITUT CATALÀ DE LA SALUT;JANSSEN (UNITED STATES);LUND UNIVERSITY;NHS LOTHIAN;UNIVERSITY HOSPITAL MÜNSTER;UNIVERSITY HOSPITAL OF ZURICH;UNIVERSITY OF BARI ALDO MORO;UNIVERSITY OF CAMBRIDGE;UNIVERSITY OF EDINBURGH;UNIVERSITY OF GLASGOW;UNIVERSITY OF GOTHENBURG;UNIVERSITY OF SOUTHAMPTON;UPPSALA UNIVERSITY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME);THN - THEMATIC NETWORK CONTRACTS (FUNDING SCHEME)","1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1","BRAIN DISORDERS;CLINICAL RESEARCH;NEUROSCIENCES;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS","1;1;1;1",NA,NA,NA,NA,NA,NA,NA,NA,"B11 COMPUTER SCIENCE AND INFORMATICS","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2001,55,8.52727272727273,2.07272727272727,0.472727272727273,0.218181818181818,0.490909090909091,1.21276595744681,1.36842105263158,1.09090909090909,1.35,0.254545454545455,2,28,11,0,12,0.51,0.2,0,0.22,71.6,1.56699920604784,NA,0.309090909090909,0.654545454545455,0.433,0.333,0.15,0.325,"PAOLO LISSONI;FABIO MALUGANI;R BUCOVEC;ETTORE BEGHI;A.J. LACAVE;ANDREA BIONDI;FRANCO ROVELLI;GABRIELE TANCINI;GARDANI GS;MARIO MANDALÁ;GIANFRANCO PARATI;KEN BARUN;LUCA FUMAGALLI;HENDRIK WAGENAAR;R. MARINA;SIMONA SECONDINO;F BRIVIO;G GARDANI;S. PECORELLI;GIUSEPPE GALBIATI","7;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CRISTINA GIANNATTASIO;A. VINCENTI;PAOLO LISSONI;ETTORE BEGHI;CLAUDIA S. ROBERTSON;MANUELA CORMIO;GIUSEPPE GALBIATI;CATERINA VENTURI;G ALBANESE;R BUCOVEC;FABIO MALUGANI;FRANCO VALAGUSSA;JOHN F. ANNEGERS;FRANCO ROVELLI;GABRIELE TANCINI;SIMONA CELOTTI;GIUSEPPE CITERIO;ANTONIO PESENTI;GABRIELLA ROTA;MARZIA CAMPIONI","1;1;0.94;0.92;0.83;0.83;0.67;0.67;0.67;0.62;0.58;0.5;0.5;0.36;0.36;0.34;0.34;0.34;0.33;0.33","PAOLO LISSONI;FABIO MALUGANI;R BUCOVEC;ETTORE BEGHI;ANDREA BIONDI;FRANCO ROVELLI;GABRIELE TANCINI;GIANFRANCO PARATI;LUCA FUMAGALLI;R. MARINA;GIUSEPPE GALBIATI;FRANCO VALAGUSSA;CATERINA VENTURI;PAOLO PERSEGHIN;ANDRÉS CADENA BONFANTI;SIMONA CELOTTI;CLAUDIA S. ROBERTSON;G ALBANESE;A. REDAELLI;GIUSEPPE GAIPA","7;5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CRISTINA GIANNATTASIO;A. VINCENTI;PAOLO LISSONI;ETTORE BEGHI;CLAUDIA S. ROBERTSON;MANUELA CORMIO;GIUSEPPE GALBIATI;CATERINA VENTURI;G ALBANESE;R BUCOVEC;FABIO MALUGANI;FRANCO VALAGUSSA;FRANCO ROVELLI;GABRIELE TANCINI;SIMONA CELOTTI;GIUSEPPE CITERIO;ANTONIO PESENTI;ALEX B. VALADKA;PAOLO PERSEGHIN;GIANFRANCO PARATI","1;1;0.94;0.92;0.83;0.83;0.67;0.67;0.67;0.62;0.58;0.5;0.36;0.36;0.34;0.34;0.34;0.33;0.33;0.31","A. LOMAZZI;A. M. FERTITTA;A. MARIANI;A. PRADA;C. CROSTA;E. MASCI;G TOTI;GIORGIO MINOLI;MARCO DINELLI;PIER ALBERTO TESTONI;RUBIS G PASSONI;SIMONA CURIONI;U COMIN;GIUSEPPE MANCIA;COSTANTINO MANGIONI;ANDREA MANEO;FABIO LANDONI;GENNARO CORMIO;ORLANDO CARUSO;PATRIZIA PEREGO","872;872;872;872;872;872;872;872;872;872;872;872;872;431;404;385;385;385;385;385","A. LOMAZZI;MARCO DINELLI;PATRIZIA PEREGO;PAOLO LISSONI;GIUSEPPE MANCIA;GUIDO CAVALETTI;ANDREA BIONDI;ANTONIO PESENTI;GIUSEPPE CITERIO;SIMONA CELOTTI;E VASCOTTO;FEDERICO VILLA;GIUSEPPE GAIPA;GERARDO ZANETTA;ETTORE BEGHI;LUIGI BERETTA;CATERINA VENTURI;G ALBANESE;G EMANUELLI;GIUSEPPE GALBIATI","872;872;385;372;329;258;229;205;205;205;204;204;140;125;118;90;84;84;84;84","PAOLO LISSONI;ETTORE BEGHI;ANDREA BIONDI;ANTONIO PESENTI;CATERINA VENTURI;FRANCO VALAGUSSA;G ALBANESE;GERARDO ZANETTA;GIUSEPPE CITERIO;GIUSEPPE GALBIATI;GIUSEPPE MANCIA;MANUELA CORMIO;PAOLO PERSEGHIN;R. MARINA;SIMONA CELOTTI;A GALLUZZI;A. ARDIZZOIA;A. CRESPÍ;A. LOMAZZI;A. REDAELLI","7;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;POLITICAL SCIENCE;PHYSICS;ECONOMICS;MATERIALS SCIENCE;COMPUTER SCIENCE;HISTORY;MATHEMATICS;PHILOSOPHY","54;12;4;4;4;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;PATHOLOGY;CARDIOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;GENETICS;RADIOLOGY;ONCOLOGY;PSYCHIATRY;FAMILY MEDICINE;LAW;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;PEDIATRICS;PHARMACOLOGY;ANATOMY;DERMATOLOGY;ECONOMIC GROWTH;EMERGENCY MEDICINE;GENERAL SURGERY;MECHANICAL ENGINEERING;METALLURGY;NUCLEAR MEDICINE;ORGANIC CHEMISTRY;PALEONTOLOGY;PHYSICAL THERAPY;UROLOGY;VIROLOGY","36;19;12;11;8;8;8;7;6;6;6;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;BLOOD PRESSURE;ANTIBODY;RANDOMIZED CONTROLLED TRIAL;CYTOKINE;DISEASE;POPULATION;PROSPECTIVE COHORT STUDY;TOXICITY;ALTERNATIVE MEDICINE;ANGIOGENESIS;CARCINOMA;GENE;INTRACRANIAL PRESSURE;PREGNANCY;REGIMEN;VEGF RECEPTORS;ALBENDAZOLE;ALLIANCE;ASYMPTOMATIC;ATRIAL FIBRILLATION;CEREBRAL BLOOD FLOW;CIRRHOSIS;CONFIDENCE INTERVAL;DIABETES MELLITUS;EPILEPSY;HEMODYNAMICS;IN VITRO;LESION;LOGISTIC REGRESSION;LUNG CANCER;MELATONIN;METHOTREXATE;MITOMYCIN C;PLATELET;PUNCHING;RADIATION THERAPY;RISK FACTOR;STEM CELL;THROMBOSIS;TRANSPLANTATION;VIRUS","14;8;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HEART RATE;CISPLATIN;COLORECTAL CANCER;PROGRESSIVE DISEASE;VASCULAR ENDOTHELIAL GROWTH FACTOR;ATRIAL FLUTTER;BLEOMYCIN;CARDIOVERSION;CD19;CD34;CEREBRAL PERFUSION PRESSURE;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;DIASTOLE;FETUS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PEDIATRIC ONCOLOGY;PERFORATION;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PLACEBO","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BAROREFLEX;ACUTE LYMPHOCYTIC LEUKEMIA;AMNIOTIC FLUID;BARORECEPTOR;BIOPHYSICAL PROFILE;BREAKPOINT;BROMOCRIPTINE;CAROTID STENTING;CD38;CENTRAL VENOUS PRESSURE;CEPHALIC PRESENTATION;COCHRANE COLLABORATION;COLONOSCOPY;COMPARATIVE GENOMIC HYBRIDIZATION;CUTANEOUS LARVA MIGRANS;CYTOGENETICS;EXTERNAL CEPHALIC VERSION;FETAL MOVEMENT;FLUORESCENCE IN SITU HYBRIDIZATION;GASTROINTESTINAL CANCER;HERPESVIRIDAE;IMMUNOGLOBULIN M;INFERIOR VENA CAVA FILTER;JC VIRUS;KARYOTYPE;MESALAZINE;METASTATIC BREAST CANCER;MUSCULOSKELETAL DISORDER;NUMBER NEEDED TO TREAT;OLIGOHYDRAMNIOS;OTOTOXICITY;OXALIPLATIN;PERFORIN;PLATELETPHERESIS;POLYHYDRAMNIOS;PRENATAL DIAGNOSIS;PROSTATECTOMY;RADICAL HYSTERECTOMY;SLOW VIRUS;SULFASALAZINE;TERATOLOGY;VIGABATRIN;VINCRISTINE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASMS;ANTINEOPLASTIC AGENTS;ADOLESCENT;TREATMENT OUTCOME;CARCINOMA, SQUAMOUS CELL;LIVER NEOPLASMS;PROSPECTIVE STUDIES;BLOOD PRESSURE;CHILD;LIVER CIRRHOSIS;;ANTICONVULSANTS;ATRIAL FLUTTER","48;32;27;26;26;24;14;12;10;9;9;8;8;8;7;7;7;6;6;6","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GYNECOLOGIC ONCOLOGY;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ATRIAL FIBRILLATION;BIOLOGY AND PATHOLOGY OF KERATINS AND RELATED DISORDERS;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;COMPREHENSIVE APPROACH TO SCHOOL HEALTH PROMOTION;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;ECTOPARASITIC DISEASES IN HUMANS AND ANIMALS;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPILEPSY AND SEIZURES;EXERCISE PHYSIOLOGY AND CARDIOVASCULAR HEALTH","3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","REGIMEN;ADOLESCENT AND YOUNG ADULT ONCOLOGY;ALBENDAZOLE;ATRIAL FLUTTER;BAROREFLEX SENSITIVITY;CARDIOPULMONARY EXERCISE TESTING;CERVICAL CANCER;CHILDHOOD CANCER SURVIVOR STUDY;CLINICAL ENDPOINT;ENDOTHELIAL CELL BEHAVIOR;EPILEPSY;HYPERTENSION;INTRACRANIAL PRESSURE;MATERNAL EPILEPSY;MELATONIN;MITOMYCIN C;PEDIATRIC ONCOLOGY;PERFORATION;TUMOR ANGIOGENESIS;ABDOMINAL COMPARTMENT SYNDROME","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","CANCER PATIENTS;ADVANCED CANCER;ATRIAL FLUTTER;CANCER COOPERATIVE;CELL CARCINOMA;COUNTRIES DEVELOPMENT;DEVELOPING COUNTRIES;EORTC GYNECOLOGICAL;GYNECOLOGICAL CANCER;II STUDY;INTRACRANIAL PRESSURE;JC VIRUS;LOW-DOSE INTERLEUKIN-;MULTICENTRE STUDY;PEDIATRIC ONCOLOGY;PHASE II;PROSPECTIVE MULTICENTER;SQUAMOUS-CELL CARCINOMA;UTERINE CERVIX;VIRUS TYPE;ABBOTT AXSYM;ABDOMINAL COMPARTMENT;ABNORMALLY ENHANCED;ACHIEVING CONTINENCE;ACIDS PUFA;ACQUISITIONS RESEARCH;ACTION REPORT;ACTIVE ULCERATIVE;ACUTE LYMPHOBLASTIC;ADDITIONAL MEASURE","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","ATRIAL FLUTTER;CHILD CLASS;CESAREAN DELIVERY;CMV IGM;NERVE TRAFFIC;SYMPATHETIC NERVE;ACTIVE ULCERATIVE;ATRIAL THROMBI;ULCERATIVE COLITIS;BREECH PRESENTATION;CD CELLSKG;CLINICAL REMISSIONIMPROVEMENT;COMBINED TREATMENT;COMPLIANCE PERFORMANCE;HEAD INJURY;IGM ASSAY;OUTPATIENT SERVICES;PLACEBO EFFECT;PORTAL HYPERTENSION;PREGNANT WOMEN;RANGE CD;ACTIVE NONDRUGRESISTANT;ATRIAL FIBRILLATION;AUTOLOGOUS TRANSPLANTATION;AXSYM CMV;BP HR;BP REDUCTION;BREATHING EXERCISES;CD CELLS;CIRRHOTIC PATIENTS","8;8;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2",12,0.22,4.27,6,0,1,0,0,7,0,2.5,6.5,0,0,1.75,0,4,1,0,1,1,0,0,76,76.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,19,2564.5,2.35,0,0,83,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy;United States","1;1","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY","1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;GENETIC TESTING;GENETICS;HUMAN GENOME;LUNG;LUNG CANCER;ORPHAN DRUG;PATIENT SAFETY;PREVENTION;RARE DISEASES;TOBACCO;TOBACCO SMOKE AND HEALTH;UROLOGIC DISEASES","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;6.1 PHARMACEUTICALS","1;1;1","BLADDER CANCER;LUNG CANCER","1;1","2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;2.4 RESOURCES AND INFRASTRUCTURE RELATED TO ETIOLOGY;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2002,61,7.63934426229508,2,0.573770491803279,0.213114754098361,0.59016393442623,1.27083333333333,1.16666666666667,1.08333333333333,1.2,0.245901639344262,6,21,10,7,20,0.34,0.16,0.11,0.33,74.77,1.35530613464069,NA,0.19672131147541,0.655737704918033,0.486,0.341,0.332,0.341,"FABIO MALUGANI;PAOLO LISSONI;ALBERTO LUCCHINI;GIUSEPPE CITERIO;ANTONIO PESENTI;MARIA DASSI;L IACOBELLI;G GARDANI;C UDERZO;M NESCI;GIUSEPPE MANCIA;GABRIELE TANCINI;S MENGO;ATTILIO ROVELLI;GIUSEPPE FOTI;M ASNAGHI;ANDREA BIONDI;ELENA FUMAGALLI;A ARDIZZOIA;SANDRO BARNI","6;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","GINO SERAVALLE;ALBERTO LUCCHINI;B REDAELLI;CRISTINA GIANNATTASIO;ALESSANDRO PULSONI;MJ WILLEMSE;L IACOBELLI;M NESCI;GIUSEPPE MANCIA;PAOLO LISSONI;GIUSEPPE CITERIO;ANTONIO PESENTI;FABIO MALUGANI;M ASNAGHI;MARIA DASSI;LUCA SALA;D LONGONI;ALBERTO ZANCHETTI;D FERRARIO;GIUSEPPE TROCINO","2;1.39;1.1;1;1;1;0.89;0.89;0.88;0.87;0.87;0.72;0.71;0.64;0.52;0.5;0.5;0.5;0.5;0.5","PAOLO LISSONI;ALBERTO LUCCHINI;GIUSEPPE CITERIO;ANTONIO PESENTI;MARIA DASSI;L IACOBELLI;C UDERZO;M NESCI;GIUSEPPE MANCIA;ATTILIO ROVELLI;GIUSEPPE FOTI;M ASNAGHI;ANDREA BIONDI;SANDRO BARNI;PAOLO PERSEGHIN;SONIA BONANOMI;ADRIANA BALDUZZI;ETTORE BEGHI;GIUSEPPE GAIPA;P. LISSONI","6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","GINO SERAVALLE;ALBERTO LUCCHINI;B REDAELLI;CRISTINA GIANNATTASIO;ALESSANDRO PULSONI;MJ WILLEMSE;L IACOBELLI;M NESCI;GIUSEPPE MANCIA;PAOLO LISSONI;GIUSEPPE CITERIO;ANTONIO PESENTI;M ASNAGHI;MARIA DASSI;LUCA SALA;D FERRARIO;MANUELA CEREDA;M CORMIO;C UDERZO;GIUSEPPE FOTI","2;1.39;1.1;1;1;1;0.89;0.89;0.88;0.87;0.87;0.72;0.64;0.52;0.5;0.5;0.5;0.5;0.46;0.43","CARLO GAMBACORTI‐PASSERINI;ANDREAS HOCHHAUS;BRIAN J. DRUKER;CHARLES A. SCHIFFER;CHARLES L. SAWYERS;DEBRA RESTA;DIETGER NIEDERWIESER;FRANÇOIS GUILHOT;HAGOP KANTARJIAN;MOSHE TALPAZ;RENAUD CAPDEVILLE;ULRIKE ZOELLNER;GIUSEPPE MANCIA;FABIO MALUGANI;GIUSEPPE CITERIO;PAOLO LISSONI;ALBERTO PIPERNO;ALESSANDRA SALVIONI;ANNA VERGANI;M. GELOSA","2184;2064;2064;2064;2064;2064;2064;2064;2064;2064;2064;2064;285;216;203;191;180;180;180;180","CARLO GAMBACORTI‐PASSERINI;GIUSEPPE CITERIO;ALBERTO PIPERNO;PAOLO LISSONI;MJ WILLEMSE;ETTORE BEGHI;ANDREA MILLUL;NICOLÒ PATRONITI;ENNIO COCCO;MONICA GATTI;C UDERZO;BARBARA CORTINOVIS;ELENA MAGGIONI;ALESSANDRO ARDIZZOIA;ALESSANDRO COLOMBO;B REDAELLI;F. PALEARI;GIOVANNI SEGALINI;GUIDO CAVALETTI;A ALBERTAZZI","2184;202;180;179;166;160;136;133;131;131;129;125;125;124;124;118;113;113;112;103","PAOLO LISSONI;GIUSEPPE CITERIO;MARIA DASSI;ETTORE BEGHI;PAOLO PERSEGHIN;ANDREA BIONDI;ANDREA MILLUL;B REDAELLI;C UDERZO;CARLO GAMBACORTI‐PASSERINI;GIUSEPPE MANCIA;GUIDO CAVALETTI;L MASCARETTI;NICOLÒ PATRONITI;P. LISSONI;A ALBERTAZZI;A. FILIBERTI;ADRIANA BALDUZZI;ALBERTO PIPERNO;ALBERTO SCHIERA","5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;CHEMISTRY;PHYSICS;PSYCHOLOGY;PHILOSOPHY;SOCIOLOGY;BUSINESS;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;HISTORY;POLITICAL SCIENCE","58;14;10;6;5;4;3;3;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;INTENSIVE CARE MEDICINE;ANESTHESIA;CARDIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;ENDOCRINOLOGY;BIOCHEMISTRY;PSYCHIATRY;MECHANICAL ENGINEERING;ENVIRONMENTAL HEALTH;PHARMACOLOGY;GENETICS;PEDIATRICS;CANCER RESEARCH;CELL BIOLOGY;NURSING;PATHOLOGY;PHYSICAL THERAPY","51;14;13;11;11;11;10;10;9;8;8;7;6;6;5;5;4;4;4;4;4","CANCER;CHEMOTHERAPY;BLOOD PRESSURE;DISEASE;POPULATION;GENE;IMMUNE SYSTEM;MECHANICAL VENTILATION;RECEPTOR;VENTILATION (ARCHITECTURE);DIABETES MELLITUS;INTENSIVE CARE;RANDOMIZED CONTROLLED TRIAL;STEM CELL;ANTIGEN;CONCOMITANT;CYTOKINE;DIALYSIS;HEART FAILURE;HORMONE;INCIDENCE (GEOMETRY);LEUKEMIA;LUNG;LYMPHOCYTE;MELATONIN;OBSERVATIONAL STUDY;REGIMEN;TOXICITY;TRANSPLANTATION","11;10;7;7;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;ALPHA INTERFERON;ANTAGONIST;ARDS;CISPLATIN;COLORECTAL CANCER;ESSENTIAL HYPERTENSION;GENOTYPE;HAEMATOPOIESIS;HUMAN LEUKOCYTE ANTIGEN;IMMUNITY;IMMUNOTHERAPY;INTERLEUKIN 2;NEUROTOXICITY;OPIOID;POSITIVE END-EXPIRATORY PRESSURE;PRESSURE SUPPORT VENTILATION;PROGRESSIVE DISEASE;TIDAL VOLUME","4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","(+)-NALOXONE;FOLINIC ACID;NALTREXONE;ABL;ACE INHIBITOR;ACUTE LYMPHOCYTIC LEUKEMIA;ACUTE PROMYELOCYTIC LEUKEMIA;ANTIGEN-PRESENTING CELL;BAROREFLEX;BROMOCRIPTINE;CD3;CD40;CD86;HAPLOTYPE;HISTOCOMPATIBILITY;IMATINIB MESYLATE;INTERFERON ALFA;JUVENILE MYELOMONOCYTIC LEUKEMIA;LYMPHOCYTE SUBSETS;MEAN BLOOD PRESSURE;METASTATIC BREAST CANCER;METHYLENETETRAHYDROFOLATE REDUCTASE;MUCOPOLYSACCHARIDOSIS TYPE I;MYELOPOIESIS;OPIOID PEPTIDE;OPIOID RECEPTOR;OXYCODONE;PEAK INSPIRATORY PRESSURE;PHILADELPHIA CHROMOSOME;PINEALOCYTE;SH-SY5Y;TAMOXIFEN;TANDEM EXON DUPLICATION;UPPER MOTOR NEURON;VIGABATRIN;VINCRISTINE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ANTINEOPLASTIC AGENTS;ADULT;BREAST NEOPLASMS;HYPERTENSION;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;INTERLEUKIN-2;CARCINOMA, RENAL CELL;KIDNEY NEOPLASMS;MONITORING, PHYSIOLOGIC;BLOOD PRESSURE;POSITIVE-PRESSURE RESPIRATION;ADOLESCENT;AGED, 80 AND OVER;CHILD","55;32;28;26;24;19;16;16;14;12;12;11;10;10;10;9;9;8;8;8","MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;HEMATOPOIETIC STEM CELL BIOLOGY;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;IMPACT OF CHRONIC STRESS ON CANCER PROGRESSION;OPTIMIZATION OF PERIOPERATIVE FLUID THERAPY;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ACUTE MYELOID LEUKEMIA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;CANCER IMMUNOTHERAPY;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHALLENGES AND OPPORTUNITIES IN TRANSLATIONAL RESEARCH;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS","5;4;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","HYPERTENSION;NONINVASIVE VENTILATION;POSITIVE END-EXPIRATORY PRESSURE;CONCOMITANT;INTRACRANIAL PRESSURE;MELATONIN;REGIMEN;CARDIAC IMAGING;ECHOCARDIOGRAPHY;ESSENTIAL HYPERTENSION;FOLINIC ACID;HEMATOPOIETIC CELL TRANSPLANTATION;HEMODYNAMIC MONITORING;NEUROINFLAMMATION;NEUROTOXICITY;OPIOID ANTAGONIST;PRESSURE SUPPORT VENTILATION;PROLACTINOMAS;STEM CELL MOBILIZATION;STROKE (ENGINE)","4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","LOW-DOSE INTERLEUKIN-;SUBCUTANEOUS LOW-DOSE;BREAST CANCER;CANCER PATIENTS;STEM CELL;ACUTE PROMYELOCYTIC;ACUTE RESPIRATORY;CELL COLLECTION;CELL TRANSPLANTATION;CONGESTIVE HEART;DISTRESS SYNDROME;ESSENTIAL HYPERTENSION;HEART FAILURE;HEMATOPOIETIC STEM;PATIENTS PROGRESSING;RESPIRATORY DISTRESS;ACCELERATED HYPERFRACTIONATED;ACUTE CEREBROVASCULAR;ACUTE GERIATRIC;ACUTE LEUKEMIA;ACUTE LYMPHOBLASTIC;ACUTE MYELOID;ACUTE PULMONARY;ACUTE SPINAL;ADJUVANT TREATMENT;ADVANCED CARCINOMA;AGENT BROMOCRIPTINE;AMP ESH;AMYOTROPHIC LATERAL;ANGIOTENSIN TYPE","4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIAC EVENTS;DE NOVO;NOVO APL;BLOOD PRESSURE;MM ID;MMHG NA;ABNORMAL ETT;ABNORMAL SCINTIGRAPHY;AGE YRS;AIRWAY PRESSURE;APL PATIENTS;BONE MARROW;CHILDREN TRANSPLANTED;CMHO NA;FOLLOW-UP TIME;GAS EXCHANGE;HEART FAILURE;ID ETT;LUNG VOLUME;MM HG;MRD LEVELS;PRECURSOR B-ALL;RAISED ICP;SHUTTLING ACTIVITY;ACUTE LYMPHOBLASTIC;ACUTE PROMYELOCYTIC;ACUTE RESPIRATORY;ARDS PATIENTS;ATHEROSCLEROTIC EVENTS;BCRABL-TRANSFORMED MYELOID","8;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2",7,0.11,5,2.5,1,1,0,1,3,0,1,3,0,0,3,0,1,0,1,2,1,0,0,100.5,100.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7.25,1667.4,5.81,0,0,80.8,0,0,2,0,3,0,0,0,0,5,0,0,0,0,0,0,0,4,1,0,5,0,0,0,0,0,0,0,0,0,"Belgium;Italy","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE","5;4;2;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;ORPHAN DRUG;CARDIOVASCULAR;HEART DISEASE;NUTRITION;PATIENT SAFETY;PEDIATRIC;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION","4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","4;2;1;1","NON-HODGKIN'S LYMPHOMA;CERVICAL CANCER;LEUKEMIA / LEUKAEMIA;PANCREATIC CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","3;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2003,57,7.89473684210526,2.31578947368421,0.56140350877193,0.298245614035088,0.543859649122807,1.25714285714286,1.33333333333333,1,1.29166666666667,0.228070175438596,2,20,12,4,16,0.35,0.21,0.07,0.28,50.96,0.96291201106991,NA,0.228070175438596,0.649122807017544,0.372,0.299,0.341,0.299,"GABRIELE TANCINI;PAOLO LISSONI;G GARDANI;FABIO MALUGANI;GIAN LUCA GRAZI;S MENGO;GIORGIO ERCOLANI;ANNA CAPPELLINI;AIMONE BERTOLINI;MARIA DASSI;MATTEO CESCON;ANDREA BIONDI;IGNACE VERGOTE;D. TRIO;PAOLO PERSEGHIN;MARTINO ROLLA;S. VILLÀ;ANTONINO CAVALLARI;PAOLO TAGLIABUE;STEFANO CELOTTO","7;7;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","ANNA CAPPELLINI;ANTONELLA ROETTO;GABRIELE TANCINI;PAOLO LISSONI;AIMONE BERTOLINI;MARTINO ROLLA;FABIO MALUGANI;G GARDANI;D. TRIO;PATRIZIA PEREGO;S. VILLÀ;STEFANO CELOTTO;ALBERTO LUCCHINI;M NESCI;S BELLANI;S MENGO;E. M. VARISCO;LUIGI ERBA;B. MONTI;A. BONGHI","1.31;1;0.99;0.99;0.7;0.57;0.56;0.55;0.51;0.5;0.45;0.4;0.4;0.4;0.4;0.38;0.37;0.37;0.37;0.37","GABRIELE TANCINI;PAOLO LISSONI;G GARDANI;FABIO MALUGANI;ANNA CAPPELLINI;AIMONE BERTOLINI;MARIA DASSI;ANDREA BIONDI;D. TRIO;PAOLO PERSEGHIN;MARTINO ROLLA;S. VILLÀ;PAOLO TAGLIABUE;STEFANO CELOTTO;E. M. VARISCO;ATTILIO ROVELLI;DANIELA DONI;B. MONTI;A. BONGHI;GIUSEPPE PATERLINI","7;7;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","ANNA CAPPELLINI;ANTONELLA ROETTO;GABRIELE TANCINI;PAOLO LISSONI;AIMONE BERTOLINI;MARTINO ROLLA;FABIO MALUGANI;G GARDANI;D. TRIO;PATRIZIA PEREGO;S. VILLÀ;STEFANO CELOTTO;S BELLANI;E. M. VARISCO;B. MONTI;A. BONGHI;E. CROCE;ANDREA BIONDI;ETTORE BEGHI;MARIA DASSI","1.31;1;0.99;0.99;0.7;0.57;0.56;0.55;0.51;0.5;0.45;0.4;0.4;0.37;0.37;0.37;0.37;0.36;0.35;0.35","IGNACE VERGOTE;C. MANGIONI;GIORGIO BOLIS;J. BAPTIST TRIMBOS;GERARDO ZANETTA;L. GIURGEA;S. PECORELLI;SAVERIO TATEO;C. COENS;C. MADROÑAL;G. SCARFONE;J. B. VERMORKEN;MASSIMO PIERGIUSEPPE FRANCHI;P.J. TIMMERS;ANDREA ALBERTO LISSONI;ANN MARIE SWART;DAVID GUTHRIE;JAN B. VERMORKEN;MAHESH PARMAR;NICOLETTA COLOMBO","1095;1074;1074;1074;785;664;664;664;643;643;643;643;643;643;573;431;431;431;431;431","C. MANGIONI;GERARDO ZANETTA;G. BUCCIANTI;PAOLO LISSONI;FRANCO VALAGUSSA;GABRIELE TANCINI;L. CERIZZA;MARIO GIOVANNI CHILELLI;S. VILLÀ;ETTORE BEGHI;GIULIO CEREA;CARLO GAMBACORTI‐PASSERINI;LUCIA TORNAGHI;NADIA CAMBIAGHI;ANTONELLA ROETTO;FRANCESCA CROSTI;PAOLO PERSEGHIN;MARIA DASSI;ANDREA BIONDI;GIOVANNI CAZZANIGA","1074;785;287;247;212;203;203;203;203;162;95;94;94;94;88;61;51;50;38;37","PAOLO LISSONI;PAOLO PERSEGHIN;ANNA CAPPELLINI;ALESSANDRO COLOMBO;ANDREA BIONDI;C. MANGIONI;E. CROCE;ETTORE BEGHI;FRANCO FRIGERIO;GERARDO ZANETTA;MARIA DASSI;PATRIZIA PEREGO;A. REDAELLI;ADELE CORBETTA;ADRIANA BALDUZZI;AIMONE BERTOLINI;ALBERTO CIARDO;ALBERTO PIPERNO;ALESSANDRA SALVIONI;ANDREA MANEO","6;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;SOCIOLOGY;ART;CHEMISTRY;ECONOMICS;ENGINEERING;POLITICAL SCIENCE","53;21;4;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;ONCOLOGY;PATHOLOGY;RADIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;PEDIATRICS;IMMUNOLOGY;BIOCHEMISTRY;CANCER RESEARCH;GYNECOLOGY;PHARMACOLOGY;CELL BIOLOGY;FAMILY MEDICINE;GENERAL SURGERY;INTENSIVE CARE MEDICINE;PALEONTOLOGY;ANATOMY;ANESTHESIA;CARDIOLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;NURSING;OBSTETRICS;OPTICS;PHYSICAL THERAPY;PSYCHIATRY;UROLOGY","45;18;12;12;9;9;6;6;6;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;GENE;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;TRANSPLANTATION;HORMONE;MELATONIN;PREGNANCY;RADIATION THERAPY;REGIMEN;LAPAROSCOPY;LAPAROTOMY;STAGE (STRATIGRAPHY);STEM CELL;ADJUVANT;ADVERSE EFFECT;ANEMIA;APOPTOSIS;BLOOD LOSS;COHORT;COHORT STUDY;CONCOMITANT;DIPLOPIA;HEMOCHROMATOSIS;IMMUNOSUPPRESSION;INCIDENCE (GEOMETRY);LEUKEMIA;LUNG CANCER;MAGNETIC RESONANCE IMAGING;MULTIPLE MYELOMA;MYOCARDIAL INFARCTION;PERIOPERATIVE;POPULATION;RESECTION;SARCOMA;THROMBOSIS;TOXICITY;URINARY SYSTEM;UTERUS","17;11;9;5;5;5;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CISPLATIN;COLORECTAL CANCER;GENOTYPE;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;OVARIAN CANCER;ADJUVANT THERAPY;ALLELE;CD34;CHROMOSOME;ENDOCRINE SYSTEM;ETOPOSIDE;HAEMATOPOIESIS;HEREDITARY HEMOCHROMATOSIS;LIVER TRANSPLANTATION;LYMPHOBLASTIC LEUKEMIA;MUTATION;RHABDOMYOSARCOMA;ACOUSTIC REFLEX;ALPHA INTERFERON;AMOXICILLIN;AMYOTROPHIC LATERAL SCLEROSIS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;B CELL;BEVACIZUMAB;BLADDER CANCER;BREAST CANCER;CAESAREAN SECTION;CANDIDATE GENE;CD19;CD20;CEREBELLAR HYPOPLASIA (NON-HUMAN);CHEMORADIOTHERAPY;CHEMOTHERAPY REGIMEN;CHROMOSOMAL TRANSLOCATION;CHRONIC HEPATITIS;CONGENITAL MUSCULAR DYSTROPHY;COSMID;DEMENTIA;DEPRESSIVE SYMPTOMS;DIABETIC NEPHROPATHY;DNA DAMAGE;DOPAMINERGIC;DYSURIA;ENDOMETRIAL HYPERPLASIA;ENDOMETRIAL POLYP;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;ERYTHROMYCIN;EXON;FERTILITY;FETUS;FLUOROURACIL;FULL TERM;FUSION GENE;GENE EXPRESSION;GENE REARRANGEMENT;GENOME;GESTATION;GLYCEMIC;GRANULOCYTE COLONY-STIMULATING FACTOR;GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR;HEART RATE;HEPATITIS C VIRUS;HEPCIDIN;IMATINIB;IMMUNOTHERAPY;ISCHEMIC STROKE;KIDNEY CANCER;LAPAROSCOPIC SURGERY;LISSENCEPHALY;LOW MOLECULAR WEIGHT HEPARIN;LOWER RISK;LUNG FUNCTION;LUNG VOLUMES;LUTEINIZING HORMONE;MELPHALAN;METASTASIS;MTT ASSAY;MUSCLE BIOPSY;MYOMA;NEUROTOXICITY;OBSTETRICS AND GYNAECOLOGY;OVARIAN CYST;PERINATAL PERIOD;PINEAL GLAND;POLYMERASE CHAIN REACTION;PORTAL HYPERTENSION;PORTAL VEIN THROMBOSIS;PROGRAMMED CELL DEATH;PROLACTIN;PROSTATE;RELATIVE RISK;RESPIRATORY TRACT;RETINOIC ACID;SOUTHERN BLOT;THROMBOLYSIS;TOLERABILITY;TRANSVAGINAL SONOGRAPHY;TYPE 2 DIABETES;TYROSINE KINASE;TYROSINE-KINASE INHIBITOR;UTERINE CAVITY;VENOUS THROMBOSIS;VENTILATOR-ASSOCIATED PNEUMONIA;VIRAL LOAD;VULVAR CANCER;WHITE MATTER;YOLK SAC","3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EMBRYONAL RHABDOMYOSARCOMA;HAPLOTYPE;ACUTE PROMYELOCYTIC LEUKEMIA;ALLELE FREQUENCY;ANTIRETROVIRAL THERAPY;APOMORPHINE;BREAKPOINT;CABERGOLINE;CASPASE 3;CHILDHOOD LEUKEMIA;COMPOUND HETEROZYGOSITY;CONTIG;DIFFUSING CAPACITY;ETV6;FERROPORTIN;FLUORESCENCE IN SITU HYBRIDIZATION;FRAMESHIFT MUTATION;FULMINANT HEPATIC FAILURE;FUSION TRANSCRIPT;GENE MUTATION;GERIATRIC DEPRESSION SCALE;GONADOTROPIN-RELEASING HORMONE;HAMP;HEMATOPOIETIC STEM CELL;HETEROZYGOTE ADVANTAGE;INTRACRANIAL THROMBOSIS;IRINOTECAN;KARYOTYPE;LOSS OF HETEROZYGOSITY;METASTATIC BREAST CANCER;MICROSATELLITE;MODIFIED RANKIN SCALE;OVARIAN CARCINOMA;OXALIPLATIN;PACHYGYRIA;PROBAND;RESPIRATORY RATE;REVERSE TRANSCRIPTASE;REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;RIBAVIRIN;SEMINAL VESICLE;TAMOXIFEN;VENTRICULOMEGALY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ANTINEOPLASTIC AGENTS;;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;OVARIAN NEOPLASMS;CARCINOMA;NEOPLASM METASTASIS;AGED, 80 AND OVER;CARCINOMA, NON-SMALL-CELL LUNG;CISPLATIN;MELATONIN;PNEUMONIA;TREATMENT OUTCOME;5-METHOXYTRYPTAMINE","41;31;28;21;19;18;17;16;12;11;11;8;8;7;7;7;7;7;7;6","GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENITOURINARY SOFT TISSUE TUMORS AND ANOMALIES;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATOCELLULAR CARCINOMA;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;PEDIATRIC CANCER AND QUALITY OF LIFE;REGULATION OF IRON METABOLISM AND ANEMIA;SARCOMA RESEARCH AND TREATMENT;UTERINE CONDITIONS AND TREATMENTS;ACUTE MYELOID LEUKEMIA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEONATAL SEPSIS","6;4;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","REGIMEN;HEMATOPOIETIC CELL TRANSPLANTATION;MELATONIN;TREATMENT;ADJUVANT THERAPY;CONCOMITANT;EMBRYONAL RHABDOMYOSARCOMA;FOUNDER EFFECT;HEREDITARY HEMOCHROMATOSIS;IMMUNOSUPPRESSION;LIVER RESECTION;METASTATIC BREAST CANCER;RADIOFREQUENCY ABLATION;RHABDOMYOSARCOMA;STEM CELL MOBILIZATION;TUMOR MODELS;ACOUSTIC REFLEX;ACUTE ABDOMEN;ACUTE PROMYELOCYTIC LEUKEMIA;ADJUNCTIVE TREATMENT","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CANCER PATIENTS;ADJUVANT CHEMOTHERAPY;CELL TRANSPLANTATION;NEOPLASM TRIAL;OVARIAN NEOPLASM;STEM CELL;COLORECTAL CANCER;EARLY-STAGE OVARIAN;EMBRYONAL RHABDOMYOSARCOMA;HEMATOPOIETIC STEM;II STUDY;LAPAROSCOPIC LIVER;LIVER RESECTION;LIVER TRANSPLANT;LUNG CANCER;METASTATIC CANCER;METASTATIC COLORECTAL;MULTIPLE MYELOMA;OVARIAN CARCINOMA;PATIENTS UNDERGOING;PHASE II;TRANSPLANT RECIPIENT;ABDOMINAL TREATMENT;ABILITY ASSESSED;ABNORMAL NEUROENDOCRINE;ACOUSTIC REFLEX;ACUTE LYMPHOBLASTIC;ACUTE PROMYELOCYTIC;ADJUNCTIVE THERAPY;ADNEXAL MASSES","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ADJUVANT CHEMOTHERAPY;RECURRENCE-FREE SURVIVAL;EARLY-STAGE OVARIAN;HR CI;OVARIAN CANCER;SIGNIFICANT INCREASE;SIR CI;CHEMOTHERAPY ARM;CHRONIC HEADACHE;MYOCARDIAL INFARCTION;RANDOMIZED TRIALS;ADDITIONAL ERYTHROMYCIN;ALEXANDRIA MONZA;ALEXANDRIA NA;BLADDER SIR;CLINICAL FEATURES;CONSISTENT PROTOCOL;CONTROLLED RANDOMIZED;CONTROLSCHRISTMAS COX;COX ORACLE;DELAY DELIVERY;FETAL INFECTION;GIOVANNI ROTONDO;INFECTION ADMISSION;INTRACAVITARY LESIONS;KIDNEY CANCER;KIDNEY SIR;LOW SUGGESTING;MONZA NA;MONZA REVIEW","15;8;7;7;7;6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",7,0.12,6,5,0,0,0,1,1.5,0,2,5,0,0,1.5,2,0,0,1,1.25,0,0,0,119,119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2004,75,8.56,2.81333333333333,0.506666666666667,0.333333333333333,0.626666666666667,1.30246913580247,1.2258064516129,1.25,1.30555555555556,0.226666666666667,3,32,16,9,14,0.43,0.21,0.12,0.19,33.43,0.710395323491528,NA,0.226666666666667,0.76,0.434,0.302,0.327,0.309,"CARLO FERRARESE;GIUSEPPE CITERIO;GUIDO CAVALETTI;ALESSANDRO BUDA;C ZOIA;ALBERTO PIPERNO;LAURA BRIGHINA;NICOLETTA COLOMBO;PAOLO LISSONI;MAURIZIO LUNATI;SIMONE BERETTA;STEFANO OLMI;MAURIZIO GASPARINI;ANDREA ALBERTO LISSONI;E. CROCE;GIORGIO BOVO;GIUSEPPE MANCIA;RAFFAELLA MARIANI;STEFANO MAGNONE;GIUSEPPE MASERA","6;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","RAFFAELLA MARIANI;DONATELLA BONAIUTI;CARMELA LANZARA;GIUSEPPE CITERIO;ALBERTO PIPERNO;CARLO FERRARESE;STEFANO OLMI;E. CROCE;STEFANO MAGNONE;M CORMIO;GIUSEPPE MANCIA;ALESSANDRO BUDA;SILVIA PELUCCHI;LAURA BRIGHINA;ANTONIO PESENTI;BRUNO TRIMARCO;C ZOIA;PAOLO LISSONI;ANDREA ALBERTO LISSONI;GUIDO CAVALETTI","1.24;1.2;1;0.98;0.85;0.7;0.7;0.7;0.7;0.64;0.56;0.52;0.5;0.47;0.45;0.45;0.44;0.43;0.41;0.41","CARLO FERRARESE;GIUSEPPE CITERIO;GUIDO CAVALETTI;ALESSANDRO BUDA;ALBERTO PIPERNO;LAURA BRIGHINA;PAOLO LISSONI;STEFANO OLMI;ANDREA ALBERTO LISSONI;E. CROCE;GIORGIO BOVO;GIUSEPPE MANCIA;RAFFAELLA MARIANI;GIUSEPPE MASERA;GIOVANNI MESSINA;ANTONIO PESENTI;A. VINCENTI;M CORMIO;ALESSANDRA SALVIONI;TIZIANA DELL’ANNA","6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2","RAFFAELLA MARIANI;DONATELLA BONAIUTI;CARMELA LANZARA;GIUSEPPE CITERIO;ALBERTO PIPERNO;CARLO FERRARESE;STEFANO OLMI;E. CROCE;M CORMIO;GIUSEPPE MANCIA;ALESSANDRO BUDA;LAURA BRIGHINA;ANTONIO PESENTI;PAOLO LISSONI;ANDREA ALBERTO LISSONI;GUIDO CAVALETTI;GIUSEPPE MASERA;GIORGIO BOVO;ELIO CLEMENTE AGOSTONI;S. IURLARO","1.24;1.2;1;0.98;0.85;0.7;0.7;0.7;0.64;0.56;0.52;0.47;0.45;0.43;0.41;0.41;0.4;0.36;0.35;0.33","CARLO FERRARESE;GIUSEPPE CITERIO;NICOLETTA COLOMBO;GUIDO CAVALETTI;ALESSANDRO BUDA;CARMELA LANZARA;SIMONE BERETTA;ANGELO COLOMBO;EMILIANA CALAPPI;FRANCESCA PAGAN;KATIA CANAVESI;LUIGI BERETTA;MANUELA CORMIO;NINO STOCCHETTI;ANDREA BIONDI;GIOVANNI CAZZANIGA;ALESSANDRO BEGHINI;CARLA B. RIPAMONTI;ENRICA MORRA;FRANCESCA ELICE","269;253;228;225;208;190;185;169;169;169;169;169;169;169;164;164;163;163;163;163","GIUSEPPE CITERIO;CARMELA LANZARA;MANUELA CORMIO;ANDREA BIONDI;ANNA CAPPELLINI;ARIELA BENIGNI;C. PICCIOLO;DANIELA MACCONI;FABIO PASTA;FRANCESCA PORRATI;GIUSEPPE REMUZZI;MARINA NORIS;MARTA TODESCHINI;PAOLA CASSIS;RAFFAELLA MAUCCI;SAMANTHA BONAZZOLA;CARLO FERRARESE;LAURA MATTAVELLI;LUCIO TREMOLIZZO;ALBERTO PIPERNO","253;190;169;163;155;155;155;155;155;155;155;155;155;155;155;155;152;149;149;127","GIUSEPPE CITERIO;CARLO FERRARESE;ALBERTO PIPERNO;GIORGIO BOVO;GIUSEPPE MANCIA;GIUSEPPE MASERA;GUIDO CAVALETTI;PAOLO LISSONI;ANDREA ALBERTO LISSONI;ALESSANDRA SALVIONI;ALESSANDRO BUDA;ALESSIA RIVA;ANDREA MANEO;ANTONIO ARDIZZOIA;COSTANTINO MANGIONI;DONATELLA BONAIUTI;E. CROCE;ELIO CLEMENTE AGOSTONI;ENRICO MARIA POGLIANI;FABIO LANDONI","6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;PSYCHOLOGY;BUSINESS;COMPUTER SCIENCE;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE","72;24;8;4;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;ENDOCRINOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;ANESTHESIA;BIOCHEMISTRY;CARDIOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;PEDIATRICS;PSYCHIATRY;GENERAL SURGERY;PATHOLOGY;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;PALEONTOLOGY;ANATOMY;CANCER RESEARCH;CELL BIOLOGY;GYNECOLOGY;MEDICAL EMERGENCY;NUCLEAR MEDICINE;OBSTETRICS;PHARMACOLOGY","56;26;15;12;11;10;10;9;8;7;7;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3","CANCER;CHEMOTHERAPY;GENE;DISEASE;HEART FAILURE;RECEPTOR;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;TOXICITY;CONFIDENCE INTERVAL;LAPAROSCOPY;REGIMEN;STAGE (STRATIGRAPHY);TRAUMATIC BRAIN INJURY;ANTIBODY;BLOOD PRESSURE;CLINICAL TRIAL;DEFEROXAMINE;DIABETES MELLITUS;ENZYME;LEUKEMIA;LUNG;OXIDATIVE STRESS;PERIPHERAL;POPULATION;THALASSEMIA;TRANSPLANTATION","15;12;10;8;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","MUTATION;BREAST CANCER;GLUTAMATE RECEPTOR;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;FETUS;GESTATION;CARDIOTOXICITY;CHROMOSOME;CISPLATIN;DEFERIPRONE;DIASTOLE;DOPAMINERGIC;ENDOCRINE SYSTEM;ETOPOSIDE;LYMPHOBLASTIC LEUKEMIA;NEUROTOXICITY;NEUTROPENIA;OVARIAN CANCER;PACLITAXEL;PERIPHERAL NEUROPATHY;SUPEROXIDE","7;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MISSENSE MUTATION;ACUTE LYMPHOCYTIC LEUKEMIA;EPIRUBICIN;INTERNATIONAL PROGNOSTIC INDEX;PLACENTA;TAXANE;VINCRISTINE;ACUTE PROMYELOCYTIC LEUKEMIA;APOMORPHINE;ARGINASE;BRAIN METASTASIS;BUTHIONINE SULFOXIMINE;CARDIAC RESYNCHRONIZATION THERAPY;CEREBRAL VASOSPASM;CERVICAL INTRAEPITHELIAL NEOPLASIA;CITRULLINE;COMPOUND HETEROZYGOSITY;CONGENITAL TOXOPLASMOSIS;CUTTING BALLOON;CYTOGENETICS;ESOPHAGITIS;EXCITATORY AMINO-ACID TRANSPORTER;EXCITOTOXICITY;FERROPORTIN;FMS-LIKE TYROSINE KINASE 3;GENE MUTATION;GESTATIONAL TROPHOBLASTIC DISEASE;HAMP;HORMONAL THERAPY;KARYOTYPE;LEBER'S HEREDITARY OPTIC NEUROPATHY;MASTECTOMY;METASTATIC BREAST CANCER;NITROTYROSINE;NODULAR REGENERATIVE HYPERPLASIA;OVARIAN CARCINOMA;OXALIPLATIN;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PEROXYNITRITE;PLASMA CELL DYSCRASIA;POINT MUTATION;PRENATAL DIAGNOSIS;RADIOIMMUNOTHERAPY;RIBAVIRIN;SH-SY5Y;SOD1;SPIRAMYCIN;TAMOXIFEN;TOTAL BODY IRRADIATION;TRANSFERRIN SATURATION;TROPHOBLASTIC NEOPLASM;TROPHOBLASTIC TUMOR","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADULT;;MALE;MIDDLE AGED;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;IRON OVERLOAD;COLORECTAL NEOPLASMS;BRAIN INJURIES;BREAST NEOPLASMS;NEOPLASMS;ALZHEIMER DISEASE;ANTINEOPLASTIC AGENTS, PHYTOGENIC;CISPLATIN;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;FIBROBLASTS;TREATMENT OUTCOME","51;30;24;23;23;22;17;13;13;11;10;10;10;9;9;9;9;8;8;8","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;REGULATION OF IRON METABOLISM AND ANEMIA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;IMPACT OF CHRONIC STRESS ON CANCER PROGRESSION;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR MECHANISMS OF AMYLOIDOSIS;THERAPEUTIC HYPOTHERMIA AND FEVER MANAGEMENT;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANTERIOR CRUCIATE LIGAMENT INJURIES IN ATHLETES;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","REGIMEN;CARDIAC RESYNCHRONIZATION THERAPY;NEUROTOXICITY;TRAUMATIC BRAIN INJURY;TREATMENT OUTCOMES;ACUTE LYMPHOCYTIC LEUKEMIA;CARDIOTOXICITY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;COMA (OPTICS);DEFERIPRONE;EPIRUBICIN;GLUTAMINE TRANSPORT;HEMOCHROMATOSIS;HYPERTENSION;INBORN ERRORS OF METABOLISM;INTERNATIONAL PROGNOSTIC INDEX;INTRACRANIAL HYPOTENSION;INTRACRANIAL PRESSURE;IRON OVERLOAD;NERVOUS SYSTEM INFLUENCE","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CANCER PATIENTS;GLUTAMATE TRANSPORT;ACUTE LYMPHOBLASTIC;ADVANCED OVARIAN;BLOOD PRESSURE;BRAIN INJURY;FAILURE PATIENTS;HEAD INJURY;HEART FAILURE;ICD ITALIAN;IRON OVERLOAD;ITALIAN REGISTRY;LAPAROSCOPIC SURGERY;LYMPHOBLASTIC LEUKEMIA;MISSENSE MUTATION;NEUROLOGICAL SEVERITY;NITRIC OXIDE;OVARIAN CANCER;OXIDATIVE STRESS;PERIPHERAL NEUROTOXICITY;RANDOMISED CONTROLLED;TRAUMATIC BRAIN;ABNORMAL LIVER;ACERULOPLASMINAEMIA STUDY;ACTIVATING MUTATIONS;ACUTE MYELOID;AD CORRELATIONS;ADULT GIMEMA;ADVANCED CANCER;ADVANCED CONGESTIVE","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","TBI PATIENTS;CANCER PATIENTS;LYMPHOCYTE COUNT;AMINO ACID;CT SCAN;INTRACRANIAL MASSES;IRON OVERLOAD;RISK FACTORS;VERSUS NA;CIRCULATING LEVELS;COLORECTAL CANCER;INTENSIVE CARE;LUMEN PATENCY;LUNG CANCER;MECHANICALLY VENTILATED;MEDIAN AGE;NORMOTENSIVE PREGNANCY;PREECLAMPTIC VILLI;PROPHYLACTIC NCPAP;RETINAL GANGLION;WEEKS GESTATION;ABDOMINAL PAIN;ABSOLUTE DIFFERENCE;ACADEMIC NEUROSURGICAL;ADVANCED OVARIAN;AIR LEAKS;ANDOR SEDATED-PARALYZED;ANIMALS RECEIVED;BRAIN INJURED;BREAST CANCER","6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2",7,0.09,6.58,2,0,1,0,0,1,0,0,2.5,0,0,0,0,2,0,0,0,0,0,0,46.5,46.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,2,3842.5,2.68,0,0,102,0,0,1,0,2,0,1,0,0,2,0,0,0,0,0,0,0,4,0,0,2,2,0,0,0,0,0,0,0,0,"Germany;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","4;3;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEALTH SERVICES;HEART DISEASE;INFECTIOUS DISEASES;LUNG;ORPHAN DRUG;PEDIATRIC;PNEUMONIA;PREVENTION;RARE DISEASES","2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","6.1 PHARMACEUTICALS;6.4 SURGERY","2;1","PANCREATIC CANCER","1",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2005,78,9.6025641025641,2.52564102564103,0.435897435897436,0.230769230769231,0.461538461538462,1.44927536231884,1.25925925925926,1.05882352941176,1.28571428571429,0.333333333333333,2,48,9,6,10,0.62,0.12,0.08,0.13,35.62,0.672702613386512,NA,0.256410256410256,0.756410256410256,0.412,0.367,0.399,0.366,"ROSSELLA PARINI;PAOLO LISSONI;L. FRONTINI;G GARDANI;ANDREA BIONDI;FRANCO VALAGUSSA;ENRICO MARIA POGLIANI;GIACOMO LEVANTESI;A. BIGNAMI;ALEJANDRO MACCHIA;LUIGI TAVAZZI;F BRIVIO;CARLO SCHWEIGER;S. PESCIA;GIUSEPPE MANCIA;ALDO P. MAGGIONI;GIUSEPPE MASERA;ROBERTO MARCHIOLI;G STRADA;ELENA OLDANI","8;8;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3","GIUSEPPE MANCIA;PAOLO LISSONI;ANDREA MANEO;ROSSELLA PARINI;G GARDANI;L. FRONTINI;GUIDO GRASSI;FRANCO VALAGUSSA;F BRIVIO;R. MARINA;LUCA QUILICI;S. PESCIA;A. BIGNAMI;GIACOMO LEVANTESI;ALEJANDRO MACCHIA;AIMONE BERTOLINI;STEFANO OLMI;E. CROCE;STEFANO MAGNONE;ENRICO MARIA POGLIANI","1.87;1.03;1;0.97;0.73;0.72;0.7;0.54;0.52;0.5;0.5;0.48;0.47;0.47;0.47;0.45;0.45;0.45;0.45;0.39","ROSSELLA PARINI;PAOLO LISSONI;L. FRONTINI;G GARDANI;ANDREA BIONDI;FRANCO VALAGUSSA;ENRICO MARIA POGLIANI;A. BIGNAMI;F BRIVIO;CARLO SCHWEIGER;S. PESCIA;GIUSEPPE MANCIA;GIUSEPPE MASERA;G STRADA;VITTORIO MANGANINI;ATTILIO ROVELLI;CARLO FERRARESE;SOFIA MEREGALLI;FAUSTO ROSSINI;FRANCESCA FURLAN","8;8;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","GIUSEPPE MANCIA;PAOLO LISSONI;ANDREA MANEO;ROSSELLA PARINI;G GARDANI;L. FRONTINI;GUIDO GRASSI;FRANCO VALAGUSSA;F BRIVIO;R. MARINA;S. PESCIA;A. BIGNAMI;STEFANO OLMI;E. CROCE;ENRICO MARIA POGLIANI;ANDREA BIONDI;G STRADA;VITTORIO MANGANINI;PAOLA VIGANÒ;CARLO SCHWEIGER","1.87;1.03;1;0.97;0.73;0.72;0.7;0.54;0.52;0.5;0.48;0.47;0.45;0.45;0.39;0.37;0.35;0.35;0.35;0.34","ROSSELLA PARINI;MARIA GRAZIA VALSECCHI;ALDO P. MAGGIONI;CARLO SCHWEIGER;FRANCO VALAGUSSA;LUIGI TAVAZZI;ROBERTO MARCHIOLI;ALEJANDRO MACCHIA;GIACOMO LEVANTESI;GIAN LUIGI NICOLOSI;GIANNI TOGNONI;MARIA GRAZIA FRANZOSI;ROSAMARIA MARFISI;G. BUCCIANTI;ANDRÉA STELLA;ALESSANDRA RIVA;AMEDEO DEVECCHI;ANDREA FAINI;ANTONIO VINCENTI;DANIELA POGLIANI","348;333;298;298;298;298;298;272;272;272;272;267;267;262;260;252;252;252;252;252","ROSSELLA PARINI;MARIA GRAZIA VALSECCHI;G. BUCCIANTI;ANDRÉA STELLA;ALESSANDRA RIVA;AMEDEO DEVECCHI;ANDREA FAINI;ANTONIO VINCENTI;DANIELA POGLIANI;FRANCESCA STEFANI;GIUSEPPE BONFORTE;IRENE ACQUISTAPACE;SIMONETTA GENOVESI;VINCENZO DECRISTOFARO;CARLO FERRARESE;PIETRO PIOLTELLI;FRANCO VALAGUSSA;COSTANTINO MANGIONI;PATRIZIA PEREGO;ROBERT FRUSCIO","308;268;262;260;252;252;252;252;252;252;252;252;252;252;220;215;184;141;141;141","PAOLO LISSONI;ROSSELLA PARINI;ENRICO MARIA POGLIANI;FRANCO VALAGUSSA;GIUSEPPE MANCIA;L. FRONTINI;CARLO FERRARESE;A. BIGNAMI;G GARDANI;GIUSEPPE MASERA;SOFIA MEREGALLI;ANDREA BIONDI;ANDRÉA STELLA;C CESTARI;CARMELO RIZZARI;COSTANTINO MANGIONI;DANIELA BELOTTI;ELIZANGELA BERTOLI;F BRIVIO;FAUSTO ROSSINI","7;6;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;ENGINEERING;COMPUTER SCIENCE;POLITICAL SCIENCE;BUSINESS;MATHEMATICS","73;25;12;5;4;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;ENDOCRINOLOGY;ONCOLOGY;GASTROENTEROLOGY;GENETICS;CARDIOLOGY;PEDIATRICS;IMMUNOLOGY;BIOCHEMISTRY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;PATHOLOGY;ANESTHESIA;PALEONTOLOGY;PHYSICAL THERAPY;PSYCHIATRY;GENERAL SURGERY;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY","61;24;17;16;13;13;11;10;9;6;6;6;6;5;5;5;5;4;4;4","CANCER;GENE;BLOOD PRESSURE;CHEMOTHERAPY;DISEASE;TRANSPLANTATION;HORMONE;POPULATION;RECEPTOR;HEART FAILURE;LEUKEMIA;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;DIABETES MELLITUS;LYMPHOMA;RISK FACTOR;VIRUS;LAPAROSCOPY;NEUROLOGY;PROPORTIONAL HAZARDS MODEL;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);STEM CELL;STIMULATION;STROKE (ENGINE)","15;11;8;8;8;8;6;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","PROSTATE CANCER;PROLACTIN;BREAST CANCER;ENDOCRINE SYSTEM;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PROSTATE;EJECTION FRACTION;GENOTYPE;HAEMATOPOIESIS;HEART RATE;LYMPHOBLASTIC LEUKEMIA;MUTATION;OVARIAN CANCER;CD34;CD8;CHROMOGRANIN A;CHRONIC HEPATIC;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;CYTARABINE;ENZYME REPLACEMENT THERAPY;EX VIVO;FABRY DISEASE;GENE KNOCKDOWN;GLUTAMATE RECEPTOR;HEPATIC FIBROSIS;HEPATITIS C VIRUS;METABOLIC SYNDROME;NEURORADIOLOGY;RELATIVE RISK;VIRAL DISEASE","7;6;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACUTE LYMPHOCYTIC LEUKEMIA;CABERGOLINE;EXCITOTOXICITY;HERPESVIRIDAE;METASTATIC BREAST CANCER;MISSENSE MUTATION;NEUROENDOCRINE DIFFERENTIATION;VINCRISTINE;ACE INHIBITOR;ACUTE PROMYELOCYTIC LEUKEMIA;ADRENERGIC AGENT;ALLELE FREQUENCY;ALPHA (FINANCE);ANGIOTENSIN RECEPTOR;AUTONOMIC NERVOUS SYSTEM;BROMOCRIPTINE;CD3;CEPHALIC PRESENTATION;CHEMOKINE RECEPTOR;COMPLEMENT MEMBRANE ATTACK COMPLEX;CRYOGLOBULINEMIA;DONOR LYMPHOCYTE INFUSION;DOPAMINE AGONIST;EATING DISORDER INVENTORY;EXTERNAL CEPHALIC VERSION;FRAMINGHAM HEART STUDY;FRIZZLED;GANCICLOVIR;GLOBOTRIAOSYLCERAMIDE;GLOMERULAR HYPERFILTRATION;HEART RATE VARIABILITY;HEPACIVIRUS;HYPERFRACTIONATION;IDARUBICIN;IMATINIB MESYLATE;KARYOTYPE;LEUKAPHERESIS;LNCAP;MAMMARY GLAND;METABOTROPIC GLUTAMATE RECEPTOR;MOXIBUSTION;MUCOPOLYSACCHARIDOSIS I;MUCOSA-ASSOCIATED LYMPHOID TISSUE;NEUROPEPTIDE Y RECEPTOR;NONSYNONYMOUS SUBSTITUTION;NUCLEAR EXPORT SIGNAL;NUCLEOPLASM;OVARIAN CARCINOMA;OXALIPLATIN;PARS PLANA;PERIPHERAL BLOOD STEM CELLS;POSTMENOPAUSAL OSTEOPOROSIS;PROLACTINOMA;PROLIFERATIVE VITREORETINOPATHY;PROSTATECTOMY;RNA SPLICING;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL INTERFERING RNA;SYMPATHETIC ACTIVITY;TAMOXIFEN;VIRAL QUASISPECIES","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;MYOCARDIAL INFARCTION;PROSTATIC NEOPLASMS;TREATMENT OUTCOME;BREAST NEOPLASMS;CYTOMEGALOVIRUS INFECTIONS;RISK FACTORS;ADOLESCENT;AGED, 80 AND OVER;PROLACTIN;BLOOD PRESSURE;CHILD;HYPERPROLACTINEMIA","46;32;31;29;25;21;16;13;13;11;10;9;9;9;8;8;8;7;7;7","EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;REGULATION OF IRON METABOLISM AND ANEMIA;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEMATOPOIETIC STEM CELL BIOLOGY;LYMPHOID NEOPLASMS;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR RESEARCH ON BREAST CANCER;PROSTATE CANCER RESEARCH AND TREATMENT;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;ACUPUNCTURE MECHANISMS AND CLINICAL APPLICATIONS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN TRANSPLANTATION PROCEDURES AND OUTCOMES;ATRIAL FIBRILLATION","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","PROSTATE CANCER;TREATMENT OUTCOMES;ACUTE LYMPHOBLASTIC LEUKEMIA;ACUTE LYMPHOCYTIC LEUKEMIA;IRON DEFICIENCY;METASTATIC PROSTATE CANCER;STROKE (ENGINE);BREAST CANCER;CABERGOLINE;CHROMOGRANIN A;CHRONIC HEPATIC;CYTOMEGALOVIRUS;EX VIVO;EXCITOTOXICITY;FABRY DISEASE;HEART RATE VARIABILITY;HEMATOPOIETIC CELL TRANSPLANTATION;HEMOSIDERIN;HEPATIC FIBROSIS;HODGKIN'S LYMPHOMA","4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","MYOCARDIAL INFARCTION;PROSTATE CANCER;ACUTE LYMPHOBLASTIC;CELL TRANSPLANTATION;LYMPHOBLASTIC LEUKEMIA;STEM CELL;BREAST CANCER;CANCER PATIENTS;METASTATIC PROSTATE;OVARIAN CANCER;BLOOD PRESSURE;CHRONIC HEPATITIS;DISEASE-FREE SURVIVAL;ENDOCRINE-RESISTANT METASTATIC;FABRY DISEASE;FABRY OUTCOME;FAVORABLE PROGNOSTIC;HEART FAILURE;HEART RATE;IRON ACCUMULATION;ITALIAN PATIENTS;METABOLIC SYNDROME;NODE-POSITIVE BREAST;OPTIMALLY DEBULKED;OUTCOME SURVEY;PATIENTS AFFECTED;PATIENTS TEN-YEAR;PELVIC LYMPHADENECTOMY;PROGNOSTIC SIGNIFICANCE;SURGERY-INDUCED HYPERPROLACTINEMIA","5;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANG II;HEPATIC IRON;PROSTATE CANCER;BREAST CANCER;CANCER PATIENTS;CH-C INFECTION;HFE MUTATIONS;IRON ACCUMULATION;MARGINAL ZONE;FABRY DISEASE;FZD EXPRESSION;GLUTAMATE UPTAKE;NYHA CLASS;ZONE LYMPHOMA;CORONARY SINUS;HEARING LOSS;HEPATIC DAMAGE;IRON DEPOSITS;LEFT PECTORAL;MEDIAN AGE;METASTATIC PROSTATE;MITRAL REGURGITATION;MSEC NA;NODAL MARGINAL;PLATELET GLUTAMATE;SIGNIFICANT IMPROVEMENT;SURGERY-INDUCED HYPERPROLACTINEMIA;AUDIOLOGICAL SYMPTOMS;CD CD;CMV INFECTION","10;8;8;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3",13,0.17,3,3,1,0,0,1,3,1,1,3,0,0,12,0,1,1,2,8,1,0,0,50,50,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,5.2,629.17,9.84,2,0.17,55.17,0,0,2,5,3,0,1,1,0,11,1,0,0,0,0,0,0,11,1,0,11,0,0,0,0,1,0,0,0,0,"Italy;Germany;United States;Belgium","3;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","12;5;4;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;ORPHAN DRUG;PATIENT SAFETY;DIGESTIVE DISEASES;PEDIATRIC;PREVENTION;TRANSPLANTATION;BIOTECHNOLOGY;CHILDHOOD LEUKEMIA;CHRONIC LIVER DISEASE AND CIRRHOSIS;CHRONIC PAIN;DENTAL/ORAL AND CRANIOFACIAL DISEASE;LIVER DISEASE;OVARIAN CANCER;PAIN RESEARCH;PANCREATIC CANCER","10;9;6;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER","6","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","6;1;1;1","LEUKEMIA / LEUKAEMIA;HEAD AND NECK CANCER;LARYNGEAL CANCER;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;OVARIAN CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;STOMACH CANCER","2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","6;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2006,80,9.6,2.3625,0.475,0.25,0.6,1.28571428571429,1.26666666666667,1.11111111111111,1.23076923076923,0.225,2,42,13,6,17,0.52,0.16,0.07,0.21,66.96,1.31097984241041,NA,0.2,0.6875,0.433,0.311,0.346,0.295,"ENRICO MARIA POGLIANI;LUIGI ERBA;STEFANO OLMI;E. CROCE;GIUSEPPE CITERIO;SANDRO SIRONI;AIMONE BERTOLINI;FAUSTO ROSSINI;MAURIZIO LUNATI;D BALLABIO;MARIA PICCHIO;ELENA DE PONTI;PELLEGRINO MUSTO;MAURIZIO GASPARINI;ALBERTO SCAINI;GIUSEPPE MANCIA;COSTANTINO MANGIONI;ANTONIO VINCENTI;FERRUCCIO FAZIO;VALENTINO CONTER","6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2","GIUSEPPE MANCIA;VALERIA ISELLA;LUIGI ERBA;STEFANO OLMI;E. CROCE;GIUSEPPE CITERIO;D BALLABIO;AIMONE BERTOLINI;ALBERTO SCAINI;ENRICO MARIA POGLIANI;PAOLO ARPA;SANDRO SIRONI;SERENA PERCIVALLE;MATTEO CACCIATORI;R. PICCINNO;M. CACCIALANZA;L. GNECCHI;ANTONIO PESENTI;ETTORE BEGHI;ELENA DE PONTI","1.18;1.07;0.89;0.89;0.89;0.89;0.67;0.64;0.59;0.56;0.5;0.5;0.5;0.5;0.5;0.5;0.5;0.48;0.46;0.43","ENRICO MARIA POGLIANI;LUIGI ERBA;STEFANO OLMI;E. CROCE;GIUSEPPE CITERIO;SANDRO SIRONI;AIMONE BERTOLINI;FAUSTO ROSSINI;MAURIZIO LUNATI;ELENA DE PONTI;MAURIZIO GASPARINI;ALBERTO SCAINI;GIUSEPPE MANCIA;COSTANTINO MANGIONI;ANTONIO VINCENTI;VALENTINO CONTER;MASSIMO TRITTO;RODOLFO MILANI;M. ZOCCATELLI;WERNER GARAVELLO","6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","GIUSEPPE MANCIA;VALERIA ISELLA;LUIGI ERBA;STEFANO OLMI;E. CROCE;GIUSEPPE CITERIO;AIMONE BERTOLINI;ALBERTO SCAINI;ENRICO MARIA POGLIANI;PAOLO ARPA;SANDRO SIRONI;MATTEO CACCIATORI;L. GNECCHI;ETTORE BEGHI;ELENA DE PONTI;ANTONIO VINCENTI;WERNER GARAVELLO;FAUSTO ROSSINI;NANCEY E.M. FRANCE;V. DE MOLFETTA","1.18;1.07;0.89;0.89;0.89;0.89;0.64;0.59;0.56;0.5;0.5;0.5;0.5;0.46;0.43;0.38;0.38;0.37;0.33;0.33","DAVIDE CHIUMELLO;GUILLERMO BUGEDO;LUCIANO GATTINONI;MASSIMO CRESSONI;MICHAEL QUINTEL;NICOLÒ PATRONITI;PIETRO CAIRONI;RODRIGO CORNEJO;SEBASTIANO G. RUSSO;V. MARCO RANIERI;GIOVANNINO CICCONE;ANTONIO PALUMBO;FAUSTO ROSSINI;MARIO BOCCADORO;MÓNICA GALLI;PELLEGRINO MUSTO;ANNA MARINA LIBERATI;CLOTILDE CANGIALOSI;ELENA ZAMAGNI;EMANUELA MERLA","1401;1401;1401;1401;1401;1401;1401;1401;1401;1401;850;828;828;828;828;828;827;827;827;827","NICOLÒ PATRONITI;FAUSTO ROSSINI;ANTONIO PELLEGRINO;COSTANTINO MANGIONI;SANDRO SIRONI;PATRIZIA PEREGO;ALESSANDRO BUDA;M. COLOMBO;ANDREA ALBERTO LISSONI;RITA ROSSI;STEFANIA CHIARI;TIZIANA DELL’ANNA;WERNER GARAVELLO;F CARINI;M BALDONI;R PAPAGNA;ATTILIO ROVELLI;C UDERZO;DANIELA LONGONI;HAIDI SANGALLI","1401;828;589;589;410;391;305;305;284;284;284;284;211;189;189;189;163;163;163;163","ENRICO MARIA POGLIANI;GIUSEPPE CITERIO;STEFANO OLMI;FAUSTO ROSSINI;SANDRO SIRONI;ANTONIO VINCENTI;ELENA DE PONTI;GIUSEPPE MANCIA;AIMONE BERTOLINI;ALBERTO FERRARI;ANDREA ALBERTO LISSONI;ANTONIO ARDIZZOIA;ANTONIO PELLEGRINO;C UDERZO;CARLO FERRARESE;COSTANTINO MANGIONI;E. CROCE;ELISABETTA TERRUZZI;ETTORE BEGHI;JENNIFER FRANCESCA SCIUCHETTI","6;5;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;PHILOSOPHY;MATHEMATICS;PSYCHOLOGY;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE","79;15;10;5;4;4;3;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;CARDIOLOGY;IMMUNOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;PATHOLOGY;RADIOLOGY;UROLOGY;ANESTHESIA;BIOCHEMISTRY;ENDOCRINOLOGY;OPTICS;PALEONTOLOGY;NUCLEAR MEDICINE;ASTROBIOLOGY;EMERGENCY MEDICINE;INTENSIVE CARE MEDICINE;NURSING;PEDIATRICS","57;39;16;12;11;9;8;8;7;7;7;6;6;6;6;6;5;4;4;4;4;4","CHEMOTHERAPY;CANCER;DISEASE;POPULATION;RADIATION THERAPY;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);TRANSPLANTATION;ADVERSE EFFECT;BLOOD PRESSURE;CARCINOMA;HEART FAILURE;HERNIA;INCIDENCE (GEOMETRY);LAPAROSCOPY;LEUKEMIA;OBSERVATIONAL STUDY;REGIMEN;DIABETES MELLITUS;MULTIVARIATE ANALYSIS;REFRACTORY (PLANETARY SCIENCE)","16;12;11;8;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4","NEUTROPENIA;CISPLATIN;CYCLOPHOSPHAMIDE;FIXATION (POPULATION GENETICS);PET-CT;SURGICAL MESH;BREAST CANCER;CELL CYCLE;CENTRAL VENOUS CATHETER;CYTARABINE;DEMENTIA;DIASTOLE;DOCETAXEL;EJECTION FRACTION;FLUOROURACIL;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HERNIA REPAIR;IMATINIB;INCISIONAL HERNIA;INGUINAL HERNIA;MEDIAN FOLLOW-UP;MELPHALAN;METABOLIC SYNDROME;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;THALIDOMIDE;TOLERABILITY;UNIVARIATE ANALYSIS","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CARDIAC RESYNCHRONIZATION THERAPY;FEBRILE NEUTROPENIA;IMATINIB MESYLATE;ONCOGENE;ABSOLUTE NEUTROPHIL COUNT;ACUTE LYMPHOCYTIC LEUKEMIA;ADVANCED CARDIAC LIFE SUPPORT;ADVANCED LIFE SUPPORT;BARORECEPTOR;BASIC LIFE SUPPORT;BUSULFAN;CARBOPLATIN;CERVICAL LYMPH NODES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;CLOFARABINE;CYSTECTOMY;DEFIBROTIDE;DIFFUSE ALVEOLAR DAMAGE;FLUDARABINE;FOLINIC ACID;GLOBOTRIAOSYLCERAMIDE;GLUTATHIONE PEROXIDASE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HYPERFRACTIONATION;INTERFERON ALFA;IRINOTECAN;LEVODOPA;MASTECTOMY;METASTATIC BREAST CANCER;MINI–MENTAL STATE EXAMINATION;MITOGEN-ACTIVATED PROTEIN KINASE 3;MYOCARDIAL BRIDGE;MYOCARDIAL BRIDGING;OSTEOCALCIN;OVARIAN CARCINOMA;OVARIAN HYPERSTIMULATION SYNDROME;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PHILADELPHIA CHROMOSOME;PRESSURE OVERLOAD;RADICAL HYSTERECTOMY;RIBAVIRIN;SPINAL MANIPULATION;THIOTEPA;TOTAL BODY IRRADIATION;VINCRISTINE","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;TREATMENT OUTCOME;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROSPECTIVE STUDIES;AGED, 80 AND OVER;ITALY;CARCINOMA, SQUAMOUS CELL;HEART FAILURE;NEOPLASM RECURRENCE, LOCAL;ADOLESCENT;RETROSPECTIVE STUDIES;LAPAROSCOPY;UTERINE CERVICAL NEOPLASMS;BLOOD PRESSURE","60;53;44;43;39;35;20;18;14;14;13;13;12;12;12;11;10;9;9;8","HERNIA REPAIR TECHNIQUES AND MATERIALS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GYNECOLOGIC ONCOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEMATOPOIETIC STEM CELL BIOLOGY;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;PELVIC FLOOR DISORDERS;PREVALENCE AND TREATMENT OF HYPERHIDROSIS;VITREORETINAL SURGERY TECHNIQUES;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;APPLICATIONS OF PLATELET-RICH PLASMA IN REGENERATIVE MEDICINE","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","REGIMEN;HEMATOPOIETIC CELL TRANSPLANTATION;HERNIA REPAIR;REFRACTORY (PLANETARY SCIENCE);ABDOMINAL WALL RECONSTRUCTION;CARDIAC RESYNCHRONIZATION THERAPY;INTERNAL FIXATION;PET-CT;RADIOTHERAPY;SURGICAL MESH;CANCER IMAGING;CARDIOTHORACIC SURGERY;CENTRAL VENOUS CATHETER;CONCOMITANT;CT SCREENING;GRADING (ENGINEERING);HEART RATE VARIABILITY;HYPERTENSION;IMATINIB MESYLATE;INCISIONAL HERNIA","5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","STEM CELL;ACUTE LYMPHOBLASTIC;CANCER PATIENTS;CELL CARCINOMA;FIBRIN GLUE;LYMPHOBLASTIC LEUKEMIA;MESH FIXATION;OBSERVATIONAL STUDY;PHASE II;SQUAMOUS CELL;AUTOLOGOUS STEM;BREAST CANCER;CELL TRANSPLANT;CELL TRANSPLANTATION;COMPOSITE MESH;CORONARY ARTERY;EPITHELIAL OVARIAN;FDG PETCT;GLUE TISSUCOL;HEART FAILURE;HERNIA REPAIR;II STUDY;INDICATIONS COMPLICATIONS;INTEGRATED FDG;LAPAROSCOPIC TRANSABDOMINAL;LAPAROSCOPIC TREATMENT;MESH INDICATIONS;OVARIAN CANCER;PERIPHERAL BLOOD;RADIOTHERAPY VERSUS","4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","UREA DISTRIBUTION;DISTRIBUTION VOLUME;PUBMED SCOPUS;BODY WEIGHT;CROSSREF PUBMED;DIALYSIS DOSE;BASELINE ALBUMIN;END-DIALYSIS BODY;ALBUMIN LEVELS;BLOOD SAMPLES;STABLE PATIENTS;DELIVERED DIALYSIS;DIALYSIS SESSION;INT -ABSTRACT;KINETIC MODEL;POTENTIALLY RECRUITABLE;RECRUITABLE LUNG;UREA KINETIC;FLOW RATE;IONIC DIALYSANCE;PLASMA UREA;UREA CLEARANCE;BLOOD PRESSURE;CLINICALLY STABLE;DIALYZER UREA;REACTIVE PROTEIN;REDUCTION RATIO;STATISTICALLY SIGNIFICANT;UREA CONCENTRATION;UREA REDUCTION","30;23;19;18;10;10;9;9;8;8;8;7;7;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5",7,0.09,19.89,18,5,1,0,0,4,0,3,23,0,1,26.5,0,0,1,8.25,17.5,4,0,0,224.5,224.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,6.17,356.83,4.55,2,0.33,42.67,0,0,2,0,3,0,0,1,0,6,0,0,0,0,0,0,0,5,1,0,6,0,0,0,0,0,0,0,0,0,"United States","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","6;3;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;PEDIATRIC;REGENERATIVE MEDICINE;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;ASSISTIVE TECHNOLOGY;BIOENGINEERING;CHRONIC PAIN;LUNG;LYMPHOMA;PAIN RESEARCH;PATIENT SAFETY;PEDIATRIC CANCER;PEDIATRIC RESEARCH INITIATIVE;PREVENTION;TRANSPLANTATION","6;5;4;4;4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;INFECTION","2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES","4;2;1","LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA","3;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","4",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2007,79,9.88607594936709,3.27848101265823,0.468354430379747,0.316455696202532,0.531645569620253,1.25242718446602,1.19354838709677,1.38888888888889,1.2,0.354430379746835,1,38,19,8,10,0.48,0.24,0.1,0.13,41,0.776868406822143,NA,0.253164556962025,0.759493670886076,0.501,0.342,0.412,0.358,"STEFANO OLMI;E. CROCE;ALBERTO SCAINI;GIUSEPPE MANCIA;LUIGI ERBA;G GARDANI;CRISTINA GIANNATTASIO;PAOLO PERSEGHIN;GIUSEPPE CITERIO;VALENTINO CONTER;A GIUBERTI;AIMONE BERTOLINI;ENRICO POGLIANI;A CAPRA;PAOLO LISSONI;MARCELLO GUAGLIÒ;VITTORIO MANGANINI;LUIGI BERETTA;E PROSERPIO;LUISA GIANI","7;7;7;6;5;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2","PAOLO PERSEGHIN;STEFANO OLMI;E. CROCE;ALBERTO SCAINI;GIUSEPPE CITERIO;LUIGI ERBA;GIUSEPPE MANCIA;AIMONE BERTOLINI;PETER ANDREWS;G GARDANI;A GIUBERTI;CRISTINA GIANNATTASIO;MARCELLO GUAGLIÒ;G CESANA;MADDALENA INCERTI;VALENTINO CONTER;VITTORIO MANGANINI;GUIDO RAFFAELE STRADA;PAOLO VIGANÒ;STEFANO PICOZZI","1.37;1.33;1.33;1.33;1.16;0.97;0.6;0.57;0.5;0.49;0.49;0.45;0.37;0.37;0.37;0.36;0.34;0.34;0.34;0.34","STEFANO OLMI;E. CROCE;ALBERTO SCAINI;GIUSEPPE MANCIA;LUIGI ERBA;G GARDANI;CRISTINA GIANNATTASIO;PAOLO PERSEGHIN;GIUSEPPE CITERIO;VALENTINO CONTER;A GIUBERTI;AIMONE BERTOLINI;ENRICO POGLIANI;A CAPRA;MARCELLO GUAGLIÒ;GUIDO GRASSI;G CESANA;FEDERICA VILLA;ELISABETTA TERRUZZI;ILARIA COLOMBO","7;7;7;6;5;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2","PAOLO PERSEGHIN;STEFANO OLMI;E. CROCE;ALBERTO SCAINI;GIUSEPPE CITERIO;LUIGI ERBA;GIUSEPPE MANCIA;AIMONE BERTOLINI;G GARDANI;A GIUBERTI;CRISTINA GIANNATTASIO;MARCELLO GUAGLIÒ;G CESANA;MADDALENA INCERTI;VALENTINO CONTER;PAOLO VIGANÒ;FABIO GRIZZI;MATTEO CACCIATORI;NICOLETTA GAGLIANO;GIORGIO ANNONI","1.37;1.33;1.33;1.33;1.16;0.97;0.6;0.57;0.49;0.49;0.45;0.37;0.37;0.37;0.36;0.34;0.33;0.33;0.33;0.33","ROBERTO MARCHIOLI;ALBERTO BOSI;ENRICO POGLIANI;AGOSTINO TAFURI;ALESSANDRO M. VANNUCCHI;ALESSANDRO RAMBALDI;EDOARDO ROSSI;ELISABETTA ANTONIOLI;FABRIZIO FABRIS;GIORGINA SPECCHIA;GIOVANNI BAROSI;GUIDO FINAZZI;LUIGI GUGLIOTTA;MARCO RUGGERI;MARIA LUIGIA RANDI;PAOLA GUGLIELMELLI;ROSA MARIA MARFISI;SABRINA CABERLON;TIZIANO BARBUI;VALERIO DE STEFANO","623;508;454;446;446;446;446;446;446;446;446;446;446;446;446;446;446;446;446;446","ENRICO POGLIANI;STEFANO OLMI;ALBERTO SCAINI;E. CROCE;LUIGI ERBA;G CESANA;MARIALUISA PIATTI;MARIO CLERICI;GIUSEPPE CITERIO;PAOLO PERSEGHIN;FRANCO VALAGUSSA;MATTEO PARMA;GIUSEPPE MANCIA;DANIELA LONGONI;FABIO GRIZZI;FAUSTO ROSSINI;GIORGIO ANNONI;NICOLETTA GAGLIANO;ALESSANDRA CASSANO;ARMANDO SANTORO","454;418;378;378;333;238;231;219;206;188;177;149;103;102;96;96;96;96;94;94","STEFANO OLMI;ALBERTO SCAINI;E. CROCE;GIUSEPPE MANCIA;LUIGI ERBA;PAOLO PERSEGHIN;GIUSEPPE CITERIO;ENRICO POGLIANI;G GARDANI;A. LOMAZZI;AIMONE BERTOLINI;CRISTINA GIANNATTASIO;ELISABETTA TERRUZZI;ENRICO MARIA POGLIANI;FAUSTO ROSSINI;FEDERICA VILLA;G CESANA;GIOVANNA CASTOLDI;GIOVANNI PAOLINI;ILARIA COLOMBO","7;6;6;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;PSYCHOLOGY;ART;COMPUTER SCIENCE;ECONOMICS;MATERIALS SCIENCE;BUSINESS;ENGINEERING;GEOGRAPHY;HISTORY;MATHEMATICS;PHILOSOPHY;SOCIOLOGY","76;17;12;3;3;2;2;2;2;1;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;IMMUNOLOGY;ONCOLOGY;GASTROENTEROLOGY;CARDIOLOGY;ANESTHESIA;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;PATHOLOGY;OPTICS;RADIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;CELL BIOLOGY;GENERAL SURGERY;GYNECOLOGY;PEDIATRICS;PHARMACOLOGY","62;29;12;12;12;11;9;7;7;7;7;6;6;4;4;4;4;4;4;4","CANCER;CHEMOTHERAPY;DISEASE;TRANSPLANTATION;ABDOMINAL SURGERY;INCIDENCE (GEOMETRY);LAPAROSCOPY;BLOOD PRESSURE;GENE;REGIMEN;DIABETES MELLITUS;HERNIA;MULTIPLE MYELOMA;POPULATION;CIRRHOSIS;CONCOMITANT;ENDOSCOPY;FIBRIN;FIBRIN GLUE;HEART FAILURE;HEPATOLOGY;IMMUNE SYSTEM;INTRACRANIAL PRESSURE;PREGNANCY;RECEPTOR;REFRACTORY (PLANETARY SCIENCE);RENAL CELL CARCINOMA;STEM CELL","17;16;10;9;6;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HEMATOPOIETIC STEM CELL TRANSPLANTATION;BREAST CANCER;CD34;CISPLATIN;HERNIA REPAIR;INGUINAL HERNIA;AMPHOTERICIN B;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CERVICAL CANCER;COLORECTAL CANCER;CUMULATIVE INCIDENCE;DECOMPRESSIVE CRANIECTOMY;DIASTOLE;EJECTION FRACTION;EX VIVO;FETUS;FLUOROURACIL;GRAFT-VERSUS-HOST DISEASE;IMMUNOTHERAPY;INSULIN RESISTANCE;LIVER TRANSPLANTATION;METASTASIS;MUCOSITIS;NEUTROPENIA;PHASES OF CLINICAL RESEARCH;PHOTOPHERESIS;SURGICAL MESH;T CELL;TYPE 2 DIABETES;VIRAL DISEASE","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EPIRUBICIN;EXTRACORPOREAL PHOTOPHERESIS;METASTATIC BREAST CANCER;VINORELBINE;ANTHRACYCLINE;CAPECITABINE;CARDIAC RESYNCHRONIZATION THERAPY;CASPOFUNGIN;CD90;CENTRAL VENOUS PRESSURE;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;CLOFARABINE;COLONOSCOPY;CUTANEOUS T-CELL LYMPHOMA;DIASTOLIC FUNCTION;DIFFUSING CAPACITY;ELISPOT;FEBRILE NEUTROPENIA;FILGRASTIM;FLUDARABINE;FOLINIC ACID;FUNCTIONAL MITRAL REGURGITATION;GENETIC STRUCTURE;GLYCATED HEMOGLOBIN;HERPESVIRIDAE;HETEROCHROMATIN;IL-2 RECEPTOR;IMPAIRED GLUCOSE TOLERANCE;LEUKAPHERESIS;LEYDIG CELL;MECONIUM;MITRAL VALVE ANNULOPLASTY;OSTEOPENIA;PERCUTANEOUS ETHANOL INJECTION;PLACENTA;POLYHYDRAMNIOS;POSACONAZOLE;PRENATAL DIAGNOSIS;THIOTEPA","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;;LAPAROSCOPY;ANTINEOPLASTIC AGENTS;ITALY;CARDIOVASCULAR DISEASES;ADOLESCENT;PAIN, POSTOPERATIVE;PROSPECTIVE STUDIES;BRAIN INJURIES;CHILD, PRESCHOOL;CORONARY ARTERY DISEASE;FOLLOW-UP STUDIES;INFLAMMATION","61;43;41;33;25;22;18;16;16;13;12;10;9;9;9;8;8;8;8;8","HERNIA REPAIR TECHNIQUES AND MATERIALS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF SPLEEN TRAUMA IN POLYTRAUMA PATIENTS;PEDIATRIC CANCER AND QUALITY OF LIFE;;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ACUPUNCTURE MECHANISMS AND CLINICAL APPLICATIONS;ACUTE MYELOID LEUKEMIA;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CANCER IMMUNOTHERAPY;CANCER OF UNKNOWN PRIMARY SITE","4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","REGIMEN;HERNIA REPAIR;CONCOMITANT;REFRACTORY (PLANETARY SCIENCE);TREATMENT;TREATMENT OUTCOMES;ANTIFUNGAL RESISTANCE;ANTIFUNGAL THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BREAST CANCER;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;CUMULATIVE INCIDENCE;DECOMPRESSIVE CRANIECTOMY;DIABETES;ECHOCARDIOGRAPHY;EPIRUBICIN;EX VIVO;EXTRACORPOREAL PHOTOPHERESIS;HEMATOPOIETIC CELL TRANSPLANTATION;HEPATOCELLULAR CARCINOMA","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ACUTE LYMPHOBLASTIC;CELL CARCINOMA;EXTRACORPOREAL PHOTOCHEMOTHERAPY;FIBRIN GLUE;GLUE TISSUCOL;II STUDY;LYMPHOBLASTIC LEUKEMIA;MULTIPLE MYELOMA;PHASE II;RENAL CELL;STEM CELL;BREAST CANCER;CANCER PATIENTS;CASE-CONTROL STUDY;CELL TRANSPLANTATION;COMPOSITE MESH;CONSERVATIVE TREATMENT;EPIRUBICIN-VINORELBINE INTRAVENOUS;FIRST-LINE TREATMENT;GRAFT-VERSUS-HOST DISEASE;HEPATOCELLULAR CARCINOMA;ICD ITALIAN;INSYNCINSYNC ICD;INTRAVENOUS COMBINATION;LAPAROSCOPIC CONSERVATIVE;LAPAROSCOPIC REPAIR;METASTATIC BREAST;METASTATIC RENAL;ORAL VINORELBINE;PATIENTS RECEIVING","3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LEFT VENTRICULAR;MASS INDEX;BLOOD PRESSURE;METABOLIC SYNDROME;BMI KGM;CLINICAL GRADE;DIASTOLIC DYSFUNCTION;HOMA INDEX;JAK VF;RENAL FAILURE;CD CD;EA RATIO;GASTRIC CANCER;INSULIN RESISTANCE;LV HYPERTROPHY;LV MASS;MUSCLE SYMPATHETIC;NERVE TRAFFIC;SYMPATHETIC NERVE;AGE YRS;CELL TRANSPLANTATION;COLLAGEN SCAFFOLDS;CONFIDENCE INTERVAL;DEGENERATIVE BONE;EFFERENT POSTGANGLIONIC;FABRY PATIENTS;FINAPRES HEART;GM EA;GRADE MEDIUM;HEART RATE","13;11;8;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",15,0.19,3,1,1,1.75,0,0,1.5,0,1,1.5,0,1,2,0,0,1,2,1,1.5,0,0,109,109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,5.5,315.88,4.12,2,0.25,46,0,0,3,0,5,0,0,0,0,8,0,0,0,0,0,0,0,8,0,0,8,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3204 IMMUNOLOGY","8;5;4;2;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES;ORPHAN DRUG;LUNG;LUNG CANCER;PEDIATRIC;STEM CELL RESEARCH;TRANSPLANTATION;BRAIN DISORDERS;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;NEURODEGENERATIVE;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC CANCER","8;6;5;5;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER","5","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.2 CELLULAR AND GENE THERAPIES","6;2;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;BLOOD CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA","5;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","6;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2008,125,10.336,2.44,0.336,0.216,0.392,1.54871794871795,1.16666666666667,1.22727272727273,1.16666666666667,0.344,0,75,22,10,10,0.6,0.18,0.08,0.08,50.38,0.918066021231112,NA,0.36,0.864,0.389,0.419,0.365,0.411,"ROBERT FRUSCIO;D. TIMMERMAN;A. C. TESTA;L. VALENTIN;C. VAN HOLSBEKE;ARTUR CZEKIERDOWSKI;ROSSELLA PARINI;S. GUERRIERO;T. BOURNE;GIUSEPPE CITERIO;L. SAVELLI;PAOLO LISSONI;D. FISCHEROVÁ;CARLO FERRARESE;F BRIVIO;SABINE VAN HUFFEL;ANTONIO PESENTI;GIACOMO BELLANI;MARIA GRAZIA VALSECCHI;GIUSEPPE MANCIA","12;10;10;10;10;9;9;8;8;8;7;7;6;6;6;6;6;5;5;5","GIUSEPPE CITERIO;ROBERT FRUSCIO;PAOLO LISSONI;ANTONIO PESENTI;F BRIVIO;D. TIMMERMAN;A. C. TESTA;L. VALENTIN;C. VAN HOLSBEKE;ROSSELLA PARINI;NINO STOCCHETTI;A. VINCENTI;CARLO FERRARESE;ARTUR CZEKIERDOWSKI;ROBERTO FUMAGALLI;LUCA FUMAGALLI;GIACOMO BELLANI;FERRUCCIO FAZIO;S. GUERRIERO;FRANCESCA ANGIERO","1.71;0.95;0.86;0.78;0.76;0.74;0.74;0.74;0.74;0.73;0.7;0.7;0.7;0.66;0.64;0.63;0.62;0.6;0.58;0.58","ROBERT FRUSCIO;ROSSELLA PARINI;GIUSEPPE CITERIO;PAOLO LISSONI;CARLO FERRARESE;F BRIVIO;GIUSEPPE MANCIA;PIETRO PIOLTELLI;GIOVANNI MESSINA;LUCA FUMAGALLI;ENRICO MARIA POGLIANI;ANTONIO VINCENTI;FRANCESCA CROSTI;GIUSEPPE FOTI;JUAN SAHUQUILLO;MIRIAM RIGOLDI;ANDRÉA STELLA;ANDREA BIONDI;LAURA ANTOLINI;LUCIO TREMOLIZZO","12;9;8;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","GIUSEPPE CITERIO;ROBERT FRUSCIO;PAOLO LISSONI;F BRIVIO;ROSSELLA PARINI;A. VINCENTI;CARLO FERRARESE;ROBERTO FUMAGALLI;LUCA FUMAGALLI;FRANCESCA ANGIERO;GIUSEPPE MANCIA;SIMONETTA GENOVESI;GIUSEPPE FOTI;GIOVANNI MESSINA;ANNA PERRI;LUCIO TREMOLIZZO;ANDRÉA STELLA;ANTONIO VINCENTI;PIETRO PIOLTELLI;ENRICO MARIA POGLIANI","1.71;0.95;0.86;0.76;0.73;0.7;0.7;0.64;0.63;0.58;0.58;0.57;0.54;0.53;0.5;0.5;0.49;0.47;0.46;0.45","COSTANTINO MANGIONI;MASSIMO PIERGIUSEPPE FRANCHI;SAVERIO TATEO;VALTER TORRI;ANDREA ALBERTO LISSONI;C. DELLA CROCE;DIANA GIANNARELLI;DIONYSSIOS KATSAROS;E CAMPAGNUTTA;F. MANESCHI;FRANCESCO RASPAGLIESI;G GAROZZO;GENNARO CORMIO;GIORGIA MANGILI;GIOVANNI SCAMBIA;M. AMOROSO;MAURO MELPIGNANO;MAURO SIGNORELLI;NICOLA RAGNI;NICOLETTA DONADELLO","1966;1938;1938;1481;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439;1439","COSTANTINO MANGIONI;ANDREA ALBERTO LISSONI;MAURO SIGNORELLI;ANTONIO VINCENTI;SIMONETTA GENOVESI;ANDRÉA STELLA;FRANCO VALAGUSSA;ROSSELLA PARINI;ANDREA GORI;ENRICO POGLIANI;FRANCESCA CROSTI;FEDERICO PIERUZZI;MASSIMO POZZI;LAURA RATTI;ALBERTO PIPERNO;P. TROMBINI;RAFFAELLA MARIANI;E. DAPRETTO;PABLO INGELMO;A STELLA","1966;1439;1439;476;413;412;393;292;290;249;229;208;200;167;157;157;157;126;118;113","ROBERT FRUSCIO;ROSSELLA PARINI;ENRICO MARIA POGLIANI;CARLO FERRARESE;F BRIVIO;ANTONIO VINCENTI;ANDRÉA STELLA;COSTANTINO MANGIONI;FRANCESCA CROSTI;GIUSEPPE CITERIO;LUCA FUMAGALLI;LUCIO TREMOLIZZO;MIRIAM RIGOLDI;PAOLO LISSONI;PIETRO PIOLTELLI;SIMONETTA GENOVESI;GIOVANNI MESSINA;GIUSEPPE FOTI;MASSIMO POZZI;MATTEO PARMA","12;9;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3","MEDICINE;BIOLOGY;MATHEMATICS;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;ENGINEERING;HISTORY;PHILOSOPHY;MATERIALS SCIENCE;POLITICAL SCIENCE","115;31;10;8;5;5;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GASTROENTEROLOGY;CARDIOLOGY;GENETICS;IMMUNOLOGY;ANESTHESIA;ONCOLOGY;ENDOCRINOLOGY;RADIOLOGY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;PSYCHIATRY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;PEDIATRICS;STATISTICS;ANATOMY;CANCER RESEARCH;NEUROSCIENCE;PALEONTOLOGY;VIROLOGY","95;31;24;21;20;19;19;18;16;13;13;11;10;10;10;9;8;8;5;4;4;4;4;4","CANCER;GENE;CHEMOTHERAPY;DISEASE;BLOOD PRESSURE;POPULATION;MALIGNANCY;RANDOMIZED CONTROLLED TRIAL;IMMUNE SYSTEM;LOGISTIC REGRESSION;TRANSPLANTATION;ADVERSE EFFECT;PROSPECTIVE COHORT STUDY;RECEIVER OPERATING CHARACTERISTIC;CLINICAL TRIAL;CONFIDENCE INTERVAL;NEUROINTENSIVE CARE;RECEPTOR;ANESTHESIOLOGY;DIABETES MELLITUS;HEART FAILURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IN VITRO;LYMPHOCYTE;MYOCARDIAL INFARCTION;ODDS RATIO;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY);STEM CELL;TRAUMATIC BRAIN INJURY","24;14;12;12;11;9;8;8;7;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","COLORECTAL CANCER;MUTATION;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;VIRAL LOAD;CD8;CLINICAL ENDPOINT;EJECTION FRACTION;LYMPHOCYTOPENIA;NEUTROPENIA;T CELL;ADNEXAL DISEASES;CHEMOTHERAPY REGIMEN;CISPLATIN;FABRY DISEASE;GEMCITABINE;GENE EXPRESSION;LYMPHADENECTOMY;PAIN MEDICINE;TOLERABILITY;UNIVARIATE ANALYSIS","6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;ABSOLUTE NEUTROPHIL COUNT;BAROREFLEX;IRINOTECAN;RNA SPLICING;TRAB;ACUTE LYMPHOCYTIC LEUKEMIA;ALPHA-GALACTOSIDASE;BIFIDOBACTERIUM;BRADYCARDIA;BRONCHUS;BUSULFAN;CAPECITABINE;CD23;CEREBRAL AUTOREGULATION;CERVICAL INTRAEPITHELIAL NEOPLASIA;CETUXIMAB;CHEMOIMMUNOTHERAPY;CHROMATID;CHROMOSOME SEGREGATION;COLD PRESSOR TEST;DASATINIB;DEOXYCYTIDINE;ELISPOT;ERLOTINIB;EXCITOTOXICITY;FERROPORTIN;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;FOLATE RECEPTOR;FRONTOTEMPORAL DEMENTIA;GAMMA SUBUNIT;GENE EXPRESSION PROFILING;HEART RATE VARIABILITY;HPV INFECTION;HYPERGLYCINEMIA;IL-2 RECEPTOR;IMATINIB MESYLATE;INTERATRIAL SEPTUM;KARYOTYPE;KETOACIDOSIS;KILLIP CLASS;LEBER'S HEREDITARY OPTIC NEUROPATHY;LENTIVIRUS;METABOTROPIC GLUTAMATE RECEPTOR;METASTATIC TUMOR;MISSENSE MUTATION;MITOCHONDRIAL ENCEPHALOMYOPATHY;MITOCHONDRIAL MYOPATHY;MYOEPITHELIOMA;NILOTINIB;PAPILLOMAVIRIDAE;PEMETREXED;POINT MUTATION;PORTAL VENOUS PRESSURE;PRIMARY TUMOR;PROTEIN CARBONYLATION;RADICAL VULVECTOMY;REPORTER GENE;RIBAVIRIN;SEVERE SEPSIS;SUBACUTE THYROIDITIS;TAU PROTEIN;TRANSFERRIN SATURATION;VARIABLE NUMBER TANDEM REPEAT;VENOUS THROMBOEMBOLIC DISEASE;VINCRISTINE;VINORELBINE;VULVECTOMY;WAIST-TO-HEIGHT RATIO","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FIBROBLASTS;RNA, MESSENGER;CARCINOMA, NON-SMALL-CELL LUNG;ITALY;LUNG NEOPLASMS;TREATMENT OUTCOME;BRAIN INJURIES;MUTATION;CARDIOVASCULAR DISEASES;CHILD;FABRY DISEASE;PROSPECTIVE STUDIES","84;63;58;44;42;39;35;17;16;15;12;12;12;12;11;11;10;10;10;10","GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS","12;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","TUMOR MODELS;POSITIVE END-EXPIRATORY PRESSURE;CLINICAL ENDPOINT;HYPERTENSION;LYMPHOCYTOPENIA;NEUROINTENSIVE CARE;ADNEXAL DISEASES;ADNEXAL MASS;ARRHYTHMIAS;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY;CHEMOTHERAPY REGIMEN;HEART RATE VARIABILITY;HIV;INTRACRANIAL PRESSURE;LYMPHADENECTOMY;NONINVASIVE VENTILATION;RADIOTHERAPY;REGIMEN;RELAPSE RISK","10;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CANCER PATIENTS;ADNEXAL MASSES;OC PROSPECTIVE;ATRIAL FIBRILLATION;BRAIN INJURY;GENE EXPRESSION;HEART RATE;HEMATOPOIETIC STEM;LUNG CANCER;PREDICTS RESPONSE;STEM CELL;TRAUMATIC BRAIN;ACUTE LYMPHOBLASTIC;BRAIN IRRADIATION-INDUCED;BRAIN METASTASES;CELL LUNG;CELL TRANSPLANTATION;CIRRHOTIC PATIENTS;GLUTAMATE TRANSPORT;HEPATOCELLULAR CARCINOMA;IMMUNE STATUS;IMPROVES NEUTROPENIA;INTERVAL PROLONGATION;IRON OVERLOAD;IRRADIATION-INDUCED LYMPHOCYTOSIS;LYMPHOBLASTIC LEUKEMIA;LYMPHOCYTOSIS PREDICTS;MASSES PRIOR;MATHEMATICAL MODELS;MULTICENTER STUDY","8;6;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PATTERN RECOGNITION;MG KG;SCORING SYSTEM;SIMPLE RULES;BLOOD PRESSURE;MM HG;RESCUE ANALGESIA;IRON OVERLOAD;OVARIAN TUMOR;ADNEXAL MASSES;CD T-CELL;CELL TRANSPLANTATION;INTERNATIONAL OVARIAN;LOGISTIC REGRESSION;STEM CELL;TUMOR ANALYSIS;ECTODERMAL DYSPLASIA;REGRESSION MODELS;TRANSPLANT-RELATED MORTALITY;BRAIN METASTASES;CARDIOGENIC SHOCK;ECTODERMAL DYSPLASIAS;HEPATIC IRON;INTENSIVE CARE;IOTA PHASE;MG KG-;PACO MMHG;PELVIC SYSTEMATIC;PRIMARY INVASIVE;PULMONARY ARTERY","13;12;11;10;9;9;9;8;8;7;7;7;7;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5",18,0.14,5.25,1.75,0,1,0,3,2.25,0,1,1.75,0,1,1,0,1,1,1,1,0,0,0,70,70,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,5.05,387.4,12.78,6,0.26,58.61,0,0,3,1,14,0,2,3,0,20,0,0,0,0,0,0,0,18,5,0,20,3,0,0,0,0,0,0,0,0,"Italy;United States;Germany;Australia","4;4;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4204 MIDWIFERY","23;10;7;5;3;3;3;2;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;HEMATOLOGY;BIOTECHNOLOGY;NEUROSCIENCES;AGING;BRAIN DISORDERS;CHRONIC PAIN;DIGESTIVE DISEASES;PAIN RESEARCH;PREVENTION;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD)","19;17;10;7;7;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2","CANCER;INFECTION;CARDIOVASCULAR;NEUROLOGICAL;BLOOD;GENERIC HEALTH RELEVANCE;REPRODUCTIVE HEALTH AND CHILDBIRTH","9;3;2;2;1;1;1","6.1 PHARMACEUTICALS;6.4 SURGERY;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;7.3 MANAGEMENT AND DECISION MAKING","15;5;4;1;1;1","LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;OVARIAN CANCER;CERVICAL CANCER;ENDOMETRIAL CANCER;HODGKIN'S DISEASE;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","4;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","8;3;2;1",1,1780000,222500,4,8,6,1,4,55625,2.24719101123596,"AZIENDA OSPEDALIERA SAN GERARDO;INSTITUT CATALÀ DE LA SALUT;KAUNAS UNIVERSITY OF TECHNOLOGY;NHS GREATER GLASGOW AND CLYDE;PERA (UNITED KINGDOM);UNIVERSITY HOSPITAL HEIDELBERG;UNIVERSITY OF GLASGOW;UPPSALA UNIVERSITY","1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP - COLLABORATIVE PROJECT (GENERIC) (FUNDING SCHEME);FP7-ICT - SPECIFIC PROGRAMME ""COOPERATION"": INFORMATION AND COMMUNICATION TECHNOLOGIES (PROGRAMME);FP7-ICT-2007-1 (CALL FOR PROPOSAL)","1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES","1;1;1","CARDIOVASCULAR","1","GENERIC HEALTH RELEVANCE","1",NA,NA,NA,NA,NA,NA,"B12 ENGINEERING","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2009,95,10.0421052631579,1.93684210526316,0.28421052631579,0.28421052631579,0.431578947368421,1.35555555555556,1.03846153846154,1.17391304347826,1.13888888888889,0.347368421052632,3,48,18,12,15,0.51,0.19,0.13,0.16,41.71,0.901594630078312,NA,0.221052631578947,0.852631578947368,0.427,0.351,0.337,0.35,"PAOLO PERSEGHIN;ANDREA BIONDI;ROSSELLA PARINI;GIUSEPPE CITERIO;LEDA DALPRÀ;ANTONIO PESENTI;ETTORE BIAGI;MARIA PICCHIO;ELENA DE PONTI;GIUSEPPE FOTI;ALESSANDRO RAMBALDI;MATTEO PARMA;GIAMPIERO GIOVACCHINI;ADRIANA BALDUZZI;GIOVANNA D’AMICO;ENRICO MARIA POGLIANI;ENRICO POGLIANI;ERICA DANDER;SANDRO SIRONI;LUIGI GIANOLLI","7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3","GIUSEPPE CITERIO;FLORIAN FISCHER;VIGANÒ;NULL AUTHOR_ID;FABIO PAGNI;PABLO INGELMO;PAOLO TAGLIABUE;ANA FUERTES ZÀRATE;ANTONIO PESENTI;ETTORE BEGHI;MARIA PICCHIO;GIAMPIERO GIOVACCHINI;GIUSEPPE FOTI;ROSSELLA PARINI;C. MESSA;PAOLO PERSEGHIN;CARLO FERRARESE;LUCIO TREMOLIZZO;VALENTINA BOZZETTI;FRANCESCA ANGIERO","1.2;1;1;1;0.77;0.69;0.67;0.67;0.66;0.64;0.61;0.61;0.58;0.55;0.51;0.51;0.5;0.5;0.5;0.5","PAOLO PERSEGHIN;ANDREA BIONDI;ROSSELLA PARINI;GIUSEPPE CITERIO;LEDA DALPRÀ;ANTONIO PESENTI;ETTORE BIAGI;ELENA DE PONTI;GIUSEPPE FOTI;MATTEO PARMA;ADRIANA BALDUZZI;ENRICO MARIA POGLIANI;ENRICO POGLIANI;SANDRO SIRONI;CARLO FERRARESE;FABIO PAGNI;ROBERTO FUMAGALLI;PABLO INGELMO;LUCIO TREMOLIZZO;PIETRO PIOLTELLI","7;6;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","GIUSEPPE CITERIO;FLORIAN FISCHER;VIGANÒ;NULL AUTHOR_ID;FABIO PAGNI;PABLO INGELMO;PAOLO TAGLIABUE;ANTONIO PESENTI;ETTORE BEGHI;GIUSEPPE FOTI;ROSSELLA PARINI;C. MESSA;PAOLO PERSEGHIN;CARLO FERRARESE;LUCIO TREMOLIZZO;VALENTINA BOZZETTI;FRANCESCA ANGIERO;ELENA DE PONTI;LEDA DALPRÀ;SANDRO SIRONI","1.2;1;1;1;0.77;0.69;0.67;0.66;0.64;0.58;0.55;0.51;0.51;0.5;0.5;0.5;0.5;0.49;0.48;0.47","PAOLO PERSEGHIN;ADRIANA BALDUZZI;ELENA DE PONTI;ROSSELLA PARINI;ANDREA BIONDI;ETTORE BIAGI;MATTEO PARMA;FAUSTA BRAMBILLASCA;MARIA GABRIELLA MEROLA;RUBENS FADINI;MARIO MIGNINI RENZINI;MB DAL CANTO;R COMI;ROBERTO FUMAGALLI;RODOLFO MILANI;LEDA DALPRÀ;GIOVANNA D’AMICO;ATTILIO ROVELLI;ADELE SANNA;ANDREA BACIGALUPO","476;421;324;323;304;304;298;285;285;285;283;283;283;266;262;250;240;234;225;225","PAOLO PERSEGHIN;ELENA DE PONTI;ADRIANA BALDUZZI;ROBERTO FUMAGALLI;MATTEO PARMA;ROSSELLA PARINI;PAOLO TAGLIABUE;ANTONIO ARDIZZOIA;G GARDANI;LEDA DALPRÀ;A. VINCENTI;A CAPRA;FOSCA QUARTI‐TREVANO;RAFFAELLA DELL’ORO;RITA FACCHETTI;ROBERTO SEGA;GIUSEPPE CITERIO;ENRICO MARIA POGLIANI;VALENTINA BOZZETTI;PIERLUIGI RUSSO","476;324;225;219;213;212;181;173;173;170;169;163;163;163;163;163;156;137;122;111","PAOLO PERSEGHIN;ENRICO POGLIANI;GIUSEPPE CITERIO;ROSSELLA PARINI;ELENA DE PONTI;ENRICO MARIA POGLIANI;CARLO FERRARESE;GIUSEPPE FOTI;LEDA DALPRÀ;LUCIO TREMOLIZZO;MATTEO PARMA;PABLO INGELMO;ANDREA GORI;ANNA CAPPELLINI;ANTONIO PESENTI;C. MESSA;DANIELA BELOTTI;DANIELE GRIONI;FABIO PAGNI;FRANCESCA ANGIERO","8;5;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;GEOLOGY;HISTORY;MATERIALS SCIENCE","92;35;10;7;6;5;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;IMMUNOLOGY;GASTROENTEROLOGY;PATHOLOGY;ANESTHESIA;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;PEDIATRICS;RADIOLOGY;CARDIOLOGY;CELL BIOLOGY;ONCOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY;ENVIRONMENTAL HEALTH;ANDROLOGY;BIOCHEMISTRY;GYNECOLOGY","63;24;20;15;14;14;12;10;9;9;9;8;8;8;7;7;6;5;5;5","DISEASE;GENE;CANCER;CHEMOTHERAPY;TRANSPLANTATION;BONE MARROW;POPULATION;STEM CELL;IN VITRO;PLATELET;POSITRON EMISSION TOMOGRAPHY;RECEPTOR;BLOOD PRESSURE;COHORT;CONCOMITANT;IMMUNE SYSTEM;MECHANICAL VENTILATION;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY)","16;13;11;9;9;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4","MUTATION;CHROMOSOME;ENZYME REPLACEMENT THERAPY;CUMULATIVE INCIDENCE;GRAFT-VERSUS-HOST DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INDUCTION CHEMOTHERAPY;PHENOTYPE;PROSTATE CANCER;ALLELE;BREAST CANCER;CD34;CHROMOSOMAL TRANSLOCATION;CISPLATIN;CRYOPRESERVATION;ED50;FERTILITY;FLUORODEOXYGLUCOSE;HEPCIDIN;ISCHEMIC STROKE;LEFT VENTRICULAR HYPERTROPHY;LEVOBUPIVACAINE;MEDIAN FOLLOW-UP;METASTASIS;MUTANT;OOCYTE;PHASES OF CLINICAL RESEARCH;POTENCY;PROGENITOR CELL;PROSTATE;REMIFENTANIL;T CELL;THROMBOTIC THROMBOCYTOPENIC PURPURA","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","KARYOTYPE;CYTOGENETICS;FERROPORTIN;FERTILITY PRESERVATION;MISSENSE MUTATION;MUCOPOLYSACCHARIDOSIS TYPE II;PROBAND;ACETABULAR LABRUM;ACUTE LYMPHOCYTIC LEUKEMIA;ADAMANTINOMA;ADAMTS13;ADIPONECTIN;ALPHA-GALACTOSIDASE;AMNIOTIC FLUID;ANTIRETROVIRAL THERAPY;BARORECEPTOR;BAROREFLEX;BREAKPOINT;CASPOFUNGIN;COMPARATIVE GENOMIC HYBRIDIZATION;CORONAVIRUS DISEASE 2019 (COVID-19);DYSTROGLYCAN;ECHINOCANDIN;EMBOLIC STROKE;EMBRYO CRYOPRESERVATION;GENETIC HETEROGENEITY;GENOME INSTABILITY;GLYCOGEN DEBRANCHING ENZYME;HAMP;HORMONAL THERAPY;HORMONE THERAPY;IMATINIB MESYLATE;INEFFECTIVE ERYTHROPOIESIS;INTERNATIONAL PROGNOSTIC INDEX;LYMPHANGIOGENESIS;LYMPHOBLASTIC LYMPHOMA;MULTIPOTENT STEM CELL;MUTANT PROTEIN;MYOEPITHELIOMA;NAV1;OSTEOPENIA;PACHYGYRIA;PERIPHERAL T-CELL LYMPHOMA;POLYMORPHISM (COMPUTER SCIENCE);PORTAL VENOUS PRESSURE;POSACONAZOLE;PRENATAL DIAGNOSIS;PRIMARY TUMOR;PROSTATECTOMY;REPRODUCTIVE TECHNOLOGY;REVERSE TRANSCRIPTASE;SERINE PROTEASE;SEROTONIN TRANSPORTER;TRANSITIONAL CELL CARCINOMA;ZYGOTE","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;ITALY;EPILEPSY;TREATMENT OUTCOME;BRAIN;AGED, 80 AND OVER;ADOLESCENT;CHILD;CHILD, PRESCHOOL;GRAFT VS HOST DISEASE;PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;CARDIOVASCULAR DISEASES;INFANT;PROSPECTIVE STUDIES","73;43;43;34;26;24;20;18;14;13;12;11;10;10;10;10;10;9;9;9","LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MULTIPOTENT MESENCHYMAL STEM CELLS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPILEPSY AND SEIZURES;FERTILITY PRESERVATION IN CANCER PATIENTS;SALIVARY GLAND TUMORS AND CARCINOMAS;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;HEMATOPOIETIC STEM CELL BIOLOGY;IMMUNOBIOLOGY OF DENDRITIC CELLS;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ROLE OF COMPLEMENT SYSTEM IN IMMUNE RESPONSE;ROLE OF PENTRAXINS IN INNATE IMMUNITY AND INFLAMMATION;;ALARM FATIGUE IN CLINICAL MONITORING SYSTEMS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANESTHESIA AND SEDATION MANAGEMENT","6;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CONCOMITANT;CUMULATIVE INCIDENCE;ENDOSCOPIC SEDATION;EPILEPSY;HEMATOPOIETIC CELL TRANSPLANTATION;INDUCTION CHEMOTHERAPY;NONINVASIVE VENTILATION;OOCYTE MATURATION;PET IMAGING;PET/CT;CANCER;CANCER TREATMENT;CRYOPRESERVED OOCYTES;ED50;ENZYME REPLACEMENT THERAPY;EPIDURAL ANALGESIA;FERROPORTIN;FLUORODEOXYGLUCOSE;GAUCHER DISEASE;GOLD STANDARD (TEST)","4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","RANDOMIZED STUDY;PHASE II;PROSTATE CANCER;THROMBOCYTOPENIC PURPURA;ADULT PATIENTS;BREAST CANCER;CANCER PATIENTS;CCHOLINE PETCT;CONCOMITANT CHEMORADIOTHERAPY;CRITICALLY ILL;CRYOPRESERVATION COMPARISON;GLUCOSE METABOLISM;GRAFT-VERSUS-HOST DISEASE;HUMAN OOCYTE;ILL PATIENTS;INTRACRANIAL PRESSURE;ITALIAN INSTITUTIONS;MAJOR ITALIAN;MULTICENTER STUDY;NEWLY DIAGNOSED;OOCYTE CRYOPRESERVATION;PROSPECTIVE RANDOMIZED;REPLACEMENT THERAPY;RETROSPECTIVE ANALYSIS;STEM CELL;THROMBOTIC THROMBOCYTOPENIC;ABSTRACT HUMAN;ABUNDANT SOURCE;ACUTE ISCHEMIC;ACUTE KIDNEY","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","MG KG;CD CELLS;EPILEPSY SYNDROME;BUPIVACAINE LEVOBUPIVACAINE;HIV PATIENTS;LOCAL ANALGESIC;MINIMUM LOCAL;OFF-PUMP CORONARY;SPINAL ANAESTHESIA;SUDDEN DEATH;ARTERY BYPASS;BYPASS GRAFTING;CORONARY ARTERY;EXTRACORPOREAL CIRCULATION;MECHANICAL VENTILATION;MINIATURIZED EXTRACORPOREAL;RANDOMLY ALLOCATED;RELATIVE POTENCY;SEIZURE TYPES;TH- CELLS;ASCEA MARINA;CHRONIC GVHD;CI MG;CONFIDENCE INTERVAL;CULTURE CONDITIONS;GENERALIZED EPILEPSIES;INTERVAL CI;LATERAL TEMPORAL;PARTIAL EPILEPSY;PARTIAL SEIZURES","16;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4",13,0.14,4,2,1,2,1,1,12.5,0,1,2,0,1,4,0,1,0,3,2,1,0,0,86,86,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,4.58,377.75,23.28,6,0.22,35.89,2,0,4,1,5,0,9,6,0,20,4,0,0,0,0,0,0,23,3,1,24,3,0,0,0,0,0,0,0,0,"Italy;United States","10;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;42 HEALTH SCIENCES;3009 VETERINARY SCIENCES;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","26;10;8;6;5;3;3;2;2;2;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;HEMATOLOGY;BRAIN DISORDERS;LUNG;LYMPHOMA;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE;NEUROSCIENCES;PEDIATRIC;BEHAVIORAL AND SOCIAL SCIENCE;CHRONIC PAIN;DIGESTIVE DISEASES;GENETICS;INFECTIOUS DISEASES;ORPHAN DRUG","21;13;9;7;6;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2","CANCER;INFECTION;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","4;4;3;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;5.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;8.2 HEALTH AND WELFARE ECONOMICS","16;5;3;2;2;1;1;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;LEUKEMIA / LEUKAEMIA;BREAST CANCER;COLON AND RECTAL CANCER;LUNG CANCER;MYELOMA;NOT SITE-SPECIFIC CANCER","7;3;3;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","7;3;1;1",1,10998270,458261.25,6,24,17,1,78,132001.875,0.719686746873861,"AZIENDA OSPEDALIERA SAN GERARDO;BRUKER (GERMANY);EUROPEAN RESPIRATORY SOCIETY;FINNISH INSTITUTE FOR HEALTH AND WELFARE;FONDAZIONE SALVATORE MAUGERI;FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS;HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO;INSTITUT SCIENTIFIQUE DE SANTÉ PUBLIQUE;INSTITUTE OF TROPICAL MEDICINE ANTWERP;INSTITUTUL DE PNEUMOFTIZIOLOGIE ""MARIUS NASTA"";INSTYTUT GRUŹLICY I CHORÓB PŁUC;IRCCS OSPEDALE SAN RAFFAELE;NORWEGIAN INSTITUTE OF PUBLIC HEALTH;PASTEUR INSTITUTE OF LILLE;PUBLIC HEALTH AGENCY OF SWEDEN;QUEEN MARY UNIVERSITY OF LONDON;RESEARCH CENTER BORSTEL - LEIBNIZ LUNG CENTER;RIGA EAST UNIVERSITY HOSPITAL;RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY;STATENS SERUM INSTITUT","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2007-B (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1","ANTIMICROBIAL RESISTANCE;HIV/AIDS;INFECTIOUS DISEASES;RARE DISEASES;TUBERCULOSIS","1;1;1;1;1","INFECTION","1",NA,NA,NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,9,"PUBLIC LIBRARY OF SCIENCE","9","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;49 MATHEMATICAL SCIENCES","14;7;7;2;2;2;2;1","GENETICS;CLINICAL RESEARCH;HIV/AIDS;HUMAN GENOME;AUTOIMMUNE DISEASE;BIOTECHNOLOGY;BRAIN DISORDERS;INFECTIOUS DISEASES;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;PREVENTION","6;3;3;3;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;INFECTION","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","4","BIOMEDICAL;CLINICAL","1;1","BASIC SCIENCE","2",NA,NA,NA,NA
"IRCCS_SANGERARDO",2010,99,10.3636363636364,2.23232323232323,0.353535353535354,0.252525252525253,0.565656565656566,1.39873417721519,1.09375,1.13636363636364,1.14285714285714,0.383838383838384,5,54,15,15,7,0.55,0.15,0.15,0.07,44.87,0.992876686741746,NA,0.272727272727273,0.828282828282828,0.432,0.309,0.388,0.392,"ANDREA BIONDI;ANTONIO PESENTI;NICOLÒ PATRONITI;GIUSEPPE MANCIA;ENRICO MARIA POGLIANI;PAOLO TAGLIABUE;ALESSANDRO RAMBALDI;SONIA BONANOMI;ROSSELLA PARINI;GIACOMO BELLANI;MARIA PICCHIO;ATTILIO ROVELLI;ALBERTO ZANELLA;GIUSEPPE FOTI;STEFANO ISGRÒ;ANDREA GORI;PAOLO PERSEGHIN;ADRIANA BALDUZZI;GIOVANNA LUCCHINI;GIUSEPPE CITERIO","8;8;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","FRANCESCA BONO;VALENTINA BOZZETTI;ANTONIO PESENTI;PAOLO TAGLIABUE;ENNIO COCCO;G GRASSI;NICOLÒ PATRONITI;ROSSELLA PARINI;PAOLO PERSEGHIN;GIUSEPPE MANCIA;ANDREA BIONDI;GIUSEPPE FOTI;GIUSEPPE PATERLINI;GIACOMO BELLANI;ALBERTO ZANELLA;STEFANO ISGRÒ;A BATTAN;ARIANNA INCONTRI;M. AZZOLINI;CLOTILDE FARINA","2.5;1.33;1.01;1.01;1;1;0.81;0.66;0.66;0.64;0.57;0.55;0.54;0.51;0.5;0.5;0.5;0.5;0.5;0.5","ANDREA BIONDI;ANTONIO PESENTI;NICOLÒ PATRONITI;GIUSEPPE MANCIA;ENRICO MARIA POGLIANI;PAOLO TAGLIABUE;SONIA BONANOMI;ROSSELLA PARINI;GIACOMO BELLANI;MARIA PICCHIO;ATTILIO ROVELLI;ALBERTO ZANELLA;GIUSEPPE FOTI;STEFANO ISGRÒ;ANDREA GORI;PAOLO PERSEGHIN;ADRIANA BALDUZZI;GIOVANNA LUCCHINI;GIUSEPPE CITERIO;CRISTINA MESSA","8;8;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","FRANCESCA BONO;VALENTINA BOZZETTI;ANTONIO PESENTI;PAOLO TAGLIABUE;ENNIO COCCO;G GRASSI;NICOLÒ PATRONITI;ROSSELLA PARINI;PAOLO PERSEGHIN;GIUSEPPE MANCIA;ANDREA BIONDI;GIUSEPPE FOTI;GIUSEPPE PATERLINI;GIACOMO BELLANI;ALBERTO ZANELLA;STEFANO ISGRÒ;A BATTAN;ARIANNA INCONTRI;M. AZZOLINI;CLOTILDE FARINA","2.5;1.33;1.01;1.01;1;1;0.81;0.66;0.66;0.64;0.57;0.55;0.54;0.51;0.5;0.5;0.5;0.5;0.5;0.5","ANNELIES E. BERDEN;CHARLES D. PUSEY;DAVID JAYNE;E. CHRISTIAAN HAGEN;FRANCO FERRARIO;INGEBORG M. BAJEMA;IRMGARD NEUMANN;J. CHARLES JENNETTE;JAN A. BRUIJN;KENSUKE JOH;LAURE-HÉLÈNE NOËL;RÜDIGER WALDHERR;SONIA BONANOMI;ALESSANDRO RAMBALDI;NICOLÒ PATRONITI;ANDREA ALBERTO LISSONI;BENGT SORBE;BENGT THOLANDER;CARLOS OLIVEIRA;CAROLINE LUNDGREN","775;775;775;775;775;775;775;775;775;775;775;775;590;492;461;446;439;439;439;439","FRANCO FERRARIO;ANDREA ALBERTO LISSONI;ANTONIO PESENTI;ENRICO MARIA POGLIANI;NICOLÒ PATRONITI;SONIA BONANOMI;A. REDAELLI;PAOLO PERSEGHIN;ROSSELLA PARINI;GIUSEPPE MANCIA;ROBERTO FUMAGALLI;GIACOMO BELLANI;CRISTINA MESSA;ANDREA COPPADORO;TOMMASO MAURI;BARBARA FRIGENI;MANUELA MILAN;MARCO GRIMALDI;E. DAPRETTO;EMANUELA SUSANI","775;446;315;309;304;293;204;196;167;156;156;150;149;145;145;135;122;116;103;101","ANTONIO PESENTI;PAOLO TAGLIABUE;ROSSELLA PARINI;ENRICO MARIA POGLIANI;GIUSEPPE CITERIO;PAOLO PERSEGHIN;NICOLÒ PATRONITI;ANDREA GORI;FRANCESCA BONO;GIUSEPPE FOTI;PABLO INGELMO;STEFANO ISGRÒ;GIUSEPPE PATERLINI;ALBERTO ZANELLA;ANDREA ALBERTO LISSONI;ANDREA BIONDI;ANDRÉA STELLA;BARBARA FRIGENI;CARLO FERRARESE;CRISTINA MESSA","5;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;COMPUTER SCIENCE;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY;MATERIALS SCIENCE;MATHEMATICS;SOCIOLOGY;ART;GEOGRAPHY;PHILOSOPHY","95;27;8;7;5;4;4;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;ANESTHESIA;SURGERY;PATHOLOGY;GENETICS;INTENSIVE CARE MEDICINE;CARDIOLOGY;PEDIATRICS;BIOCHEMISTRY;IMMUNOLOGY;GASTROENTEROLOGY;RADIOLOGY;ENDOCRINOLOGY;PHARMACOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;PSYCHIATRY;VIROLOGY;CANCER RESEARCH;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;NURSING","69;20;20;17;15;14;13;13;12;12;11;10;8;8;7;7;7;7;6;5;5;5","CANCER;GENE;DISEASE;BLOOD PRESSURE;CHEMOTHERAPY;LUNG;POPULATION;TRANSPLANTATION;IMMUNE SYSTEM;LEUKEMIA;EXTRACORPOREAL MEMBRANE OXYGENATION;HEALTH CARE;HEART FAILURE;IN VITRO;LYMPH NODE;MALIGNANCY;MECHANICAL VENTILATION;MYOCARDIAL INFARCTION;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;STEM CELL;VENTILATION (ARCHITECTURE);VIRUS","14;10;9;8;7;7;7;7;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;T CELL;CYTARABINE;ENZYME REPLACEMENT THERAPY;GENOTYPE;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;SEPTIC SHOCK;ALLELE;ANGIOTENSIN-CONVERTING ENZYME;B CELL;BRONCHOALVEOLAR LAVAGE;CARDIOGENIC SHOCK;CD34;CD8;CHROMOSOME;CYTOTOXIC T CELL;EJECTION FRACTION;ENDOMETRIAL CANCER;GESTATIONAL AGE;GRAFT-VERSUS-HOST DISEASE;IMATINIB;MINIMAL RESIDUAL DISEASE;MUTATION;OVARIAN CANCER;PLACEBO;PROSTATE CANCER;PULSE WAVE VELOCITY;RETINOIC ACID;TRACHEAL TUBE;TYPE 2 DIABETES;VIREMIA","4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IDARUBICIN;ACUTE PROMYELOCYTIC LEUKEMIA;ANTHRACYCLINE;BAROREFLEX;COMPOUND HETEROZYGOSITY;IMATINIB MESYLATE;PROSTATE-SPECIFIC ANTIGEN;ACHÉ;ACUTE LYMPHOCYTIC LEUKEMIA;ADJUVANT CHEMOTHERAPY;ADOPTIVE CELL TRANSFER;AEDES ALBOPICTUS;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEPRIVATION THERAPY;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ANTIRETROVIRAL THERAPY;ARTIFICIAL VENTILATION;ATRIAL ACTION POTENTIAL;B-CELL ACTIVATING FACTOR;BLADDER NEOPLASM;BRONCHOPULMONARY DYSPLASIA;CD23;CD28;CD38;CHEMOKINE RECEPTOR;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;CHIMERIC ANTIGEN RECEPTOR;CHORIOAMNIONITIS;CORONAVIRUS DISEASE 2019 (COVID-19);CRIZOTINIB;DASATINIB;DOPAMINE TRANSPORTER;ELISPOT;ENALAPRIL;ERLOTINIB;ESOPHAGEAL VARICES;FABRY'S DISEASE;FLUORESCENCE IN SITU HYBRIDIZATION;FOSINOPRIL;FRUCTOSE-BISPHOSPHATE ALDOLASE;GENE EXPRESSION PROFILING;GLYCOGEN STORAGE DISEASE TYPE II;GYNECOLOGIC CANCER;HETEROZYGOTE ADVANTAGE;HISTONE DEACETYLASE;IGFBP3;IRINOTECAN;JC VIRUS;KARYOTYPE;LEUKAPHERESIS;LOSS OF HETEROZYGOSITY;MICROARRAY ANALYSIS TECHNIQUES;MICROHEMATURIA;MISSENSE MUTATION;MOLECULAR EPIDEMIOLOGY;MONOAMINE NEUROTRANSMITTER;NILOTINIB;OVARIAN TUMOR;OXALIPLATIN;PAX5;PEAK INSPIRATORY PRESSURE;POINT MUTATION;PRIMARY TUMOR;PROSTATE DISEASE;PROSTATECTOMY;RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS;RESPIRATORY RATE;TRANSFERRIN SATURATION;TRANSITIONAL CELL CARCINOMA;UNDERWEIGHT;USUAL INTERSTITIAL PNEUMONIA;VECTOR (MOLECULAR BIOLOGY);VINCRISTINE","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;ADULT;AGED;HIV INFECTIONS;CHILD;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;RESPIRATORY INSUFFICIENCY;ADOLESCENT;BIOMARKERS;HEART FAILURE;HYPOXIA;LUNG NEOPLASMS;PROSTATIC NEOPLASMS;RESPIRATION, ARTIFICIAL;TREATMENT OUTCOME","59;44;40;37;34;26;25;13;12;10;10;10;9;8;8;8;8;8;8;8","NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GYNECOLOGIC ONCOLOGY;HEMATOPOIETIC STEM CELL BIOLOGY;IMPACT OF HIV INFECTION ON CARDIOVASCULAR HEALTH;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;NEONATAL BRAIN INJURY AND DEVELOPMENTAL CONSEQUENCES;ROLE OF RETINOIC ACID IN BIOLOGICAL PROCESSES;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1","POSITIVE END-EXPIRATORY PRESSURE;EXTRACORPOREAL MEMBRANE OXYGENATION;PRETERM INFANTS;BOLUS (DIGESTION);ENZYME REPLACEMENT THERAPY;HIV;IDARUBICIN;IMMUNOSUPPRESSION;TREATMENT OUTCOMES;ACUTE PROMYELOCYTIC LEUKEMIA;ADJUVANT CHEMOTHERAPY;ANTIRETROVIRAL THERAPY;BAROREFLEX SENSITIVITY;CARDIAC SUPPORT DEVICE;COMPOUND HETEROZYGOSITY;EPIDURAL ANALGESIA;EXTRACORPOREAL;FETAL LUNG DEVELOPMENT;GRAFT-VERSUS-HOST DISEASE;HIGH-FLOW OXYGEN THERAPY","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","NORTHERN ITALY;PRETERM INFANTS;STEM CELL;ACUTE PROMYELOCYTIC;ADULT PATIENTS;BLOOD PRESSURE;CELL LINES;CELL TRANSPLANTATION;ENDOMETRIAL CANCER;ENZYME REPLACEMENT;EXTRACORPOREAL LIFE;EXTRACORPOREAL MEMBRANE;INTENSIVE CARE;ITALY LEUKEMIA;LATE PRETERM;LIFE SUPPORT;MEMBRANE OXYGENATION;PATIENTS FAILING;PERITONEAL DIALYSIS;PROMYELOCYTIC LEUKEMIA;PROSTATE CANCER;REPLACEMENT THERAPY;RESPIRATORY FAILURE;SYNDROME PATIENTS;ACCUMULATION RATE;ACID ASPIRATION;ACUTE ANTERIOR;ACUTE HYPOXIC;ACUTE LIFE;ACUTE LYMPHOBLASTIC","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","BLOOD PRESSURE;AIDS PATIENTS;PEEP CMHO;OXYGEN CONSUMPTION;CKD STAGE;RENAL DAMAGE;SUBJECTIVE EVALUATION;EPIDURAL INFUSION;NEUROLOGICAL OUTCOME;REPLACEMENT THERAPY;ANTIHYPERTENSIVE TREATMENT;BLOOD LACTATE;BP MMHG;CM HO;ENDOMETRIAL CANCER;FLUID LEAKAGE;GUAYULE LATEX;INTENSIVE CARE;LUNG VOLUME;MRI LESIONS;NEWLY DIAGNOSED;PRESSURE SUPPORT;PVC CUFFS;ADULT CARDIAC;CANCER PATIENTS;CARDIAC PATIENTS;CARDIOVASCULAR EVENTS;CENTRAL BP;CEREBRAL LESIONS;CHRONIC HYPOXIA","10;8;8;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3",15,0.15,5.62,6.5,2,1,0,0,6,0,1,6.5,0,1,6.5,0,1.75,1,1.5,8,1.25,0,0,137,115,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,4.92,1105.21,13.19,3,0.16,60.84,0,0,3,1,9,0,2,4,0,10,4,0,0,0,0,0,0,15,3,1,13,5,0,1,0,0,0,0,0,0,"Italy;United States;France;Spain","6;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;39 EDUCATION;3904 SPECIALIST STUDIES IN EDUCATION;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","18;10;5;3;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LUNG;PEDIATRIC;CHRONIC PAIN;GENETICS;OVARIAN CANCER;PAIN RESEARCH;PATIENT SAFETY;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BIOTECHNOLOGY;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;DIGESTIVE DISEASES;INFECTIOUS DISEASES;LUNG CANCER","12;10;8;6;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;INFECTION;NEUROLOGICAL;INFLAMMATORY AND IMMUNE SYSTEM;INJURIES AND ACCIDENTS","4;2;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","11;3;2;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;OVARIAN CANCER;NON-HODGKIN'S LYMPHOMA;SARCOMA;STOMACH CANCER","2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","4;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,"PUBLIC LIBRARY OF SCIENCE","7","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;38 ECONOMICS;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;44 HUMAN SOCIETY;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY;3105 GENETICS;3210 NUTRITION AND DIETETICS;3215 REPRODUCTIVE MEDICINE;3801 APPLIED ECONOMICS;4403 DEMOGRAPHY","6;3;2;2;2;2;2;2;1;1;1;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;GENETICS;HUMAN GENOME;HYPERTENSION;KIDNEY DISEASE;PREVENTION","1;1;1;1;1;1;1","CARDIOVASCULAR","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE","3",NA,NA,NA,NA
"IRCCS_SANGERARDO",2011,130,11.7307692307692,2.78461538461538,0.292307692307692,0.223076923076923,0.469230769230769,1.3457249070632,1.05555555555556,1.26086956521739,1.10909090909091,0.369230769230769,0,65,36,12,12,0.5,0.28,0.09,0.09,28.76,0.676196558230708,NA,0.346153846153846,0.923076923076923,0.484,0.382,0.408,0.411,"ANTONIO PESENTI;NICOLÒ PATRONITI;ROSSELLA PARINI;GIUSEPPE MANCIA;GIACOMO BELLANI;GIUSEPPE FOTI;MICHELA BOMBINO;CARLO FERRARESE;CARLO GAMBACORTI‐PASSERINI;ROBERTO FUMAGALLI;PAOLO TAGLIABUE;GUIDO GRASSI;STEFANO ISGRÒ;FRANCESCA CESANA;ROCCO PIAZZA;ANDREA BIONDI;CRISTINA GIANNATTASIO;ENRICO MARIA POGLIANI;LUCA GUERRA;ATTILIO ROVELLI","11;10;9;8;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4","ANTONIO PESENTI;NICOLÒ PATRONITI;GIACOMO BELLANI;CARLO FERRARESE;GIUSEPPE FOTI;GIUSEPPE MANCIA;ROBERTO FUMAGALLI;MICHELA BOMBINO;PAOLO TAGLIABUE;STEFANO ISGRÒ;ROSSELLA PARINI;LUCIO TREMOLIZZO;GIACOMO GRASSELLI;CARLO GAMBACORTI‐PASSERINI;ALBERTO ZANELLA;ILDEBRANDO APPOLLONIO;PIETRO CAIRONI;ROCCO PIAZZA;TOMMASO MAURI;SANDRO SIRONI","1.38;1.29;1.23;0.97;0.91;0.78;0.76;0.75;0.69;0.69;0.68;0.64;0.55;0.53;0.52;0.5;0.5;0.49;0.48;0.47","ANTONIO PESENTI;NICOLÒ PATRONITI;ROSSELLA PARINI;GIUSEPPE MANCIA;GIACOMO BELLANI;GIUSEPPE FOTI;MICHELA BOMBINO;CARLO FERRARESE;CARLO GAMBACORTI‐PASSERINI;ROBERTO FUMAGALLI;PAOLO TAGLIABUE;GUIDO GRASSI;STEFANO ISGRÒ;ROCCO PIAZZA;ANDREA BIONDI;CRISTINA GIANNATTASIO;ENRICO MARIA POGLIANI;LUCA GUERRA;ATTILIO ROVELLI;ALBERTO ZANELLA","11;10;9;8;7;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4","ANTONIO PESENTI;NICOLÒ PATRONITI;GIACOMO BELLANI;CARLO FERRARESE;GIUSEPPE FOTI;GIUSEPPE MANCIA;ROBERTO FUMAGALLI;MICHELA BOMBINO;PAOLO TAGLIABUE;STEFANO ISGRÒ;ROSSELLA PARINI;LUCIO TREMOLIZZO;GIACOMO GRASSELLI;CARLO GAMBACORTI‐PASSERINI;ALBERTO ZANELLA;ILDEBRANDO APPOLLONIO;ROCCO PIAZZA;SANDRO SIRONI;MARIA FRANCA MELONI;GUIDO GRASSI","1.38;1.29;1.23;0.97;0.91;0.78;0.76;0.75;0.69;0.69;0.68;0.64;0.55;0.53;0.52;0.5;0.49;0.47;0.46;0.45","ROSSELLA PARINI;MARIA TERESA PETRUCCI;MARIA ALICE DONATI;ANGELO MICHELE CARELLA;ANNA MARIA CAFRO;ANTONIO PALUMBO;ARNON NAGLER;CLAUDIA CRIPPA;FEDERICA CAVALLO;FRANCESCA PATRIARCA;JACOPO PECCATORI;LUCIO CATALANO;MARIO BOCCADORO;AGOSTINA SINISCALCHI;ALESSANDRA LAROCCA;ANDREA EVANGELISTA;ANFISA STANEVSKY;ANNA FALANGA;DINA BEN YEHUDA;ELOISE BEGGIATO","675;406;378;332;332;332;332;332;332;332;332;332;332;276;276;276;276;276;276;276","ROSSELLA PARINI;SARA PEZZATTI;MARIA FRANCA MELONI;ATTILIO ROVELLI;ANTONIO PESENTI;MARIA RITA PANELLI;GIUSEPPE FOTI;GIUSEPPE CITERIO;FRANCO FERRARIO;MAURO SIGNORELLI;CAMMILLO TALEI FRANZESI;ENRICO MARIA POGLIANI;GILDA RECHICHI;PATRIZIA PEREGO;SANDRO SIRONI;ROBERTO FUMAGALLI;ALESSANDRO ROBERTO DODESINI;ANELIYA PARVANOVA;ANGELO SGHIRLANZONI;ANNA FASSI","641;276;264;222;183;164;145;127;112;112;111;111;111;111;111;105;95;95;95;95","ROSSELLA PARINI;GIUSEPPE FOTI;CARLO GAMBACORTI‐PASSERINI;MICHELA BOMBINO;ANTONIO PESENTI;CARLO FERRARESE;PAOLO TAGLIABUE;ROBERTO FUMAGALLI;GIACOMO GRASSELLI;ENRICO MARIA POGLIANI;GIORGIO BOVO;LUCIO TREMOLIZZO;MARIA FRANCA MELONI;NICOLÒ PATRONITI;STEFANO ISGRÒ;ANTONIO CIRÒ;ANTONIO VINCENTI;GIUSEPPE TROCINO;LUCA GUERRA;PAOLO PERSEGHIN","7;6;6;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;PHILOSOPHY;POLITICAL SCIENCE;ECONOMICS;SOCIOLOGY;HISTORY;GEOGRAPHY;MATERIALS SCIENCE","119;39;17;12;9;9;7;6;5;4;3;3;2;1;1","INTERNAL MEDICINE;GENETICS;SURGERY;CARDIOLOGY;RADIOLOGY;PATHOLOGY;ANESTHESIA;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;IMMUNOLOGY;OPTICS;PSYCHIATRY;BIOCHEMISTRY;EMERGENCY MEDICINE;ENDOCRINOLOGY;ANATOMY;MECHANICAL ENGINEERING;NEUROSCIENCE;VIROLOGY","88;27;27;21;20;17;16;16;14;14;10;10;10;10;9;9;9;7;7;7;7","GENE;DISEASE;BLOOD PRESSURE;CHEMOTHERAPY;LUNG;POPULATION;CANCER;TRANSPLANTATION;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;COHORT;CONFIDENCE INTERVAL;MECHANICAL VENTILATION;ODDS RATIO;RANDOMIZED CONTROLLED TRIAL;HEART FAILURE;HUMAN IMMUNODEFICIENCY VIRUS (HIV);INSULIN;OBSERVATIONAL STUDY;PREGNANCY;RESPIRATORY DISTRESS;RESPIRATORY FAILURE;RESPIRATORY SYSTEM","19;14;12;11;10;10;9;8;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5","MUTATION;ACUTE RESPIRATORY DISTRESS;GENOTYPE;ARDS;CHROMOSOME;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INSULIN RESISTANCE;NEURORADIOLOGY;CYCLOPHOSPHAMIDE;ENZYME REPLACEMENT THERAPY;EXON;IMATINIB;PHENOTYPE;VIRAL LOAD;AIRWAY RESISTANCE;ARTERIAL STIFFNESS;ATRIUM (ARCHITECTURE);BRONCHOALVEOLAR LAVAGE;CARCINOGENESIS;CD34;CHEMOTHERAPY REGIMEN;CHRONIC HEPATITIS;CROHN'S DISEASE;CUMULATIVE INCIDENCE;DEMENTIA;EJECTION FRACTION;ELECTRICAL IMPEDANCE TOMOGRAPHY;FABRY DISEASE;GESTATIONAL AGE;HEAD AND NECK CANCER;INFLAMMATORY BOWEL DISEASE;LENALIDOMIDE;MICROWAVE ABLATION;MULTICENTER STUDY;NEUTROPENIA;POSITIVE-PRESSURE RESPIRATION;RATE RATIO;RESPIRATORY DISEASE;RNA;SYMPATHETIC NERVOUS SYSTEM;TIDAL VOLUME;TYPE 1 DIABETES;TYPE 2 DIABETES;ULCERATIVE COLITIS","7;5;5;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANTIRETROVIRAL THERAPY;EXOME SEQUENCING;MISSENSE MUTATION;SINGLE-NUCLEOTIDE POLYMORPHISM;ADIPONECTIN;ANEUPLOIDY;COMPARATIVE GENOMIC HYBRIDIZATION;CYTOGENETICS;IMATINIB MESYLATE;KARYOTYPE;METHACHOLINE;PROBAND;ACUTE LYMPHOCYTIC LEUKEMIA;ADJUVANT CHEMOTHERAPY;ALTERNATIVE SPLICING;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ANTIVIRAL TREATMENT;BAROREFLEX;BILIARY ATRESIA;BLASTOCYST;BREAKPOINT;BRONCHIAL HYPERRESPONSIVENESS;CARBOPLATIN;CASPOFUNGIN;CD23;CD3;CD90;CHIMERIC ANTIGEN RECEPTOR;CLINICAL PHENOTYPE;COLONOSCOPY;CONTINUOUS GLUCOSE MONITORING;COPY-NUMBER VARIATION;CORONAVIRUS DISEASE 2019 (COVID-19);CRISTA TERMINALIS;CXCR4;DASATINIB;EMBRYO CULTURE;ESTROGEN RECEPTOR;EXCITATORY AMINO-ACID TRANSPORTER;EXENATIDE;FEBRILE NEUTROPENIA;GLIMEPIRIDE;HAPLOTYPE;HEART FAILURE WITH PRESERVED EJECTION FRACTION;INSULIN SENSITIVITY;INTEGRON;INTESTINAL ISCHEMIA;INTRAVENTRICULAR HEMORRHAGE;LEGIONNAIRES' DISEASE;MICROARRAY;MICROSCOPIC POLYANGIITIS;MILAN CRITERIA;MUCOPOLYSACCHARIDOSIS TYPE I;MUCOPOLYSACCHARIDOSIS TYPE II;NALIDIXIC ACID;NILOTINIB;PENETRANCE;PERIVENTRICULAR LEUKOMALACIA;PHILADELPHIA CHROMOSOME;PIM1;POLY ADP RIBOSE POLYMERASE;POLYMORPHISM (COMPUTER SCIENCE);PREMATURE BIRTH;PULSED-FIELD GEL ELECTROPHORESIS;RESPIRATORY RATE;RETINOPATHY OF PREMATURITY;REVERSE TRANSCRIPTASE;RNA SPLICING;SINOATRIAL NODE;SUBSTANTIA NIGRA;TAMOXIFEN;THIOPURINE METHYLTRANSFERASE;TLR2;TRASTUZUMAB;UREA CYCLE;VANCOMYCIN;VENTRICULOMEGALY;VINCRISTINE;WHITE COAT HYPERTENSION;ZYGOTE","3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;ITALY;TREATMENT OUTCOME;ADOLESCENT;CHILD;YOUNG ADULT;CHILD, PRESCHOOL;RETROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS;DIABETES MELLITUS, TYPE 2;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ATRIAL FIBRILLATION;LIVER NEOPLASMS;THALIDOMIDE","79;58;57;46;42;37;31;22;18;17;15;15;12;12;11;11;10;10;10;10","LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;EFFICACY AND RESISTANCE IN CML TREATMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF CONGENITAL HEART DISEASE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;GASTRIC CANCER RESEARCH AND TREATMENT;GENETIC BASIS OF NEUTROPENIA DISORDERS;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;HEPATOCELLULAR CARCINOMA;HISTORICAL EVOLUTION OF NEUROLOGICAL STUDIES AND DISCOVERIES;LYMPHOID NEOPLASMS;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;MULTIPOTENT MESENCHYMAL STEM CELLS;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY","6;5;5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","POSITIVE END-EXPIRATORY PRESSURE;NEURORADIOLOGY;ANTIRETROVIRAL THERAPY;CARDIAC IMAGING;EXOME;IMATINIB;INSULIN THERAPY;NONINVASIVE VENTILATION;REFRACTORY (PLANETARY SCIENCE);STEM CELL MOBILIZATION;SURGICAL ONCOLOGY;TREATMENT;TYPE 2 DIABETES;ATRIAL FIBRILLATION;ATRIUM (ARCHITECTURE);BREAST CANCER;CHEMOTHERAPY REGIMEN;CLINICAL SIGNIFICANCE;COMPARATIVE GENOMIC HYBRIDIZATION;CONCOMITANT","5;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","ACUTE RESPIRATORY;DISTRESS SYNDROME;RESPIRATORY DISTRESS;EXTRACORPOREAL MEMBRANE;HEART FAILURE;ITALIAN ASSOCIATION;MEMBRANE OXYGENATION;MULTICENTER STUDY;PATIENTS UNDERGOING;STEM CELL;ACUTE CARDIOGENIC;ACUTE LYMPHOBLASTIC;ADJUSTED VENTILATORY;ARTERIAL STIFFNESS;ATRIAL ELECTROPHYSIOLOGY;ATRIAL FIBRILLATION;BOWEL DISEASE;CARDIOGENIC PULMONARY;CELL MOBILIZATION;CELL TRANSPLANTATION;CHALLENGE TEST;CHRONIC HEPATITIS;CHRONIC MYELOID;CRITICALLY ILL;DIAGNOSED MULTIPLE;ECHOCARDIOGRAPHIC EVALUATION;EDEMA ACPE;EJECTION FRACTION;ELECTRICAL IMPEDANCE;ENZYME REPLACEMENT","6;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CR PATIENTS;CD T-CELL;INTENSIVE CARE;MSC INFUSION;ACUTE RESPIRATORY;GM GANGLIOSIDOSIS;GVHD PLASMATIC;LOW-VOLUME CENTERS;MSC INFUSIONS;NAVA LEVELS;PLASMATIC MARKERS;CELL LINE;COMBINED THERAPY;INFLAMMATORY CYTOKINES;PATIENTS UNDERGOING;RESPIRATORY DISTRESS;SDS PATIENTS;STEM CELLS;TIDAL VENTILATION;AMINO ACID;CHRONIC GVHD;DISTRESS SYNDROME;HEALTH CARE;HEALTHY DONORS;HESN INDIVIDUALS;HRQL SCORES;LYMPHOCYTE COUNTS;MECHANICAL VENTILATION;MEMBRANE OXYGENATION;PATIENTS RECEIVING","10;9;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",21,0.16,7.75,4,1,1,0,1,4,0,2,4,0,1,2,0,1.5,1,1,1,1,0,0,118,118,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4.14,190.89,11.76,3,0.1,27.2,2,0,9,0,7,0,4,8,0,21,7,0,0,0,0,0,0,26,3,1,28,2,0,0,0,0,0,0,0,0,"Italy;United States;Switzerland;Belgium;Finland;Japan;United Kingdom","8;6;3;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4204 MIDWIFERY","29;15;10;6;3;3;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;INFECTIOUS DISEASES;PREVENTION;CARDIOVASCULAR;HEART DISEASE;HEMATOLOGY;AGING;LYMPHOMA;DIGESTIVE DISEASES;HIV/AIDS;IMMUNIZATION;LUNG;PATIENT SAFETY;VACCINE RELATED;BIODEFENSE;BIOMEDICAL IMAGING;BIOTECHNOLOGY","24;15;10;9;6;6;5;5;5;4;4;3;3;3;3;3;3;2;2;2","INFECTION;CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;ORAL AND GASTROINTESTINAL;RESPIRATORY","7;6;4;2;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.4 VACCINES","15;3;2;2;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;PANCREATIC CANCER","3;3;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","8;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,"PUBLIC LIBRARY OF SCIENCE","4","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3005 FISHERIES SCIENCES;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;49 MATHEMATICAL SCIENCES;4905 STATISTICS","4;3;1;1;1;1;1;1","BIOTECHNOLOGY;CANCER;GENETICS;HUMAN GENOME;PREVENTION;UROLOGIC DISEASES","1;1;1;1;1;1","CANCER","1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1","BIOMEDICAL","1","CLINICAL MEDICINE AND SCIENCE","1","BLADDER CANCER","1",NA,NA
"IRCCS_SANGERARDO",2012,156,11.8589743589744,2.06410256410256,0.237179487179487,0.243589743589744,0.557692307692308,1.59405940594059,1.08823529411765,1.40740740740741,1.33846153846154,0.333333333333333,3,88,25,14,18,0.56,0.16,0.09,0.12,29.73,0.711801640027454,5.53181076672105,0.358974358974359,0.92948717948718,0.441,0.375,0.382,0.349,"ALESSANDRO RAMBALDI;ENRICO MARIA POGLIANI;GIUSEPPE CITERIO;PAOLO BIDOLI;CARLO GAMBACORTI‐PASSERINI;DIEGO CORTINOVIS;CRISTINA MESSA;MARIA PICCHIO;ELENA DE PONTI;RENATO BASSAN;LUIGI GIANOLLI;ELENA OLDANI;FABIO CICERI;CHIARA BRIANI;PAOLA ALBERTI;MARINA ELENA CAZZANIGA;GUIDO CAVALETTI;GIUSEPPE GAIPA;ELENA MARIA ELLI;ANTONIO PESENTI","11;10;8;8;7;7;7;6;6;5;5;5;5;5;5;5;5;5;5;5","GIUSEPPE CITERIO;GIORGIO CATTORETTI;PAOLO PERSEGHIN;ANTONIO VINCENTI;VALENTINA BOZZETTI;DIEGO CORTINOVIS;CRISTINA MESSA;PAOLO BIDOLI;ANTONIO PESENTI;ELENA DE PONTI;PAOLO TAGLIABUE;LUIGI GIANOLLI;GIUSEPPE PATERLINI;MARIA PICCHIO;ALESSANDRO RAMBALDI;ANTONELLA FONTANA;GIUSEPPE TROCINO;SANDRO SIRONI;PAOLA MAPELLI;MARIABEATRICE DAL CANTO","1.28;1.23;1.19;1;0.92;0.81;0.75;0.73;0.71;0.7;0.67;0.63;0.62;0.61;0.61;0.6;0.6;0.6;0.55;0.53","ENRICO MARIA POGLIANI;GIUSEPPE CITERIO;PAOLO BIDOLI;CARLO GAMBACORTI‐PASSERINI;DIEGO CORTINOVIS;CRISTINA MESSA;ELENA DE PONTI;MARINA ELENA CAZZANIGA;GIUSEPPE GAIPA;ELENA MARIA ELLI;LUCA GUERRA;SANDRO SIRONI;PAOLO TAGLIABUE;VALENTINA BOZZETTI;GIUSEPPE PATERLINI;ANDREA BIONDI;ROBERT FRUSCIO;PAOLO PERSEGHIN;ADRIANA BALDUZZI;ROSSELLA PARINI","10;8;8;7;7;7;6;5;5;5;4;4;4;4;4;4;4;4;4;4","GIUSEPPE CITERIO;GIORGIO CATTORETTI;PAOLO PERSEGHIN;ANTONIO VINCENTI;VALENTINA BOZZETTI;DIEGO CORTINOVIS;CRISTINA MESSA;PAOLO BIDOLI;ELENA DE PONTI;PAOLO TAGLIABUE;GIUSEPPE PATERLINI;ANTONELLA FONTANA;GIUSEPPE TROCINO;SANDRO SIRONI;ANDREA BIONDI;VALENTINA CHIAPPA;ENRICO MARIA POGLIANI;DANIELE BONACINA;ROBERT FRUSCIO;GIORGIO BOVO","1.28;1.23;1.19;1;0.92;0.81;0.75;0.73;0.7;0.67;0.62;0.6;0.6;0.6;0.5;0.49;0.48;0.48;0.47;0.45","ROBERTO MARCHIOLI;ELENA MARIA ELLI;ALESSANDRA IURLO;ALESSIA TIEGHI;ANTONIO SPADEA;ARIANNA MASCIULLI;CATERINA MUSOLINO;DANIELA CILLONI;DAVIDE RAPEZZI;ELISA RUMI;FRANCESCA LUNGHI;GIORGINA SPECCHIA;GIOVANNI QUARTA;GIUSEPPE VISANI;GUIDO FINAZZI;MARCO RUGGERI;MARIA LUIGIA RANDI;MONIA LUNGHI;ROBERTO LATAGLIATA;ROSA MARIA MARFISI","741;714;713;713;713;713;713;713;713;713;713;713;713;713;713;713;713;713;713;713","ELENA MARIA ELLI;ELENA DE PONTI;CARLO GAMBACORTI‐PASSERINI;ENRICO MARIA POGLIANI;FÁBIO ROSSI;DIEGO CORTINOVIS;MARINA ELENA CAZZANIGA;GIUSEPPE CITERIO;CRISTINA MESSA;CARLO A. AUGUSTI;DANIELE MUNEGATO;DIEGO GADDI;MARCO BIGONI;MARCO TURATI;SANDRO SIRONI;LUCA GUERRA;ROBERT FRUSCIO;MARCO DINELLI;ROBERTO FREGO;PAOLO BIDOLI","713;480;420;383;373;330;322;303;212;160;160;160;160;160;146;143;137;127;127;119","ENRICO MARIA POGLIANI;GIUSEPPE CITERIO;PAOLO BIDOLI;CARLO GAMBACORTI‐PASSERINI;DIEGO CORTINOVIS;ELENA DE PONTI;CRISTINA MESSA;MARINA ELENA CAZZANIGA;PAOLO PERSEGHIN;ELENA MARIA ELLI;GIUSEPPE PATERLINI;LUCA GUERRA;PAOLO TAGLIABUE;VALENTINA BOZZETTI;ROBERT FRUSCIO;ADRIANA BALDUZZI;ANDREA BIONDI;ANDREA GORI;ANTONELLA FONTANA;GIUSEPPE GAIPA","10;8;8;7;7;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;CHEMISTRY;PHILOSOPHY;MATHEMATICS;ECONOMICS;SOCIOLOGY;ART;MATERIALS SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY","145;47;19;13;9;8;6;6;5;4;4;3;3;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;ONCOLOGY;PATHOLOGY;RADIOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;ANESTHESIA;ENVIRONMENTAL HEALTH;PSYCHIATRY;IMMUNOLOGY;OPTICS;PEDIATRICS;BIOCHEMISTRY;ENDOCRINOLOGY;NUCLEAR MEDICINE;CARDIOLOGY;PALEONTOLOGY;ARTIFICIAL INTELLIGENCE;CANCER RESEARCH;MECHANICAL ENGINEERING","111;48;28;28;25;23;20;20;19;16;14;13;13;12;11;11;11;10;10;7;7;7","CANCER;CHEMOTHERAPY;TRANSPLANTATION;GENE;POPULATION;CLINICAL TRIAL;INCIDENCE (GEOMETRY);PREGNANCY;RETROSPECTIVE COHORT STUDY;STEM CELL;LEUKEMIA;MECHANICAL VENTILATION;POSITRON EMISSION TOMOGRAPHY;ALTERNATIVE MEDICINE;BONE MARROW;COHORT;DISEASE;MYELOID LEUKEMIA;RANDOMIZED CONTROLLED TRIAL;ULTRASOUND","34;23;20;17;16;11;11;9;9;9;8;8;8;7;7;7;7;7;7;7","HEMATOPOIETIC STEM CELL TRANSPLANTATION;COLORECTAL CANCER;CUMULATIVE INCIDENCE;CLINICAL ENDPOINT;MUTATION;VIRAL LOAD;HAEMATOPOIESIS;CHROMOSOME;CYCLOPHOSPHAMIDE;GESTATIONAL AGE;IMATINIB;PROSTATE CANCER;ALLELE;CD34;CERVICAL CANCER;CHROMOSOMAL TRANSLOCATION;FLUOROURACIL;GENOTYPE;HAZARD RATIO;LYMPHADENECTOMY;METASTASIS;MINIMAL RESIDUAL DISEASE;OOCYTE;OVARIAN CANCER;PERIPHERAL NEUROPATHY;PLACEBO;RITUXIMAB;SALVAGE THERAPY","11;10;8;6;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","OXALIPLATIN;DASATINIB;IMATINIB MESYLATE;NILOTINIB;ANTIRETROVIRAL THERAPY;EXOME SEQUENCING;IRINOTECAN;KARYOTYPE;KRAS;BLASTOCYST;BRAIN METASTASIS;BUSULFAN;CAPECITABINE;COMPOUND HETEROZYGOSITY;ERLOTINIB;FLUDARABINE;FOLINIC ACID;HEMATOPOIETIC CELL;IN VITRO MATURATION;LEUKAPHERESIS;LOSS OF HETEROZYGOSITY;OVARIAN TUMOR;PEMETREXED;SANGER SEQUENCING;SINGLE-NUCLEOTIDE POLYMORPHISM;VINCRISTINE","5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;NEOPLASM RECURRENCE, LOCAL;RETROSPECTIVE STUDIES;ADOLESCENT;PROSTATIC NEOPLASMS;TREATMENT OUTCOME;CHILD;COLORECTAL NEOPLASMS;YOUNG ADULT;ANTINEOPLASTIC AGENTS;TOMOGRAPHY, X-RAY COMPUTED;OVARIAN NEOPLASMS","83;71;57;54;40;37;36;23;19;16;16;15;14;14;12;12;12;11;11;10","EFFICACY AND RESISTANCE IN CML TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY;LYMPHOID NEOPLASMS;GYNECOLOGIC ONCOLOGY;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;FERTILITY PRESERVATION IN CANCER PATIENTS;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANESTHESIA AND SEDATION MANAGEMENT;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CELLULAR SENESCENCE AND AGING-RELATED DISEASES","8;5;5;5;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2","CUMULATIVE INCIDENCE;CLINICAL ENDPOINT;ACUTE MYELOID LEUKEMIA;HEMATOPOIETIC CELL TRANSPLANTATION;TREATMENT OUTCOMES;ANTIRETROVIRAL THERAPY;CANCER IMAGING;EMBRYO DEVELOPMENT;HEMATOLOGY;IMATINIB;IMATINIB MESYLATE;OXALIPLATIN;PET/CT;PONATINIB;BOSUTINIB;CERVICAL CANCER;CONCORDANCE;EXOME;FOLFOX;LYMPHADENECTOMY","8;6;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3","CELL TRANSPLANTATION;MYELOID LEUKEMIA;STEM CELL;ACUTE LYMPHOBLASTIC;CHRONIC MYELOID;LYMPHOBLASTIC LEUKEMIA;CANCER PATIENTS;CELL LUNG;COLORECTAL CANCER;LUNG CANCER;NON-SMALL CELL;ADVANCED NONSQUAMOUS;ALLOGENEIC STEM;BSC VERSUS;CARE BSC;CERVICAL CANCER;CHROMOSOME-POSITIVE ACUTE;COMPLETE REMISSION;CONTRAST ENHANCED;LEUKEMIA PH;MAINTENANCE PEMETREXED;MULTICENTER ITALIAN;PACE TRIAL;PAIN MANAGEMENT;PEMETREXED PEM;PHILADELPHIA CHROMOSOME-POSITIVE;POLYCYTHEMIA VERA;RETROSPECTIVE ANALYSIS;SUPPORTIVE CARE;VERSUS PLACEBO","8;8;8;6;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PERINATAL OUTCOME;GESTATIONAL AGE;IVM BABIES;ICSI CHILDREN;CD CELL;CRITICAL CARE;EBV-DNA LOAD;NATURAL CYCLES;SIGNIFICANT DIFFERENCES;TEMPERATURE MANAGEMENT;HR CI;MEDIAN LATENCY;OVARIAN STIMULATION;PREFERRED SEARCH;SINGLE TWIN;TWIN BIRTHS;BLOOD FLOW;BLOOD PRESSURE;CELL COUNT;CONFIDENCE INTERVAL;ELDERLY ADULTS;ICSI DELIVERIES;INTENSIVE CARE;INVESTIGATORS CHOICE;PARAMETRIAL INFILTRATION;PMAB RECHALLENGE;SEARCH DIRECTION;STEM CELL;VLBW INFANTS;ADC VALUES","12;9;9;8;7;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;4",42,0.27,3.15,2,3,2.5,0,3.25,1.75,0,1,4,0,1,2,0,2.75,1,6,2,3,0,0,77.75,81.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,6.79,995.37,10.38,9,0.47,70.47,0,0,3,0,10,0,2,4,0,16,3,0,0,0,0,0,0,18,1,0,19,0,0,0,0,0,0,0,0,0,"Italy;United States;Spain;Belgium;France;Germany;Switzerland","6;3;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3213 PAEDIATRICS","19;10;9;4;3;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PATIENT SAFETY;LUNG;LYMPHOMA;CARDIOVASCULAR;GENETICS;NEUROSCIENCES;ORPHAN DRUG;PEDIATRIC;AGING;BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;HEART DISEASE;LUNG CANCER","17;13;11;10;7;6;5;4;3;3;3;3;3;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;RESPIRATORY;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","7;3;2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","13;3;2;2;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LUNG CANCER;HODGKIN'S DISEASE;OVARIAN CANCER","4;3;3;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","9;2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_SANGERARDO",2013,210,11.9714285714286,2.24761904761905,0.252380952380952,0.261904761904762,0.357142857142857,1.80842911877395,1.29268292682927,1.52777777777778,1.27118644067797,0.352380952380952,2,119,37,29,9,0.57,0.18,0.14,0.04,25.2,0.722353376094681,5.29324324324325,0.323809523809524,0.919047619047619,0.484,0.385,0.443,0.402,"CARLO GAMBACORTI‐PASSERINI;MASSIMO CLERICI;ROSSELLA PARINI;ANTONIOS DAKANALIS;ALESSANDRO RAMBALDI;DONG‐WOOK KIM;JORGE E. CORTÉS;ROCCO PIAZZA;ANDREA BIONDI;ELISABETTA ABRUZZESE;HAGOP M. KANTARJIAN;H. JEAN KHOURY;ANTONIO PESENTI;CRISTINA MESSA;PAOLO TAGLIABUE;MOSHE TALPAZ;PHILIPP D. LE COUTRE;MICHELE BACCARANI;DELPHINE RÉA;JOHN F. DIPERSIO","17;15;12;9;9;9;8;8;8;8;8;8;8;8;7;7;7;7;7;7","MASSIMO CLERICI;ESTER DI GIACOMO;ROSSELLA PARINI;PAOLO PERSEGHIN;ANTONIOS DAKANALIS;PAOLO TAGLIABUE;GIUSEPPE MANCIA;GIUSEPPE CITERIO;CARLO GAMBACORTI‐PASSERINI;ANTONIO PESENTI;EMANUELE PIRONDINI;GUIDO GRASSI;GIUSEPPE RIVA;MARIA ASSUNTA ZANETTI;LUCA DI LULLO;RODOLFO RIVERA;FABIO MADEDDU;CRISTINA MESSA;ANDREA BIONDI;VALENTINA BOZZETTI","2.75;2.31;1.78;1.69;1.49;1.26;1.06;1.05;1;0.98;0.92;0.89;0.87;0.82;0.78;0.78;0.78;0.77;0.75;0.72","CARLO GAMBACORTI‐PASSERINI;MASSIMO CLERICI;ROSSELLA PARINI;ANTONIOS DAKANALIS;ROCCO PIAZZA;ANDREA BIONDI;ANTONIO PESENTI;CRISTINA MESSA;PAOLO TAGLIABUE;PAOLO PERSEGHIN;ENRICO MARIA POGLIANI;LUCA GUERRA;GIACOMO BELLANI;ESTER DI GIACOMO;ELENA DE PONTI;ANGELO SELICORNI;ANDRÉA STELLA;DIEGO CORTINOVIS;FRANCESCA FURLAN;GIUSEPPE MANCIA","17;15;12;9;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6","MASSIMO CLERICI;ESTER DI GIACOMO;ROSSELLA PARINI;PAOLO PERSEGHIN;ANTONIOS DAKANALIS;PAOLO TAGLIABUE;GIUSEPPE MANCIA;GIUSEPPE CITERIO;CARLO GAMBACORTI‐PASSERINI;ANTONIO PESENTI;EMANUELE PIRONDINI;GUIDO GRASSI;RODOLFO RIVERA;CRISTINA MESSA;ANDREA BIONDI;VALENTINA BOZZETTI;GIACOMO BELLANI;ANGELO SELICORNI;ELENA DE PONTI;LIDIA LIBRETTI","2.75;2.31;1.78;1.69;1.49;1.26;1.06;1.05;1;0.98;0.92;0.89;0.78;0.77;0.75;0.72;0.72;0.69;0.68;0.67","ROSSELLA PARINI;DIEGO CORTINOVIS;MASSIMO CLERICI;ANTONIOS DAKANALIS;GIUSEPPE RIVA;ANDREA BIONDI;GUIDO CAVALETTI;PAOLO PERSEGHIN;ALESSANDRO RAMBALDI;GIACOMO BELLANI;ETTORE BIAGI;ANTONIO PESENTI;TOMMASO MAURI;CRISTINA MESSA;ERICA DANDER;GIOVANNA D’AMICO;MAURO SIGNORELLI;ANDREA COPPADORO;NICOLÒ PATRONITI;ELENA DE PONTI","597;355;341;338;336;330;329;318;294;290;289;281;280;272;268;268;267;258;258;251","ROSSELLA PARINI;DIEGO CORTINOVIS;PAOLO PERSEGHIN;GIACOMO BELLANI;ANDREA BIONDI;ANTONIO PESENTI;TOMMASO MAURI;MASSIMO CLERICI;NICOLÒ PATRONITI;ELENA DE PONTI;FRANCESCA FURLAN;ADRIANA BALDUZZI;ENRICO POGLIANI;ETTORE BIAGI;GIUSEPPE GAIPA;MARINA ELENA CAZZANIGA;ATTILIO ROVELLI;DANIELA BELOTTI;DANIELA LONGONI;FABIO PAVAN","597;355;318;289;285;280;279;259;257;251;250;248;247;244;244;238;215;215;215;215","CARLO GAMBACORTI‐PASSERINI;ROSSELLA PARINI;MASSIMO CLERICI;ANDREA BIONDI;ELENA DE PONTI;PAOLO PERSEGHIN;GIUSEPPE CITERIO;FRANCESCA FURLAN;ANTONIO PESENTI;DIEGO CORTINOVIS;PAOLO TAGLIABUE;ANGELO SELICORNI;ENRICO MARIA POGLIANI;LUCA GUERRA;MARINA ELENA CAZZANIGA;PIETRO PIOLTELLI;RODOLFO RIVERA;ADRIANA BALDUZZI;ANNA CEREDA;CRISTINA MESSA","13;12;9;7;7;7;6;6;6;6;6;6;5;5;5;5;5;4;4;4","MEDICINE;BIOLOGY;PSYCHOLOGY;MATHEMATICS;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;BUSINESS;HISTORY","188;61;19;15;14;12;10;8;8;6;5;3;2;1;1","INTERNAL MEDICINE;PATHOLOGY;GENETICS;SURGERY;ONCOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;PSYCHIATRY;CARDIOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;ANESTHESIA;IMMUNOLOGY;RADIOLOGY;BIOCHEMISTRY;CLINICAL PSYCHOLOGY;CANCER RESEARCH;ENDOCRINOLOGY;PALEONTOLOGY;NUCLEAR MEDICINE;STATISTICS","142;44;43;41;36;30;25;25;22;21;21;20;16;16;14;13;12;11;10;9;9","GENE;DISEASE;CANCER;CHEMOTHERAPY;POPULATION;PREGNANCY;ADVERSE EFFECT;BLOOD PRESSURE;MYELOID LEUKEMIA;PROSPECTIVE COHORT STUDY;TRANSPLANTATION;BONE MARROW;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);BIOPSY;RECEPTOR;ANTIBODY;BODY MASS INDEX;INTENSIVE CARE;LEUKEMIA;LYMPHOMA;POSITRON EMISSION TOMOGRAPHY","33;30;24;18;17;13;12;11;11;11;11;9;9;8;8;8;8;7;7;6;6;6;6;6;6","MUTATION;IMATINIB;HEART RATE;BREAST CANCER;CLINICAL ENDPOINT;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PHENOTYPE;CHROMOSOME;ENZYME REPLACEMENT THERAPY;COLORECTAL CANCER;FETUS;MYELODYSPLASTIC SYNDROMES;CUMULATIVE INCIDENCE;GENE EXPRESSION;GESTATIONAL AGE;GRAFT-VERSUS-HOST DISEASE;BEVACIZUMAB;ENDOMETRIAL CANCER;ENTERAL ADMINISTRATION;FABRY DISEASE;GENOTYPE;METABOLIC SYNDROME;MITOCHONDRIAL DNA;OVARIAN CANCER;OVERWEIGHT;PAIN MEDICINE;PARKINSON'S DISEASE;PLACEBO;RITUXIMAB","12;9;8;7;7;7;7;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","NILOTINIB;DASATINIB;BAROREFLEX;IMATINIB MESYLATE;EXOME SEQUENCING;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KRAS;MASTECTOMY;MISSENSE MUTATION;PRENATAL DIAGNOSIS;SINGLE-NUCLEOTIDE POLYMORPHISM;AMNIOTIC FLUID;ANAPLASTIC LYMPHOMA KINASE;ANTIRETROVIRAL THERAPY;AUTONOMIC NERVOUS SYSTEM;CLINICAL PHENOTYPE;COMPARATIVE GENOMIC HYBRIDIZATION;CRIZOTINIB;DNA METHYLATION;DUCTAL CARCINOMA;EXTRACORPOREAL PHOTOPHERESIS;GERMINAL VESICLE;HORMONE RECEPTOR;HORMONE THERAPY;INTRAUTERINE GROWTH RESTRICTION;MALE BREAST CANCER;OXALIPLATIN;POINT MUTATION;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETINOPATHY OF PREMATURITY;TRANSFERRIN SATURATION","8;6;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;ADOLESCENT;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CHILD;CHILD, PRESCHOOL;INFANT, NEWBORN;YOUNG ADULT;AGED, 80 AND OVER;INFANT;PROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS, MALE","117;90;82;77;47;44;39;33;24;23;18;18;15;14;14;13;13;13;12;12","EFFICACY AND RESISTANCE IN CML TREATMENT;EATING DISORDERS AND BODY IMAGE CONCERNS;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ACUTE MYELOID LEUKEMIA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GYNECOLOGIC ONCOLOGY;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;MULTIPOTENT MESENCHYMAL STEM CELLS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;PEDIATRIC PAIN ASSESSMENT AND MANAGEMENT;SUICIDAL BEHAVIOR AND PREVENTION STRATEGIES;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BODY DYSMORPHIC DISORDER: PSYCHOSOCIAL, CLINICAL, AND TREATMENT ASPECTS;BORDERLINE PERSONALITY DISORDER: PSYCHOPATHOLOGY AND TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE","12;8;8;6;5;5;4;3;3;3;3;3;3;3;3;3;2;2;2;2","TREATMENT;CLINICAL ENDPOINT;PONATINIB;POSITIVE END-EXPIRATORY PRESSURE;BOSUTINIB;IMMUNOSUPPRESSION;ACUTE MYELOID LEUKEMIA;CUMULATIVE INCIDENCE;DASATINIB;DEPRESSION (ECONOMICS);EATING DISORDERS;GLYCOGEN STORAGE DISEASES;HYPERTENSION;IMATINIB;IMATINIB MESYLATE;PAIN MANAGEMENT;PSYCHOLOGICAL AUTOPSY;STROKE (ENGINE);SUICIDAL BEHAVIOR;TREATMENT OUTCOMES","8;7;7;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","MYELOID LEUKEMIA;CHRONIC MYELOID;STEM CELL;BREAST CANCER;CANCER PATIENTS;CELL TRANSPLANTATION;CHRONIC PHASE;PHASE CHRONIC;ACUTE LYMPHOBLASTIC;BLOOD PRESSURE;CONTROL STUDY;F-FDG PETCT;LEUKEMIA CP-CML;LYMPHOBLASTIC LEUKEMIA;PHASE II;PROSPECTIVE STUDY;ADULT PATIENTS;ATTEMPTED SUICIDE;ATYPICAL CHRONIC;BODY IMAGE;BONE MARROW;COLORECTAL CANCER;EATING DISORDER;LEUKEMIA PATIENTS;MESENCHYMAL STROMAL;MYELODYSPLASTIC SYNDROMES;OVARIAN CANCER;PACE TRIAL;PAIN CONTROL;PATIENTS PTS","12;10;9;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","STEM CELLS;MESENCHYMAL STEM;ROPIVACAINE NEBULIZATION;DS FETUSES;INTRAPERITONEAL NEBULIZATION;RENAL DENERVATION;CONFIDENCE INTERVAL;AUTOLOGOUS MESENCHYMAL;FS LASER;GSC LINES;MEDIAN AGE;MMHG NA;NORMAL SALINE;PATIENTS UNDERGOING;RISK FACTORS;SALINE ML;SHOULDER PAIN;SURGICAL DISSECTION;VPA TREATMENT;BLOOD PRESSURE;FETAL MALFORMATIONS;LAPAROSCOPIC CHOLECYSTECTOMY;STATISTICALLY SIGNIFICANT;STEM CELL;UA PATIENTS;ACUTE OXAIPN;ADENOCARCINOMA PATIENTS;AMBULATORY BP;CHROMOSOME ALIGNMENT;COLORECTAL CANCER","12;9;9;8;8;8;7;6;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4",58,0.28,5,6,2,1,1,9,2,1,1,6,1,1,4,1,3,1,1.25,3,2.5,0,0,104.75,100.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,5.62,542.88,11.39,14,0.52,80.26,1,1,7,4,8,0,0,6,0,23,3,0,0,0,0,0,0,23,4,0,26,1,0,0,0,0,0,0,0,0,"United States;Italy;Belgium;France;Japan;Switzerland;United Kingdom","5;4;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;4206 PUBLIC HEALTH","27;13;10;3;3;3;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;BREAST CANCER;CARDIOVASCULAR;HEMATOLOGY;PATIENT SAFETY;STEM CELL RESEARCH;HEART DISEASE;LUNG;ORPHAN DRUG;REGENERATIVE MEDICINE;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;HEART DISEASE - CORONARY HEART DISEASE;LUNG CANCER;AGING;DIGESTIVE DISEASES;OVARIAN CANCER","25;19;16;9;5;5;5;5;5;4;4;4;4;4;4;3;3;2;2;2","CANCER;CARDIOVASCULAR","11;3","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.4 SURGERY","16;2;2;2;1;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;OVARIAN CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;MELANOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;SARCOMA","5;5;4;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","15;2;2;1",1,29998904,769202.67,8,39,16,1,297,172527.208333333,1.21719931614651,"ANTWERP UNIVERSITY HOSPITAL;ARTTIC (FRANCE);ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AUCKLAND UNIVERSITY OF TECHNOLOGY;AZIENDA OSPEDALIERA SAN GERARDO;CAPITAL REGION OF DENMARK;CHARITÉ - UNIVERSITY MEDICINE BERLIN;ERASMUS MC;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;GABO:MI;ICOMETRIX (BELGIUM);IMPERIAL COLLEGE LONDON;KAROLINSKA INSTITUTET;LEIDEN UNIVERSITY MEDICAL CENTER;MEDICAL RESEARCH COUNCIL;MONASH UNIVERSITY;NHS BLOOD AND TRANSPLANT;NHS GREATER GLASGOW AND CLYDE;OSLO UNIVERSITY HOSPITAL;OXFORD BROOKES UNIVERSITY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CP-IP - LARGE-SCALE INTEGRATING PROJECT (FUNDING SCHEME);FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2013-INNOVATION-1 (CALL FOR PROPOSAL)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","BRAIN DISORDERS;CLINICAL RESEARCH;COMPARATIVE EFFECTIVENESS RESEARCH;HEALTH SERVICES;NEUROSCIENCES;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;TRAUMATIC BRAIN INJURY (TBI);TRAUMATIC HEAD AND SPINE INJURY","1;1;1;1;1;1;1;1","INJURIES AND ACCIDENTS","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1","3 GOOD HEALTH AND WELL BEING","1",28,"PUBLIC LIBRARY OF SCIENCE","28","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;34 CHEMICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;49 MATHEMATICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY;46 INFORMATION AND COMPUTING SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3203 DENTISTRY;38 ECONOMICS;3803 ECONOMIC THEORY;4607 GRAPHICS, AUGMENTED REALITY AND GAMES;4905 STATISTICS;52 PSYCHOLOGY","36;12;6;4;4;3;3;3;3;3;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;DIGESTIVE DISEASES;LIVER DISEASE;CHRONIC LIVER DISEASE AND CIRRHOSIS;GENETICS;HEMATOLOGY;HEPATITIS;HEPATITIS - B;HIV/AIDS;RARE DISEASES;BIOTECHNOLOGY;CARDIOVASCULAR;EMERGING INFECTIOUS DISEASES;HEPATITIS - C;HUMAN GENOME;INFECTIOUS DISEASES;PREVENTION;BRAIN CANCER;BRAIN DISORDERS;CANCER","7;6;6;5;5;3;3;3;3;3;2;2;2;2;2;2;2;1;1;1","INFECTION;CANCER;CARDIOVASCULAR","3;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;2;2;1","CLINICAL;BIOMEDICAL","2;1","CLINICAL MEDICINE AND SCIENCE","10","LIVER CANCER;BRAIN TUMOR;CERVICAL CANCER;KAPOSI'S SARCOMA;KIDNEY CANCER;NOT SITE-SPECIFIC CANCER","2;1;1;1;1;1",NA,NA
"IRCCS_SANGERARDO",2014,200,13.68,2.15,0.25,0.21,0.315,1.6412213740458,1.13636363636364,1.61538461538462,1.21153846153846,0.46,3,113,34,22,13,0.56,0.17,0.11,0.06,51.38,1.35942544369971,5.0781990521327,0.46,0.945,0.469,0.378,0.387,0.361,"ROSSELLA PARINI;CARLO GAMBACORTI‐PASSERINI;GIUSEPPE CITERIO;ANTONIO PESENTI;CARLO FERRARESE;ROCCO PIAZZA;ANGELO SELICORNI;ANDREA GORI;PAOLO BIDOLI;ALESSANDRA PIROLA;GIACOMO BELLANI;ANDREA ANTINORI;ALBERTO BOSI;MARINA ELENA CAZZANIGA;TOMMASO MAURI;DIEGO CORTINOVIS;GIUSEPPE LAPADULA;ELENA MARIA ELLI;ALFIO BRONCO;FEDERICO CAPPUZZO","11;10;10;9;7;7;7;7;7;6;5;5;5;5;5;5;5;5;5;4","GIUSEPPE CITERIO;PAOLO PERSEGHIN;MOMCILO JANKOVIC;ANTONIO PESENTI;LUCA BILUCAGLIA;LUCA DI LULLO;FULVIO FLOCCARI;RODOLFO RIVERA;CARLO FERRARESE;CARLO GAMBACORTI‐PASSERINI;ROSSELLA PARINI;ANDREA GORI;GIORGIO CATTORETTI;ALFIO BRONCO;ROCCO PIAZZA;GIOVANNI ZATTI;MARTA SOMAINI;VALENTINA CHIAPPA;TOMMASO MAURI;ANDREA ALBERTO LISSONI","1.36;1.35;1.23;1.07;1;0.87;0.87;0.87;0.85;0.84;0.77;0.71;0.7;0.69;0.64;0.61;0.61;0.59;0.59;0.58","ROSSELLA PARINI;CARLO GAMBACORTI‐PASSERINI;GIUSEPPE CITERIO;ANTONIO PESENTI;CARLO FERRARESE;ROCCO PIAZZA;ANGELO SELICORNI;ANDREA GORI;PAOLO BIDOLI;GIACOMO BELLANI;MARINA ELENA CAZZANIGA;TOMMASO MAURI;DIEGO CORTINOVIS;GIUSEPPE LAPADULA;ELENA MARIA ELLI;ALFIO BRONCO;GIOVANNI ZATTI;SANDRO SIRONI;ATTILIO ROVELLI;ILDEBRANDO APPOLLONIO","11;10;10;9;7;7;7;7;7;5;5;5;5;5;5;5;4;4;4;4","GIUSEPPE CITERIO;PAOLO PERSEGHIN;MOMCILO JANKOVIC;ANTONIO PESENTI;LUCA BILUCAGLIA;RODOLFO RIVERA;CARLO FERRARESE;CARLO GAMBACORTI‐PASSERINI;ROSSELLA PARINI;ANDREA GORI;GIORGIO CATTORETTI;ALFIO BRONCO;ROCCO PIAZZA;GIOVANNI ZATTI;MARTA SOMAINI;VALENTINA CHIAPPA;TOMMASO MAURI;ANDREA ALBERTO LISSONI;ILDEBRANDO APPOLLONIO;GIACOMO BELLANI","1.36;1.35;1.23;1.07;1;0.87;0.85;0.84;0.77;0.71;0.7;0.69;0.64;0.61;0.61;0.59;0.59;0.58;0.58;0.57","PAOLO BIDOLI;ROBERTO FUMAGALLI;ROBERTO LATINI;CATERINA FANIZZA;GIANNI TOGNONI;LUCIANO GATTINONI;MARILENA ROMERO;PIETRO CAIRONI;SERGE MASSON;FEDERICO CAPPUZZO;MICHAEL THOMAS;JOO-HANG KIM;ANTONIO PESENTI;ALEXANDRU GRIGORESCU;ANDREAS SASHEGYI;C. LEWANSKI;EDWARD B. GARON;EKATERINE ALEXANDRIS;GRZEGORZ CZYŻEWICZ;JOANNA PIKIEL","1369;1325;1292;1286;1286;1286;1286;1286;1286;1223;1189;1166;1164;1154;1154;1154;1154;1154;1154;1154","PAOLO BIDOLI;GIACOMO GRASSELLI;GIUSEPPE CITERIO;SARA PEZZATTI;MADDALENA LETTINO;ROSSELLA PARINI;ANDREA BIONDI;ANGELO SELICORNI;GIOVANNI CAZZANIGA;SONIA BONANOMI;CARLO GAMBACORTI‐PASSERINI;MIRIAM RIGOLDI;SILVIA BOLIS;ROBERTO FUMAGALLI;STEFANO ISGRÒ;PATRIZIA PEREGO;GIOVANNI ZATTI;GIUSEPPE BELLELLI;ELENA MARIA ELLI;PIETRO PIOLTELLI","1283;1097;832;714;552;467;345;345;338;335;270;246;240;214;214;212;208;198;189;189","ROSSELLA PARINI;CARLO GAMBACORTI‐PASSERINI;GIUSEPPE CITERIO;ANDREA GORI;ANGELO SELICORNI;ANTONIO PESENTI;PAOLO BIDOLI;ELENA MARIA ELLI;GIUSEPPE LAPADULA;DIEGO CORTINOVIS;MARINA ELENA CAZZANIGA;ATTILIO ROVELLI;CARLO FERRARESE;GIORGIO CATTORETTI;LUISA VERGA;MIRIAM RIGOLDI;ROBERT FRUSCIO;RODOLFO RIVERA;PATRIZIA PEREGO;ALFIO BRONCO","11;10;10;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;CHEMISTRY;SOCIOLOGY;PHILOSOPHY;POLITICAL SCIENCE;ECONOMICS;HISTORY;MATERIALS SCIENCE;GEOGRAPHY","191;52;17;15;15;13;11;10;6;5;5;3;2;2;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;ONCOLOGY;GENETICS;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;IMMUNOLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;PSYCHIATRY;NUCLEAR MEDICINE;PEDIATRICS;CARDIOLOGY;CANCER RESEARCH;BIOCHEMISTRY;ENDOCRINOLOGY;CLINICAL PSYCHOLOGY;OPTICS;PHYSICAL THERAPY","146;51;49;39;35;30;26;23;22;18;18;17;16;16;15;12;11;11;10;10;10","CANCER;GENE;CHEMOTHERAPY;DISEASE;POPULATION;TRANSPLANTATION;ALTERNATIVE MEDICINE;LUNG CANCER;BONE MARROW;CONFIDENCE INTERVAL;HUMAN IMMUNODEFICIENCY VIRUS (HIV);RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;DISCONTINUATION;LUNG;MYELOID LEUKEMIA;RETROSPECTIVE COHORT STUDY;STEM CELL;CLINICAL TRIAL;INCIDENCE (GEOMETRY);LYMPHOMA;PROSPECTIVE COHORT STUDY","33;30;25;20;17;16;13;11;10;10;10;10;9;9;9;9;9;8;7;7;7;7","MUTATION;VIRAL LOAD;HEMATOPOIETIC STEM CELL TRANSPLANTATION;COLORECTAL CANCER;PLACEBO;HAZARD RATIO;BREAST CANCER;CISPLATIN;PHENOTYPE;CLINICAL ENDPOINT;GENOTYPE;IMATINIB;MYELODYSPLASTIC SYNDROMES;NEUTROPENIA;PACLITAXEL;ENDOMETRIAL CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;HAEMATOPOIESIS;AMYOTROPHIC LATERAL SCLEROSIS;ARDS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BRONCHOALVEOLAR LAVAGE;GENE EXPRESSION;HEART RATE;HIP FRACTURE;MYELOFIBROSIS;OVARIAN CANCER;PAIN MEDICINE;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;UNIVARIATE ANALYSIS","11;10;9;8;8;7;6;6;6;5;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","ANTIRETROVIRAL THERAPY;DASATINIB;EXOME SEQUENCING;GEFITINIB;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;NILOTINIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CARBOPLATIN;COLONOSCOPY;DIGITAL POLYMERASE CHAIN REACTION;ERLOTINIB;HEART RATE VARIABILITY;IRINOTECAN;KRAS;LAMIVUDINE;METASTATIC BREAST CANCER;MISSENSE MUTATION;PEMETREXED;TOTAL BODY IRRADIATION;TRANSCRIPTOME","9;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MALE;FEMALE;;MIDDLE AGED;ADULT;AGED;AGED, 80 AND OVER;TREATMENT OUTCOME;ITALY;ADOLESCENT;CHILD;LUNG NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, NON-SMALL-CELL LUNG;MUTATION;HIV INFECTIONS;YOUNG ADULT;CHILD, PRESCHOOL;PROSPECTIVE STUDIES","126;88;84;71;58;51;51;26;26;25;23;22;22;21;18;18;17;17;15;14","ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;EFFICACY AND RESISTANCE IN CML TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ATRIAL FIBRILLATION;GYNECOLOGIC ONCOLOGY;LYMPHOID NEOPLASMS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY","7;7;7;7;6;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2","DISCONTINUATION;ANTIRETROVIRAL THERAPY;REGIMEN;CLINICAL ENDPOINT;CART;COMPUTED TOMOGRAPHY;DIFFUSION-WEIGHTED IMAGING;EXOME;PERFUSION IMAGING;RITONAVIR;ACUTE MYELOID LEUKEMIA;AFATINIB;ANTICOAGULANT THERAPY;ATRIAL FIBRILLATION;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BREAST CANCER;BREAST MRI;CARBOPLATIN;DARUNAVIR;ENDOMETRIAL CARCINOMA","9;7;7;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","MYELOID LEUKEMIA;CELL TRANSPLANTATION;LUNG CANCER;CHRONIC MYELOID;STEM CELL;BREAST CANCER;CANCER PATIENTS;COMPUTED TOMOGRAPHY;CONTROLLED TRIAL;HIV-INFECTED PATIENTS;MULTICENTER STUDY;OBSERVATIONAL STUDY;PHASE III;ACUTE LYMPHOBLASTIC;ACUTE MYELOID;ATRIAL FIBRILLATION;ATYPICAL CHRONIC;FIELD BLOCK;HIP FRACTURE;HODGKIN LYMPHOMA;INTENSIVE CARE;ITALIAN PATIENTS;LEFT VENTRICULAR;LEUKEMIA PATIENTS;NONSMALL-CELL LUNG;OVARIAN CANCER;PAIN CONTROL;PATIENTS RESULTS;PROSPECTIVE OBSERVATIONAL;PROSPECTIVE STUDY","9;8;7;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CROSSREF PUBMED;PUBMED SCOPUS;CD CELLS;STEM CELL;C-CHOLINE PETCT;BONE MARROW;CELL TRANSPLANTATION;DISEASE PROGRESSION;ELOSULFASE ALFA;FANCA PATIENTS;FANCONI ANEMIA;MAPK INHIBITION;BOEHRINGER INGELHEIM;CLINICAL TRIALS;HS PATIENTS;MPS VI;OVARIAN CANCER;CLINICAL PRACTICE;MEDIAN FOLLOW-UP;PROGNOSTIC FACTORS;ADVISORY BOARD;BAL FLUID;CD COUNT;HEMATOPOIETIC STEM;HR CI;INTENSIVE CARE;LUNG CANCER;CRITICALLY ILL;GPI-NEGATIVE POPULATION;MARROW FAILURE","20;20;18;15;12;11;11;11;11;11;11;11;10;10;10;10;10;9;9;9;8;8;8;8;8;8;8;7;7;7",90,0.45,6.95,6,1.75,2.75,4.75,4.5,2.75,1,2,7,1,1,5.5,0,3,2,3,4,3,0,0,90.75,90.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,4.4,1399.13,6.28,7,0.47,65.4,0,0,5,3,3,0,0,4,0,11,4,0,0,0,0,0,0,13,1,1,15,0,0,0,0,0,0,0,0,0,"United States;Belgium;Germany;United Kingdom","4;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","14;8;5;4;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PREVENTION;RARE DISEASES;LUNG;BRAIN DISORDERS;HEMATOLOGY;LUNG CANCER;PATIENT SAFETY;PEDIATRIC;ACQUIRED COGNITIVE IMPAIRMENT;AGING;DIGESTIVE DISEASES;NEUROSCIENCES;ORPHAN DRUG;ACUTE RESPIRATORY DISTRESS SYNDROME;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BEHAVIORAL AND SOCIAL SCIENCE","15;9;7;6;6;4;3;3;3;3;3;2;2;2;2;2;1;1;1;1","CANCER;INFECTION;NEUROLOGICAL","5;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY","8;2;1;1;1","LUNG CANCER;BLOOD CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER","3;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","6;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;KARGER PUBLISHERS","29;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;34 CHEMICAL SCIENCES;31 BIOLOGICAL SCIENCES;49 MATHEMATICAL SCIENCES;4905 STATISTICS;3105 GENETICS;3204 IMMUNOLOGY;3213 PAEDIATRICS;3401 ANALYTICAL CHEMISTRY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;4605 DATA MANAGEMENT AND DATA SCIENCE;5202 BIOLOGICAL PSYCHOLOGY","50;6;6;6;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;CANCER;LUNG;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;RARE DISEASES;BRAIN DISORDERS;GENETICS;KIDNEY DISEASE;MENTAL HEALTH;NEUROSCIENCES;PATIENT SAFETY;ACQUIRED COGNITIVE IMPAIRMENT;AGING;APHASIA;BIOTECHNOLOGY;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEART DISEASE;HEMATOLOGY","9;7;7;5;5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;RESPIRATORY;CARDIOVASCULAR;INFECTION;MENTAL HEALTH;NEUROLOGICAL;RENAL AND UROGENITAL","8;5;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","5;4;3;3;2;1;1","CLINICAL;BIOMEDICAL","9;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;HEALTH SERVICES RESEARCH;PUBLIC HEALTH","20;2;1;1","NOT SITE-SPECIFIC CANCER;KIDNEY CANCER;HODGKIN'S DISEASE;KAPOSI'S SARCOMA;LEUKEMIA / LEUKAEMIA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER","4;3;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANGERARDO",2015,218,12.894495412844,2.46788990825688,0.261467889908257,0.293577981651376,0.339449541284404,1.8551724137931,1.26666666666667,1.68421052631579,1.32142857142857,0.596330275229358,0,113,42,17,15,0.52,0.19,0.08,0.07,31.75,0.851994109411197,5.5203426124197,0.394495412844037,0.977064220183486,0.47,0.437,0.459,0.424,"ANTONIO PESENTI;ROSSELLA PARINI;CARLO GAMBACORTI‐PASSERINI;PAOLO BIDOLI;GIUSEPPE CITERIO;VITTORIO SCARAVILLI;GIACOMO BELLANI;ALBERTO ZANELLA;ANDREA BIONDI;DIEGO CORTINOVIS;ALESSANDRO RAMBALDI;ANDREA GORI;ALESSANDRA PIROLA;FEDERICO MAGNI;DAVIDE IPPOLITO;ROCCO PIAZZA;ANGELO SELICORNI;SILVIA RUSSO;GIUSEPPE MANCIA;RODOLFO RIVERA","16;13;12;11;9;8;8;8;8;8;7;7;6;6;6;6;6;6;6;6","ANTONIO PESENTI;CARLO GAMBACORTI‐PASSERINI;MARTIN BROWN;SAM SEIDU;L. MARTÍNEZ;ROSSELLA PARINI;GIUSEPPE CITERIO;GIACOMO BELLANI;PAOLO BIDOLI;ROCCO PIAZZA;DAVIDE IPPOLITO;VITTORIO SCARAVILLI;ALBERTO ZANELLA;SANDRO SIRONI;FABIO PAGNI;GIUSEPPE BELLELLI;RODOLFO RIVERA;DIEGO CORTINOVIS;LUCA GUERRA;FEDERICO MAGNI","1.8;1.52;1.33;1.33;1.33;1.06;1.05;0.98;0.94;0.93;0.93;0.84;0.81;0.8;0.79;0.79;0.72;0.71;0.71;0.69","ANTONIO PESENTI;ROSSELLA PARINI;CARLO GAMBACORTI‐PASSERINI;PAOLO BIDOLI;GIUSEPPE CITERIO;GIACOMO BELLANI;ANDREA BIONDI;DIEGO CORTINOVIS;ANDREA GORI;FEDERICO MAGNI;DAVIDE IPPOLITO;ROCCO PIAZZA;ANGELO SELICORNI;GIUSEPPE MANCIA;RODOLFO RIVERA;LUCA GUERRA;SANDRO SIRONI;ATTILIO ROVELLI;GUIDO GRASSI;STEFANIA CANOVA","16;13;12;11;9;8;8;8;7;6;6;6;6;6;6;5;5;5;5;5","ANTONIO PESENTI;CARLO GAMBACORTI‐PASSERINI;MARTIN BROWN;SAM SEIDU;L. MARTÍNEZ;ROSSELLA PARINI;GIUSEPPE CITERIO;GIACOMO BELLANI;PAOLO BIDOLI;ROCCO PIAZZA;DAVIDE IPPOLITO;SANDRO SIRONI;FABIO PAGNI;GIUSEPPE BELLELLI;RODOLFO RIVERA;DIEGO CORTINOVIS;LUCA GUERRA;FEDERICO MAGNI;PIETRO ANDREA BONAFFINI;ANDREA BIONDI","1.8;1.52;1.33;1.33;1.33;1.06;1.05;0.98;0.94;0.93;0.93;0.8;0.79;0.79;0.72;0.71;0.71;0.69;0.68;0.66","CHIARA CREMOLINI;FOTIOS LOUPAKIS;SARA LONARDI;ALBERTO ZANIBONI;ALFREDO FALCONE;CRISTINA GRANETTO;GIUSEPPE TONINI;LUCA BONI;MAURO D’AMICO;CARLOTTA ANTONIOTTI;GIANLUCA TOMASELLO;MARINA ELENA CAZZANIGA;CHIARA CARLOMAGNO;CRISTIANA LUPI;ELISA SENSI;GABRIELLA FONTANINI;GIACOMO ALLEGRINI;MONICA RONZONI;SILVANA CHIARA;SILVIA MEZI","1133;1133;1133;1103;1089;1089;1089;1089;1089;963;963;933;919;919;919;919;919;919;919;919","MARINA ELENA CAZZANIGA;ROSSELLA PARINI;GIUSEPPE CITERIO;ANTONIO PESENTI;CARLO GAMBACORTI‐PASSERINI;ATTILIO ROVELLI;ALBERTO PESCI;SARA LONNI;STEFANO ALIBERTI;ANGELO SELICORNI;ALBERTO LUCCHINI;GIACOMO GRASSELLI;STEFANO ISGRÒ;MILENA MARIANI;ALESSIA VARGIOLU;ANDREA BIONDI;EVA CIRUELOS;GIUSEPPE BELLELLI;ELENA DE PONTI;R. LONGARINI","933;801;508;368;367;299;286;286;286;281;277;265;252;248;236;233;226;178;175;170","ROSSELLA PARINI;ANTONIO PESENTI;CARLO GAMBACORTI‐PASSERINI;PAOLO BIDOLI;GIUSEPPE CITERIO;DIEGO CORTINOVIS;DAVIDE IPPOLITO;ANDREA GORI;ELENA DE PONTI;ANDREA BIONDI;RODOLFO RIVERA;ANGELO SELICORNI;ATTILIO ROVELLI;GIACOMO BELLANI;GIUSEPPE BELLELLI;GIUSEPPE LAPADULA;LUCA GUERRA;MONICA CARPENEDO;STEFANIA CANOVA;SANDRO SIRONI","13;13;11;10;9;8;6;6;6;6;6;5;5;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PHILOSOPHY;ECONOMICS;POLITICAL SCIENCE;ART;HISTORY;MATERIALS SCIENCE;SOCIOLOGY;ENVIRONMENTAL SCIENCE","202;59;20;20;18;15;11;8;5;4;4;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;GASTROENTEROLOGY;PATHOLOGY;ANESTHESIA;PEDIATRICS;INTENSIVE CARE MEDICINE;PSYCHIATRY;IMMUNOLOGY;CARDIOLOGY;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;NUCLEAR MEDICINE;FAMILY MEDICINE;CANCER RESEARCH;EMERGENCY MEDICINE;OPTICS","146;66;41;38;35;30;28;26;23;23;20;19;19;17;17;16;14;13;12;9;9","DISEASE;GENE;CANCER;CHEMOTHERAPY;POPULATION;TRANSPLANTATION;CLINICAL TRIAL;COHORT;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;DIABETES MELLITUS;MYELOID LEUKEMIA;BLOOD PRESSURE;LEUKEMIA;ADVERSE EFFECT;ANTIBODY;BONE MARROW;MAGNETIC RESONANCE IMAGING;DISCONTINUATION;KIDNEY DISEASE;MECHANICAL VENTILATION","32;32;25;24;16;15;13;13;12;11;11;11;10;9;8;8;8;8;7;7;7","HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;HAZARD RATIO;CLINICAL ENDPOINT;COLORECTAL CANCER;IMATINIB;DEMENTIA;PHENOTYPE;BREAST CANCER;CHROMOSOME;NEUTROPENIA;GENE EXPRESSION;GENOTYPE;HEART RATE;VIRAL LOAD;CO2 REMOVAL;DIFFUSION MRI;EXON;FABRY DISEASE;HAEMATOPOIESIS;LYMPHOBLASTIC LEUKEMIA","12;11;9;8;8;8;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4","DASATINIB;IMATINIB MESYLATE;ACUTE LYMPHOCYTIC LEUKEMIA;ANAPLASTIC LYMPHOMA KINASE;ANTIRETROVIRAL THERAPY;CRIZOTINIB;FIBROBLAST GROWTH FACTOR 23;HEART RATE VARIABILITY;NILOTINIB;PEMETREXED;TRABECTEDIN;BREAKPOINT;CEREBRAL AMYLOID ANGIOPATHY;COGNITIVE DECLINE;DEEP BRAIN STIMULATION;DNA METHYLATION;EXOME SEQUENCING;IN VITRO MATURATION;IRINOTECAN;KARYOTYPE;KRAS;METASTATIC BREAST CANCER;MISSENSE MUTATION;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;PHILADELPHIA CHROMOSOME;POINT MUTATION;PROBAND;SENTINEL LYMPH NODE;TRASTUZUMAB;VINORELBINE;VITAMIN K ANTAGONIST","5;5;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED, 80 AND OVER;ADOLESCENT;FOLLOW-UP STUDIES;YOUNG ADULT;PROSPECTIVE STUDIES;CHILD;HIV INFECTIONS;RISK FACTORS;BREAST NEOPLASMS","120;95;90;81;61;60;49;35;27;27;26;25;23;21;21;20;19;19;16;15","EFFICACY AND RESISTANCE IN CML TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ACUTE MYELOID LEUKEMIA;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;EPIDEMIOLOGY AND IMPLICATIONS OF MULTIMORBIDITY IN HEALTHCARE;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;MINERAL METABOLISM IN CHRONIC KIDNEY DISEASE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;REGULATION OF CHROMATIN STRUCTURE AND FUNCTION;RHEUMATOID ARTHRITIS;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE","11;7;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2","POSITIVE END-EXPIRATORY PRESSURE;CLINICAL ENDPOINT;DISCONTINUATION;HIGH-FLOW OXYGEN THERAPY;IMATINIB;IMATINIB MESYLATE;REFRACTORY (PLANETARY SCIENCE);TREATMENT OUTCOMES;NONINVASIVE VENTILATION;REGIMEN;CO2 REMOVAL;COLOPHON;DIFFUSION-WEIGHTED IMAGING;EXTRACORPOREAL;EXTRACORPOREAL MEMBRANE OXYGENATION;FABRY DISEASE;HEALTH CARE UTILIZATION;MALIGNANT PLEURAL MESOTHELIOMA;PROGRESSION-FREE SURVIVAL;ACUTE LYMPHOCYTIC LEUKEMIA","9;8;8;6;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;3","PHASE III;CELL TRANSPLANTATION;MALIGNANT PLEURAL;MESOTHELIOMA MPM;PLEURAL MESOTHELIOMA;ACUTE LYMPHOBLASTIC;CARE DIABETES;COHORT STUDY;DIABETES EUROPE;EUROPE PCDE;FABRY DISEASE;PCDE COLOPHON;PHASE II;PRIMARY CARE;ACUTE MYELOID;ACUTE RESPIRATORY;BLOOD PRESSURE;BREAST CANCER;CHRONIC MYELOID;CLINICAL TRIAL;COLORECTAL CANCER;DISEASE PATIENTS;FIBROBLAST GROWTH;GROWTH FACTOR;II STUDY;IMMUNE THROMBOCYTOPENIA;LUNG CANCER;LYMPHOBLASTIC LEUKEMIA;MYELOID LEUKAEMIA;MYELOID LEUKEMIA","7;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ADVERSE EVENTS;BLUE DYE;MEDIAN AGE;GT GT;HR CI;CELL LINES;CONFIDENCE INTERVAL;CRITICALLY ILL;CLINICAL PRACTICE;ELDERLY PATIENTS;GENE THERAPY;MPS VI;PV ISOLATION;CELL TRANSPLANTATION;EPIDURAL INFUSION;HAZARD RATIO;MEDIAN PFS;MPS IH;NERVOUS SYSTEM;PATIENTS PTS;PATIENTS TREATED;PROGRESSION-FREE SURVIVAL;RAM DOC;RISK FACTORS;SINGLE AGENT;STEM CELL;TAZ GENE;TOTAL DOSE;CLINICAL TRIALS;COLORECTAL CANCER","12;12;11;10;10;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;7;7;7;7;7;7;7;6;6",85,0.39,7.35,6,2,1.75,1,2,2,1,1,6,0,1,4.75,0,1.75,2,4,4.75,2,0,0,89,91,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3.62,958.54,9.29,9,0.36,80.48,0,0,8,0,5,0,1,11,0,16,8,0,0,0,0,0,0,23,2,0,23,1,0,1,0,0,0,0,0,0,"United States;Germany;Japan;Italy;Netherlands;Switzerland;Australia;Belgium;France","6;3;3;2;2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3213 PAEDIATRICS;42 HEALTH SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;48 LAW AND LEGAL STUDIES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","25;10;3;3;3;3;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;LUNG;PEDIATRIC;HEMATOLOGY;PATIENT SAFETY;AUTOIMMUNE DISEASE;NEUROSCIENCES;HIV/AIDS;INFECTIOUS DISEASES;STEM CELL RESEARCH;BREAST CANCER;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;DIGESTIVE DISEASES;HEART DISEASE;INFANT MORTALITY;LUNG CANCER","23;17;11;8;6;6;5;5;4;4;3;3;3;2;2;2;2;2;2;2","CANCER;INFECTION;RESPIRATORY;REPRODUCTIVE HEALTH AND CHILDBIRTH;BLOOD;CARDIOVASCULAR;EYE;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;NEUROLOGICAL;ORAL AND GASTROINTESTINAL","6;3;3;2;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","18;3;2;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;BREAST CANCER;BLOOD CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;NON-HODGKIN'S LYMPHOMA","5;3;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","9;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","15;5","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;49 MATHEMATICAL SCIENCES;4905 STATISTICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3004 CROP AND PASTURE PRODUCTION;33 BUILT ENVIRONMENT AND DESIGN","29;5;5;5;4;3;2;1;1;1","HIV/AIDS;INFECTIOUS DISEASES;CLINICAL RESEARCH;UROLOGIC DISEASES;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEPATITIS;HEPATITIS - C;LIVER DISEASE;DIABETES;PREVENTION;CANCER;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;KIDNEY DISEASE;RARE DISEASES","7;7;6;4;3;3;3;3;3;3;2;2;1;1;1;1;1;1","INFECTION;CANCER;GENERIC HEALTH RELEVANCE;INFLAMMATORY AND IMMUNE SYSTEM","7;2;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","5;1;1;1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","7;2","KIDNEY CANCER;NON-HODGKIN'S LYMPHOMA","1;1",NA,NA
"IRCCS_SANGERARDO",2016,230,14.6217391304348,2.39565217391304,0.269565217391304,0.282608695652174,0.339130434782609,1.9469964664311,1.26530612244898,1.58536585365854,1.3448275862069,0.473913043478261,1,118,58,29,11,0.51,0.25,0.13,0.05,45.65,1.40541697758222,5.32350142721218,0.352173913043478,0.947826086956522,0.47,0.349,0.435,0.407,"DIEGO CORTINOVIS;PAOLO BIDOLI;ANTONIO PESENTI;A. CRESPÍ;N. PARUCCINI;ELENA DE PONTI;MARCELLO TISEO;GIACOMO BELLANI;LUCA GIANOTTI;VLASTA BARI;R. VILLA;DOMENICO GALETTA;C. PASQUALI;ALBERTO PORTA;DAVIDE IPPOLITO;ANGELO SELICORNI;BEATRICE DE MARIA;ANNA RADICE;ANDREA MARCHI;CLAUDIA SPADAVECCHIA","19;14;12;11;11;9;8;7;7;7;7;7;7;7;7;7;7;7;7;7","A. CRESPÍ;DIEGO CORTINOVIS;N. PARUCCINI;R. VILLA;C. PASQUALI;CLAUDIA SPADAVECCHIA;ANTONIO PESENTI;PAOLO PERSEGHIN;PAOLO BIDOLI;GIACOMO BELLANI;VLASTA BARI;ALBERTO PORTA;BEATRICE DE MARIA;ANDREA MARCHI;DAVIDE IPPOLITO;ANNA RADICE;ELENA DE PONTI;MASSIMO CLERICI;VITTORIO SCARAVILLI;NICOLÒ PATRONITI","1.77;1.71;1.57;1.16;1.16;1.16;1.13;1.05;1.04;1.03;1.03;1.03;1.03;1.03;0.99;0.98;0.96;0.88;0.87;0.84","DIEGO CORTINOVIS;PAOLO BIDOLI;ANTONIO PESENTI;A. CRESPÍ;N. PARUCCINI;ELENA DE PONTI;GIACOMO BELLANI;LUCA GIANOTTI;R. VILLA;C. PASQUALI;DAVIDE IPPOLITO;ANGELO SELICORNI;ANNA RADICE;ANDREA MARCHI;CLAUDIA SPADAVECCHIA;ANDREA GORI;GIORGIO BOVO;ROSSELLA PARINI;VITTORIO SCARAVILLI;LUCA GUERRA","19;14;12;11;11;9;7;7;7;7;7;7;7;7;7;6;6;6;5;5","A. CRESPÍ;DIEGO CORTINOVIS;N. PARUCCINI;R. VILLA;C. PASQUALI;CLAUDIA SPADAVECCHIA;ANTONIO PESENTI;PAOLO PERSEGHIN;PAOLO BIDOLI;GIACOMO BELLANI;ANDREA MARCHI;DAVIDE IPPOLITO;ANNA RADICE;ELENA DE PONTI;MASSIMO CLERICI;VITTORIO SCARAVILLI;NICOLÒ PATRONITI;LUCA GIANOTTI;DAVIDE FIOR;SANDRO SIRONI","1.77;1.71;1.57;1.16;1.16;1.16;1.13;1.05;1.04;1.03;1.03;0.99;0.98;0.96;0.88;0.87;0.84;0.79;0.72;0.69","DIEGO CORTINOVIS;ACHIM RITTMEYER;DANIEL WATERKAMP;DARIUSZ M. KOWALSKI;DAVID R. GANDARA;FABRICE BARLÉSI;FORTUNATO CIARDIELLO;JOACHIM VON PAWEL;JONATHAN POLIKOFF;JOSEPH W. LEACH;MANUEL COBO;MARCIN KOWANETZ;SHIRISH M. GADGEEL;TOYOAKI HIDA;FILIPPO DE MARINIS;ALAN SANDLER;CARLOS H. BARRIOS;DANIEL S. CHEN;FAIROOZ F. KABBINAVAR;HANDE TURNA","4321;4194;4194;4194;4194;4194;4194;4194;4194;4194;4194;4194;4194;4194;4175;4127;4127;4127;4127;4127","DIEGO CORTINOVIS;GIACOMO BELLANI;GIORGIO BOVO;NICOLA ZUCCHINI;ELISABETTA TERRUZZI;LUCA GIANOTTI;MAURO TOTIS;ANTONIO PESENTI;GIUSEPPE BELLELLI;ELENA MARIA ELLI;ERMELLINA ZANETTI;ANDREA MARCHI;ANDREA GORI;ROSSELLA PARINI;ELENA DE PONTI;DAVIDE IPPOLITO;PAOLO BIDOLI;SILVIA MAITZ;DAVIDE FIOR;FEDERICA ELISEI","4321;919;604;583;568;558;557;352;320;236;228;217;214;171;169;150;143;135;130;130","DIEGO CORTINOVIS;PAOLO BIDOLI;A. CRESPÍ;N. PARUCCINI;ELENA DE PONTI;ANGELO SELICORNI;ANNA RADICE;CLAUDIA SPADAVECCHIA;R. VILLA;ANDREA MARCHI;C. PASQUALI;GIORGIO BOVO;DAVIDE IPPOLITO;ANDREA GORI;GIACOMO BELLANI;ROSSELLA PARINI;CARLO FERRARESE;FEDERICA ELISEI;GIUSEPPE BELLELLI;LUCA GUERRA","19;13;11;11;8;7;7;7;7;7;7;6;6;6;6;6;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY;CHEMISTRY;ENGINEERING;ECONOMICS;MATERIALS SCIENCE;BUSINESS;POLITICAL SCIENCE;SOCIOLOGY;ART;PHILOSOPHY;GEOLOGY;HISTORY","214;62;27;22;16;15;14;9;8;6;4;3;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GENETICS;RADIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;NUCLEAR MEDICINE;IMMUNOLOGY;PALEONTOLOGY;ANESTHESIA;CARDIOLOGY;INTENSIVE CARE MEDICINE;OPTICS;BIOCHEMISTRY;PSYCHIATRY;ARTIFICIAL INTELLIGENCE;PEDIATRICS;CANCER RESEARCH;ENDOCRINOLOGY","170;57;45;33;31;28;27;26;23;22;22;21;19;19;18;16;16;13;13;11;11","CANCER;GENE;POPULATION;CHEMOTHERAPY;DISEASE;COHORT;LUNG CANCER;CLINICAL TRIAL;STAGE (STRATIGRAPHY);ADVERSE EFFECT;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;LUNG;TRANSPLANTATION;BONE MARROW;EXTRACORPOREAL MEMBRANE OXYGENATION;CONTRAST (VISION);MECHANICAL VENTILATION;RECEPTOR;REGIMEN","52;31;28;26;23;17;17;14;14;13;12;12;12;11;10;10;9;9;8;8;8;8","BREAST CANCER;GENE EXPRESSION;COLORECTAL CANCER;HAZARD RATIO;ADENOCARCINOMA;DOCETAXEL;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOTHERAPY;CUMULATIVE INCIDENCE;PHASES OF CLINICAL RESEARCH;PLACEBO;CLINICAL ENDPOINT;AMYOTROPHIC LATERAL SCLEROSIS;ARDS;CISPLATIN;DEMENTIA;EPIDERMAL GROWTH FACTOR RECEPTOR;FETUS;MYELODYSPLASTIC SYNDROMES;NEUTROPENIA;OVARIAN CANCER;SPLENECTOMY","15;11;9;8;7;7;7;7;6;6;6;5;4;4;4;4;4;4;4;4;4;4","DNA METHYLATION;NIVOLUMAB;OXALIPLATIN;SENTINEL LYMPH NODE;SENTINEL NODE;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;COMPARATIVE GENOMIC HYBRIDIZATION;GEFITINIB;METASTATIC BREAST CANCER;SINGLE-NUCLEOTIDE POLYMORPHISM;ANTIRETROVIRAL THERAPY;CAPECITABINE;CYBERKNIFE;ERLOTINIB;FEBRILE NEUTROPENIA;INDUCED PLURIPOTENT STEM CELL;KRAS;MAMMOGRAPHY;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;MEF2C;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SANGER SEQUENCING;VINORELBINE","5;5;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;YOUNG ADULT;ADOLESCENT;ANTINEOPLASTIC AGENTS;CHILD;POSTOPERATIVE COMPLICATIONS;PROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","135;106;93;92;77;67;65;38;36;33;32;28;23;22;19;17;17;15;15;14","ADVANCEMENTS IN LUNG CANCER RESEARCH;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;CANCER IMMUNOTHERAPY;GYNECOLOGIC ONCOLOGY;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ACUTE MYELOID LEUKEMIA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;BREAST CANCER SCREENING TECHNOLOGY;COLORECTAL CANCER RESEARCH AND TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;GLIOMAS;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;PANCREATIC CANCER RESEARCH AND TREATMENT;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING","10;8;6;6;6;6;6;4;4;4;3;3;3;3;3;3;3;3;3;3","REGIMEN;EXTRACORPOREAL MEMBRANE OXYGENATION;HEART RATE VARIABILITY;CUMULATIVE INCIDENCE;DISCONTINUATION;POSITIVE END-EXPIRATORY PRESSURE;CLINICAL ENDPOINT;EXTRACORPOREAL;SENTINEL LYMPH NODE BIOPSY;TREATMENT;CARDIAC SUPPORT DEVICE;CONCOMITANT;CONTRAST-ENHANCED MAMMOGRAPHY;DEPRESSION (ECONOMICS);ECMO;ETIOLOGY;HEMATOPOIETIC CELL TRANSPLANTATION;INDOCYANINE GREEN;METASTATIC COLORECTAL CANCER;NON-SMALL CELL LUNG CANCER","8;7;7;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4","LUNG CANCER;CELL LUNG;PHASE III;CELL TRANSPLANTATION;CONTRAST DETECTABILITY;PATIENTS PTS;RANDOMIZED PHASE;STEM CELL;CANCER PATIENTS;EXTRACORPOREAL MEMBRANE;LOW CONTRAST;MEMBRANE OXYGENATION;NON-SMALL CELL;PHASE II;ACUTE LYMPHOBLASTIC;AMYOTROPHIC LATERAL;BREAST CANCER;COHORT STUDY;COMPUTED TOMOGRAPHY;III STUDY;ITALIAN COHORT;LATERAL SCLEROSIS;NODE MAPPING;NON-SMALL-CELL LUNG;PRELIMINARY RESULTS;ACUTE MYELOID;ADVANCED BREAST;ATRIAL FIBRILLATION;BONE MARROW;CANCER NSCLC","15;8;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","ADVERSE EVENTS;LUNG CANCER;PATIENTS RECEIVING;PD-L EXPRESSION;PSUBMUSSUBEASUBDISUB INDEX;RENAL RELAPSE;MONZA ITALY;POSITIVE END-EXPIRATORY;CHILDHOOD CANCER;CIK CELLS;HR CI;INTENSIVE CARE;BLOOD PRESSURE;DAILY NURSING;DETECTION RATE;MEDIAN AGE;PATIENTS PTS;PATIENTS RECEIVED;PATIENTS TREATED;SLN MAPPING;STEM CELL;CANCER SURVIVORS;CARE UNITS;CLINICAL PRACTICE;ITALY OSPEDALE;RESPONSE RATE;RISK FACTORS;SURVIVAL OS;UNEXPLAINED FALLS;ACTIVITY SCORE","16;13;13;12;12;12;11;10;9;9;9;9;8;8;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;6",94,0.41,8.97,7,2.25,2,2,2.25,11,0,1.5,7,1,1,6.75,1,1,2,4.75,5,3,0,0,72,72.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3.76,611.76,6.51,5,0.29,53,0,0,4,0,6,0,0,7,0,11,6,0,0,0,0,0,0,17,0,0,17,0,0,0,0,0,0,0,0,0,"Italy;Spain;Germany;Hungary;United Kingdom;United States","2;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;46 INFORMATION AND COMPUTING SCIENCES","15;7;7;3;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;LUNG;RARE DISEASES;CARDIOVASCULAR;INFANT MORTALITY;LYMPHOMA;PATIENT SAFETY;PREVENTION;HEART DISEASE;LUNG CANCER;ORPHAN DRUG;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;AGING;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING","16;10;7;5;5;5;3;3;3;3;3;2;2;2;2;2;2;1;1;1","CANCER;CARDIOVASCULAR;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","6;3;2;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING","10;3;2;2;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA","2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,"PUBLIC LIBRARY OF SCIENCE","21","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3103 ECOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;49 MATHEMATICAL SCIENCES;39 EDUCATION;3904 SPECIALIST STUDIES IN EDUCATION","30;12;5;3;2;2;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HIV/AIDS;INFECTIOUS DISEASES;IMMUNIZATION;KIDNEY DISEASE;LUNG;MENTAL HEALTH;PEDIATRIC;PEDIATRIC AIDS;PNEUMONIA;PNEUMONIA & INFLUENZA;PREVENTION;VACCINE RELATED","2;2;2;2;1;1;1;1;1;1;1;1;1;1","INFECTION;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM","3;2;1","3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","1;1;1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","7","CERVICAL CANCER;KIDNEY CANCER","1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_SANGERARDO",2017,258,15.7945736434109,2.14341085271318,0.205426356589147,0.224806201550388,0.248062015503876,1.95406360424028,1.35897435897436,1.52631578947368,1.42222222222222,0.538759689922481,0,148,54,18,14,0.57,0.21,0.07,0.05,25.71,0.872371659170527,5.74273504273505,0.368217054263566,0.98062015503876,0.505,0.507,0.46,0.487,"DIEGO CORTINOVIS;PAOLO BIDOLI;RODOLFO MILANI;DOMENICO GALETTA;STEFANO MANODORO;MATTEO FRIGERIO;MARINA ELENA CAZZANIGA;MASSIMO CLERICI;FABRIZIA COLMEGNA;ANGELO DELMONTE;ROSSELLA PARINI;FEDERICO CAPPUZZO;FILIPPO DE MARINIS;LUCIO CRINÓ;GIUSEPPE BELLELLI;PAOLO MARCHETTI;LORENZA BORIN;ESTER DI GIACOMO;ALESSANDRO RAMBALDI;FEDERICO SPELZINI","25;17;13;12;12;12;12;11;10;10;10;8;8;8;8;8;8;7;7;7","RODOLFO MILANI;STEFANO MANODORO;MATTEO FRIGERIO;MASSIMO CLERICI;FABRIZIA COLMEGNA;DIEGO CORTINOVIS;FEDERICO SPELZINI;PAOLO BIDOLI;ESTER DI GIACOMO;ROSSELLA PARINI;ANTONIOS DAKANALIS;GIUSEPPE RIVA;STEFANIA PALMIERI;GIUSEPPE CITERIO;LUCA GIANOTTI;ALICE COLA;MARINA ELENA CAZZANIGA;ROBERTO GIUGLIANI;ANTONIO PESENTI;FELICE ACHILLI","2.85;2.68;2.68;1.83;1.66;1.49;1.4;1.12;1.01;0.95;0.82;0.82;0.78;0.78;0.74;0.73;0.72;0.7;0.67;0.65","DIEGO CORTINOVIS;PAOLO BIDOLI;RODOLFO MILANI;STEFANO MANODORO;MATTEO FRIGERIO;MARINA ELENA CAZZANIGA;MASSIMO CLERICI;FABRIZIA COLMEGNA;ROSSELLA PARINI;GIUSEPPE BELLELLI;LORENZA BORIN;ESTER DI GIACOMO;ANDREA GORI;ALESSANDRA BANDERA;LUCIO TREMOLIZZO;ANTONIO PESENTI;FELICE ACHILLI;GIACOMO BELLANI;LUCA GIANOTTI;GIORGIO ANNONI","25;17;13;12;12;12;11;10;10;8;8;7;7;7;6;6;5;5;5;5","RODOLFO MILANI;STEFANO MANODORO;MATTEO FRIGERIO;MASSIMO CLERICI;FABRIZIA COLMEGNA;DIEGO CORTINOVIS;PAOLO BIDOLI;ESTER DI GIACOMO;ROSSELLA PARINI;STEFANIA PALMIERI;GIUSEPPE CITERIO;LUCA GIANOTTI;ALICE COLA;MARINA ELENA CAZZANIGA;ANTONIO PESENTI;FELICE ACHILLI;GIACOMO GRASSELLI;GIUSEPPE BELLELLI;GIORGIO CATTORETTI;ANDREA GORI","2.85;2.68;2.68;1.83;1.66;1.49;1.12;1.01;0.95;0.78;0.78;0.74;0.73;0.72;0.67;0.65;0.59;0.59;0.58;0.58","DIEGO CORTINOVIS;LUÍS PAZ-ARES;DENIS MORO‐SIBILOT;ALEXIS B. CORTOT;CHONG‐JEN YU;CHUN‐MING TSAI;FABRICE BRANLE;GILBERTO DE CASTRO;JEAN‐CHARLES SORIA;PARAMITA SEN;ROSARIO GARCÍA CAMPELO;SARAYUT LUCIEN GEATER;TRACEY MCCULLOCH;YI‐LONG WU;RITA CHIARI;CRISTIAN MASSACESI;DANIEL S.W. TAN;JUERGEN WOLF;MARGARET DUGAN;MAXIMILLIAN HOCHMAIR","1418;1068;1067;1024;1024;1024;1024;1024;1024;1024;1024;1024;1024;1024;1016;1010;1010;1010;1010;1010","DIEGO CORTINOVIS;GIACOMO BELLANI;NILDE ERONIA;PAOLO BIDOLI;GIUSEPPE BELLELLI;R.M. NIESPOLO;FRANCESCA RIVA;STEFANO MANODORO;RODOLFO MILANI;MATTEO FRIGERIO;ADRIANA BALDUZZI;ROSSELLA PARINI;CARLO FERRARESE;MASSIMO CLERICI;ATTILIO ROVELLI;NICOLÒ PATRONITI;GIORGIO ANNONI;ANDREA GORI;FABRIZIA COLMEGNA;ANNA MARIA PERI","1418;669;529;506;340;221;173;171;165;162;160;158;155;148;139;139;137;136;129;127","DIEGO CORTINOVIS;PAOLO BIDOLI;MARINA ELENA CAZZANIGA;ROSSELLA PARINI;STEFANO MANODORO;RODOLFO MILANI;FABRIZIA COLMEGNA;MATTEO FRIGERIO;LORENZA BORIN;GIUSEPPE BELLELLI;MASSIMO CLERICI;FELICE ACHILLI;ADRIANA BALDUZZI;ANDREA GORI;ALESSANDRA BANDERA;CARLO FERRARESE;ELENA DE PONTI;FRANCESCA CESANA;GIORGIO ANNONI;GIUSEPPE GAIPA","25;17;10;10;10;10;10;9;8;7;7;5;5;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;ENGINEERING;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;PHILOSOPHY;SOCIOLOGY;MATHEMATICS;HISTORY;BUSINESS;MATERIALS SCIENCE;POLITICAL SCIENCE","254;64;24;24;19;12;10;7;6;6;4;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;GENETICS;INTENSIVE CARE MEDICINE;PSYCHIATRY;GASTROENTEROLOGY;PEDIATRICS;CARDIOLOGY;IMMUNOLOGY;PHYSICAL THERAPY;RADIOLOGY;ANESTHESIA;BIOCHEMISTRY;NURSING;CLINICAL PSYCHOLOGY;MECHANICAL ENGINEERING;CANCER RESEARCH;OPTICS","210;71;70;44;42;36;34;31;30;29;24;23;18;17;16;16;15;13;13;12;12","CANCER;POPULATION;CHEMOTHERAPY;DISEASE;COHORT;GENE;LUNG CANCER;ADVERSE EFFECT;BONE MARROW;CONFIDENCE INTERVAL;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;TRANSPLANTATION;ANXIETY;RANDOMIZED CONTROLLED TRIAL;STEM CELL;HEART FAILURE;INCIDENCE (GEOMETRY);OBSERVATIONAL STUDY;PREGNANCY","55;38;37;34;24;23;22;20;17;17;16;15;15;13;13;13;11;11;11;11","BREAST CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;CISPLATIN;COLORECTAL CANCER;DOCETAXEL;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CYCLOPHOSPHAMIDE;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;ENZYME REPLACEMENT THERAPY;GENOTYPE;MUTATION;MYELODYSPLASTIC SYNDROMES;NATIVE TISSUE;PHASES OF CLINICAL RESEARCH;PLACEBO;ARDS;HAEMATOPOIESIS;MALIGNANT PLEURAL EFFUSION;MULTICENTER STUDY;PROGRESSION-FREE SURVIVAL;TOLERABILITY","19;14;13;12;12;12;11;9;8;6;6;6;6;6;6;6;6;5;5;5;5;5;5","METASTATIC BREAST CANCER;NIVOLUMAB;PEMETREXED;OXALIPLATIN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TAXANE;VINORELBINE;BINGE-EATING DISORDER;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CRIZOTINIB;KRAS;NILOTINIB;ROS1;SENTINEL NODE;TRIPLE-NEGATIVE BREAST CANCER;ALLELE FREQUENCY;ANAPLASTIC LYMPHOMA KINASE;ANTHRACYCLINE;ANTIRETROVIRAL THERAPY;BOSENTAN;BUSULFAN;CAPECITABINE;CARBOPLATIN;CD3;DNA METHYLATION;EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION;FERTILITY PRESERVATION;FLUDARABINE;HEMATOPOIETIC CELL;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MEDDRA;NEOADJUVANT THERAPY;NON-SMALL CELL LUNG CANCER (NSCLC);PEMBROLIZUMAB;SACUBITRIL;SENTINEL LYMPH NODE;SEXUAL ABUSE;TAMOXIFEN;THIOTEPA;TRABECTEDIN","11;11;6;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;;MALE;MIDDLE AGED;ADULT;AGED;ITALY;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;YOUNG ADULT;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;ADOLESCENT;CARCINOMA, NON-SMALL-CELL LUNG;HEMATOPOIETIC STEM CELL TRANSPLANTATION;PROSPECTIVE STUDIES;RISK FACTORS;PELVIC ORGAN PROLAPSE","141;125;113;105;83;69;69;58;36;35;34;31;29;27;26;23;21;19;19;18","ADVANCEMENTS IN LUNG CANCER RESEARCH;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;PELVIC FLOOR DISORDERS;CANCER IMMUNOTHERAPY;ACUTE MYELOID LEUKEMIA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GYNECOLOGIC ONCOLOGY;EATING DISORDERS AND BODY IMAGE CONCERNS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF HEART FAILURE;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;EFFICACY AND RESISTANCE IN CML TREATMENT;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;LYMPHOID NEOPLASMS;PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING","16;11;10;8;7;7;7;6;5;5;4;4;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;REGIMEN;NON-SMALL CELL LUNG CANCER;REFRACTORY (PLANETARY SCIENCE);STROKE (ENGINE);ATEZOLIZUMAB;BREAST CANCER;METASTATIC BREAST CANCER;MUCOPOLYSACCHARIDOSES;NATIVE TISSUE;PEMETREXED;TREATMENT GUIDELINES;EXPANDED ACCESS;PROGRESSION-FREE SURVIVAL;TOLERABILITY;TREATMENT;CARDIAC IMAGING;CHEMOTHERAPY-INDUCED NAUSEA;DISCONTINUATION;DSM-5","14;9;7;7;7;6;6;6;6;6;6;6;5;5;5;5;4;4;4;4","LUNG CANCER;BREAST CANCER;NON-SMALL-CELL LUNG;STEM CELL;CELL TRANSPLANTATION;PATIENTS PTS;III STUDY;CANCER NSCLC;EXPANDED ACCESS;PHASE III;RANDOMIZED PHASE;ELDERLY PATIENTS;MYELOID LEUKEMIA;PHASE II;PRELIMINARY RESULTS;ACCESS PROGRAMME;ADVANCED NSCLC;BONE MARROW;HEMATOPOIETIC STEM;MULTICENTER STUDY;OBSERVATIONAL STUDY;ACUTE LEUKEMIA;ACUTE LYMPHOBLASTIC;ACUTE MYELOID;ADVANCED BREAST;ADVANCED NON-SMALL-CELL;CANCER PATIENTS;CELL LUNG;COHORT STUDY;ELOSULFASE ALFA","19;11;11;10;9;9;8;7;7;7;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","CPKO MICE;FERROXIDASE ACTIVITY;HR CI;ADVERSE EVENTS;ITALY SEARCH;LUNG CANCER;MGKG ATLG;SAFETY PROFILE;WT MICE;CLINICAL TRIAL;MEDIAN FOLLOW-UP;MILAN ITALY;RESPONSE RATE;CARDIOPULMONARY RESUSCITATION;DISEASE CONTROL;INSTITUTE MILAN;IRCCS-SAN RAFFAELE;PROGRESSION-FREE SURVIVAL;RAFFAELE SCIENTIFIC;SCIENTIFIC INSTITUTE;ADMINISTERED CP;HIP FRACTURE;MEDIAN AGE;STAGE III;STEM CELL;COHORT STUDY;CONFIDENCE INTERVAL;PD-L EXPRESSION;BIOCHEMISTRY DIVISION;BIOLOGY IRCCS-SAN","40;24;23;19;18;16;16;14;14;13;13;13;13;12;12;12;12;12;12;12;11;11;11;11;11;10;10;10;9;9",106,0.41,9.3,10.75,2,1,1,4,37,0,1,11.75,1,1,10,0,3,2,4,8,3,0,0,74.5,72.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,4.41,872.41,14.29,24,0.65,82.57,1,2,10,1,13,0,1,9,0,30,7,0,0,0,0,0,0,34,3,0,37,0,0,0,0,0,0,0,0,0,"Italy;United States;Germany;Japan;United Kingdom;Denmark;Switzerland","8;7;2;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","36;19;16;6;4;4;3;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;RARE DISEASES;LUNG CANCER;PATIENT SAFETY;BRAIN DISORDERS;HEMATOLOGY;BREAST CANCER;PREVENTION;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;NEUROSCIENCES;PEDIATRIC;AGING;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;GENETICS","32;23;18;16;16;7;7;6;6;4;4;3;3;3;3;2;2;2;2;2","CANCER;RESPIRATORY;CARDIOVASCULAR;CONGENITAL;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;NEUROLOGICAL","17;4;2;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES;6.7 PHYSICAL;7.3 MANAGEMENT AND DECISION MAKING","28;5;4;1;1;1;1","LUNG CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;HODGKIN'S DISEASE;MYELOMA;NOT SITE-SPECIFIC CANCER;RESPIRATORY SYSTEM","11;4;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","14;3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,"PUBLIC LIBRARY OF SCIENCE","22","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;44 HUMAN SOCIETY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;37 EARTH SCIENCES;3704 GEOINFORMATICS;4406 HUMAN GEOGRAPHY;49 MATHEMATICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4303 HISTORICAL STUDIES;4403 DEMOGRAPHY;4905 STATISTICS","28;5;5;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;HIV/AIDS;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN CANCER;BRAIN DISORDERS;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;COMPLEMENTARY AND INTEGRATIVE HEALTH;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;HEPATITIS;HEPATITIS - C;INFECTIOUS DISEASES;LIVER DISEASE;LYMPHOMA;NEUROSCIENCES;PEDIATRIC;PEDIATRIC AIDS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INFECTION;CANCER;ORAL AND GASTROINTESTINAL","9;3;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION","3;2;1;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","3;1;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","10;2;2","NON-HODGKIN'S LYMPHOMA;HODGKIN'S DISEASE;LIVER CANCER;CERVICAL CANCER;BRAIN TUMOR","4;3;3;2;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_SANGERARDO",2018,265,16.2830188679245,1.94716981132075,0.2,0.207547169811321,0.415094339622642,1.94716981132075,1.23255813953488,1.83333333333333,1.41025641025641,0.558490566037736,3,146,62,9,17,0.55,0.23,0.03,0.06,26.9,0.881666743817396,5.60450660450661,0.362264150943396,0.973584905660377,0.501,0.457,0.353,0.464,"DIEGO CORTINOVIS;ALESSANDRA IURLO;ELENA MARIA ELLI;FRANCESCA PALANDRI;PAOLO BIDOLI;MATTEO FRIGERIO;GIUSEPPE BELLELLI;NICOLA VIANELLI;MARCO SCARCI;GIOVANNI ROVARIS;GIUSEPPE CITERIO;STEFANIA PALMIERI;RODOLFO MILANI;STEFANO MANODORO;CARLO GAMBACORTI‐PASSERINI;DANIELE CATTANEO;PIETRO PIOLTELLI;FEDERICO CAPPUZZO;CHIARA ELENA;LUCA BERTOLACCINI","14;12;12;10;10;9;9;9;9;9;9;9;8;8;7;7;7;6;6;6","MARCO SCARCI;DIEGO CORTINOVIS;MATTEO FRIGERIO;STEFANIA PALMIERI;RODOLFO MILANI;STEFANO MANODORO;GIUSEPPE BELLELLI;FABRIZIO MINERVINI;ALICE COLA;SERGIO DE SALVATORE;LUCA BERTOLACCINI;BENEDETTA BEDETTI;SABRINA MORZENTI;DAVIDE PATRINI;ELENA DE PONTI;CARLO GAMBACORTI‐PASSERINI;DAVIDE IPPOLITO;ALBERTO PIPERNO;FEDERICO SPELZINI;GIUSEPPE CITERIO","2.66;2.2;1.55;1.55;1.5;1.5;1.21;1.13;1.1;1;0.96;0.96;0.82;0.82;0.8;0.78;0.76;0.75;0.73;0.7","DIEGO CORTINOVIS;ELENA MARIA ELLI;PAOLO BIDOLI;MATTEO FRIGERIO;GIUSEPPE BELLELLI;MARCO SCARCI;GIOVANNI ROVARIS;GIUSEPPE CITERIO;STEFANIA PALMIERI;RODOLFO MILANI;STEFANO MANODORO;CARLO GAMBACORTI‐PASSERINI;PIETRO PIOLTELLI;FEDERICO CAPPUZZO;LUCA BERTOLACCINI;MARINA ELENA CAZZANIGA;DAVIDE IPPOLITO;ANDREA BIONDI;ANDREA GORI;ROSSELLA PARINI","14;12;10;9;9;9;9;9;9;8;8;7;7;6;6;6;6;6;6;6","MARCO SCARCI;DIEGO CORTINOVIS;MATTEO FRIGERIO;STEFANIA PALMIERI;RODOLFO MILANI;STEFANO MANODORO;GIUSEPPE BELLELLI;FABRIZIO MINERVINI;ALICE COLA;SERGIO DE SALVATORE;LUCA BERTOLACCINI;BENEDETTA BEDETTI;SABRINA MORZENTI;DAVIDE PATRINI;ELENA DE PONTI;CARLO GAMBACORTI‐PASSERINI;DAVIDE IPPOLITO;ALBERTO PIPERNO;GIUSEPPE CITERIO;GIOVANNI ROVARIS","2.66;2.2;1.55;1.55;1.5;1.5;1.21;1.13;1.1;1;0.96;0.96;0.82;0.82;0.8;0.78;0.76;0.75;0.7;0.67","ALESSANDRO BUDA;ALDO LÓPEZ;ANDREAS OBERMAIR;DAVID ISLA;JAMES NICKLIN;KRISTY ROBLEDO;MARCELO VIEIRA;MARIANO TAMURA;MICHAEL FRUMOVITZ;NAVEN CHETTY;PEDRO T. RAMÍREZ;REBECCA ASHER;REITAN RIBEIRO;RENÉ PAREJA;ROBERT L. COLEMAN;SHUZHONG YAO;TAO ZHU;VAL GEBSKI;VANESSA BEHAN;XIAOJIAN YAN","1566;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511;1511","ALESSANDRO BUDA;PAOLO BIDOLI;DIEGO CORTINOVIS;GIUSEPPE CITERIO;GIUSEPPE BELLELLI;ANTONIO CIRÒ;ALBERTO PESCI;ALBERTO CASTELNUOVO;DANIELE MUNEGATO;GIOVANNI ZATTI;L RIGAMONTI;MARCO BIGONI;MARCO TURATI;MASSIMILIANO PIATTI;ALESSIA VARGIOLU;GIULIO LEONE;STEFANIA CANOVA;MANUELA CARUGATI;ELENA MARIA ELLI;ALESSANDRO SORIA","1566;667;577;356;331;327;239;214;214;214;214;214;214;214;190;185;154;131;130;125","DIEGO CORTINOVIS;ELENA MARIA ELLI;GIOVANNI ROVARIS;PAOLO BIDOLI;GIUSEPPE CITERIO;GIUSEPPE BELLELLI;PIETRO PIOLTELLI;MARCO SCARCI;MATTEO FRIGERIO;RODOLFO MILANI;STEFANIA PALMIERI;ALICE COLA;CARLO GAMBACORTI‐PASSERINI;MARINA ELENA CAZZANIGA;MONICA CARPENEDO;ROSSELLA PARINI;ELENA DE PONTI;SABRINA MORZENTI;ALBERTO PESCI;ALBERTO PIPERNO","14;12;9;9;8;7;7;7;7;7;7;6;6;6;6;6;5;5;4;4","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;MATHEMATICS;ECONOMICS;PSYCHOLOGY;SOCIOLOGY;ART;GEOGRAPHY;HISTORY;MATERIALS SCIENCE;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE","252;60;21;18;15;13;13;11;11;6;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;GENETICS;INTENSIVE CARE MEDICINE;PSYCHIATRY;IMMUNOLOGY;PEDIATRICS;BIOCHEMISTRY;ANESTHESIA;NUCLEAR MEDICINE;NURSING;GENERAL SURGERY;MECHANICAL ENGINEERING;OPTICS","200;91;54;46;35;32;28;28;28;28;27;25;25;22;19;19;12;11;11;11","CANCER;CHEMOTHERAPY;COHORT;DISEASE;POPULATION;BONE MARROW;GENE;CONFIDENCE INTERVAL;LUNG CANCER;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;MULTIVARIATE ANALYSIS;PROSPECTIVE COHORT STUDY;LUNG;OBSERVATIONAL STUDY;TRANSPLANTATION;ALTERNATIVE MEDICINE;CLINICAL TRIAL;INCIDENCE (GEOMETRY);LYMPHOMA;ODDS RATIO;STEM CELL","45;29;28;27;26;22;22;18;17;17;17;15;14;14;13;13;13;11;11;10;10;10;10","HAZARD RATIO;IMMUNOTHERAPY;CLINICAL ENDPOINT;BREAST CANCER;UNIVARIATE ANALYSIS;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DOCETAXEL;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MYELOFIBROSIS;PROGRESSION-FREE SURVIVAL;IMMUNE THROMBOCYTOPENIA;RITUXIMAB;DEMENTIA;GENE EXPRESSION;HAEMATOPOIESIS;IMATINIB;MUTATION;MYELODYSPLASTIC SYNDROMES;CUMULATIVE INCIDENCE;FETUS;INTERSTITIAL LUNG DISEASE;ISCHEMIC STROKE;NEUTROPENIA;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;TOLERABILITY","13;12;11;9;9;7;7;7;7;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4","NIVOLUMAB;OXALIPLATIN;ELTROMBOPAG;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KRAS;RUXOLITINIB;THROMBOPOIETIN;DNA METHYLATION;IMATINIB MESYLATE;KARYOTYPE;METASTATIC BREAST CANCER;NILOTINIB;POINT MUTATION;ANAPLASTIC LYMPHOMA KINASE;ANTIRETROVIRAL THERAPY;ANTISYNTHETASE SYNDROME;CD3;CONNECTIVE TISSUE DISEASE;CRIZOTINIB;CYTOGENETICS;DIFFUSING CAPACITY;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;IDIOPATHIC INTERSTITIAL PNEUMONIA;INEFFECTIVE ERYTHROPOIESIS;MICROANGIOPATHIC HEMOLYTIC ANEMIA;MISSENSE MUTATION;MODIFIED RANKIN SCALE;MYELOPROLIFERATIVE NEOPLASM;POSACONAZOLE;PRENATAL DIAGNOSIS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;VINORELBINE","10;6;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;AGED;MIDDLE AGED;ADULT;LUNG NEOPLASMS;RETROSPECTIVE STUDIES;ITALY;CARCINOMA, NON-SMALL-CELL LUNG;TREATMENT OUTCOME;AGED, 80 AND OVER;ADOLESCENT;ANTINEOPLASTIC AGENTS;CHILD;PROSPECTIVE STUDIES;ANTIBODIES, MONOCLONAL;CHILD, PRESCHOOL;RISK FACTORS","133;130;108;99;69;67;46;44;39;36;33;33;31;25;24;19;19;17;17;17","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ATRIAL FIBRILLATION;PELVIC FLOOR DISORDERS;CANCER IMMUNOTHERAPY;LYMPHOID NEOPLASMS;EFFICACY AND RESISTANCE IN CML TREATMENT;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;ACUTE MYELOID LEUKEMIA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GYNECOLOGIC ONCOLOGY;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;HEMATOPOIETIC STEM CELL BIOLOGY;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH","10;8;8;8;7;6;5;5;4;4;4;4;4;4;4;4;4;4;4;3","CLINICAL ENDPOINT;TREATMENT;REGIMEN;UNIVARIATE ANALYSIS;CANCER IMAGING;STROKE (ENGINE);DISCONTINUATION;HEMATOPOIETIC CELL TRANSPLANTATION;PROGRESSION-FREE SURVIVAL;INTERQUARTILE RANGE;MYELOFIBROSIS;PET/CT;REFRACTORY (PLANETARY SCIENCE);ATRIAL FIBRILLATION;DIAGNOSTIC IMAGING;ELTROMBOPAG;FOLFOX;ATEZOLIZUMAB;CUMULATIVE INCIDENCE;PELVIC ORGAN PROLAPSE","11;11;9;9;8;8;7;7;7;6;6;6;6;5;5;5;5;4;4;4","LUNG CANCER;NON-SMALL-CELL LUNG;CELL LUNG;CELL TRANSPLANTATION;RETROSPECTIVE STUDY;STEM CELL;ACUTE LYMPHOBLASTIC;BREAST CANCER;CANCER PATIENTS;COLORECTAL CANCER;LYMPHOBLASTIC LEUKEMIA;MYELOID LEUKEMIA;NON-SMALL CELL;OBSERVATIONAL STUDY;PATIENTS TREATED;BRAIN INJURY;III STUDY;PHASE III;PRELIMINARY RESULTS;RISK FACTORS;ACUTE RESPIRATORY;ADVANCED BREAST;ADVANCED NON-SMALL-CELL;ATRIAL FIBRILLATION;CARE UNIT;CHRONIC MYELOID;CLINICAL OUTCOMES;ELDERLY PATIENTS;ENDOMETRIAL CANCER;HEALTH CARE","17;7;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;RESEARCH FUNDING;HONORARIA MEMBERSHIP;ADVISORY BOARD;PATIENTS TREATED;CONSULTANCY HONORARIA;BONE MARROW;HONORARIA RESEARCH;ADVERSE EVENTS;LUNG CANCER;BOARD SPEAKERS;MEDIAN AGE;SURVIVAL OS;ACUTE RESPIRATORY;FUNDING SPEAKERS;HR CI;CONSULTANCY NOVARTIS;DISTRESS SYNDROME;GENERIC IMATINIB;LIQUID BIOPSY;MELF PATTERN;MULTIVARIATE ANALYSIS;NOVARTIS CONSULTANCY;RESPIRATORY DISTRESS;TISSUE BIOPSY;CELGENE HONORARIA;MEDIAN TIME;PATIENTS RECEIVED","88;88;59;49;47;39;30;25;22;22;20;17;16;15;14;13;13;13;12;12;12;12;12;12;12;12;12;11;11;11",88,0.33,8.65,10.25,2,5.5,1.75,2.75,2.25,1,2,11.25,1,1,12,1,2.5,2,4.25,7.25,4,0,0,75.25,75.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,4.26,643.48,17.99,25,0.58,94.37,2,1,7,1,18,0,1,13,0,33,10,0,0,0,0,0,0,39,4,0,42,0,0,0,1,0,0,0,0,0,"United States;Japan;Italy;United Kingdom;Netherlands","10;5;4;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES","42;21;16;6;5;5;3;3;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;PATIENT SAFETY;LUNG;PREVENTION;BRAIN DISORDERS;BREAST CANCER;PEDIATRIC;CARDIOVASCULAR;HEMATOLOGY;LUNG CANCER;NEUROSCIENCES;DIGESTIVE DISEASES;NEURODEGENERATIVE;AGING;AUTOIMMUNE DISEASE;EMERGING INFECTIOUS DISEASES;HEART DISEASE","39;31;19;14;10;8;8;6;6;6;5;5;5;5;4;4;3;3;3;3","CANCER;CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;BLOOD;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY;STROKE","16;5;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.3 MEDICAL DEVICES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","30;4;4;3;2;2;1;1","BREAST CANCER;LUNG CANCER;LEUKEMIA / LEUKAEMIA;CERVICAL CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;KIDNEY CANCER;LIVER CANCER;OVARIAN CANCER","6;5;3;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","14;5;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;TAYLOR & FRANCIS GROUP;SAGE JOURNALS","9;4;2;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;4905 STATISTICS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;44 HUMAN SOCIETY;3103 ECOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;4403 DEMOGRAPHY;4404 DEVELOPMENT STUDIES;50 PHILOSOPHY AND RELIGIOUS STUDIES","8;8;8;4;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;PATIENT SAFETY;RARE DISEASES;ACUTE RESPIRATORY DISTRESS SYNDROME;CONTRACEPTION/REPRODUCTION;GENETIC TESTING;GENETICS;HEMATOLOGY;INFANT MORTALITY;LUNG;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN","3;2;2;1;1;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;CONGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","3;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;7.3 MANAGEMENT AND DECISION MAKING;8.1 ORGANISATION AND DELIVERY OF SERVICES","1;1;1;1","BIOMEDICAL;CLINICAL","1;1","CLINICAL MEDICINE AND SCIENCE","6","LIVER CANCER;NOT SITE-SPECIFIC CANCER","4;1","3 GOOD HEALTH AND WELL BEING","4"
"IRCCS_SANGERARDO",2019,279,17.9175627240143,2.02867383512545,0.14336917562724,0.186379928315412,0.243727598566308,1.92517006802721,1.17647058823529,1.44444444444444,1.21428571428571,0.594982078853047,1,128,81,8,20,0.46,0.29,0.03,0.07,20.71,0.851805637381625,5.82031789910158,0.39426523297491,0.96415770609319,0.487,0.492,0.39,0.462,"ELENA MARIA ELLI;FRANCESCA PALANDRI;ALESSANDRA IURLO;GIULIA BENEVOLO;NICOLA VIANELLI;DIEGO CORTINOVIS;ALESSANDRO RAMBALDI;MASSIMILIANO BONIFACIO;ROSSELLA PARINI;DANIELE CATTANEO;ALESSIA TIEGHI;DOMENICO GALETTA;MARCO SCARCI;ANDREA GORI;MASSIMO BRECCIA;ROBERTO LATAGLIATA;NICOLA POLVERELLI;ALESSANDRO BUDA;MARIO TIRIBELLI;ATTILIO ROVELLI","18;15;15;12;12;12;12;12;12;11;10;10;10;10;10;9;9;9;9;9","MARCO SCARCI;FELICE ACHILLI;GIACOMO BELLANI;ROSSELLA PARINI;LUCA DI LULLO;FULVIO FLOCCARI;RODOLFO RIVERA;FEDERICO RAVEGLIA;FRANCESCO FORMICA;STEFANO D’ALESSANDRO;ROBERT FRUSCIO;GIUSEPPE FOTI;RODOLFO MILANI;ATTILIO ROVELLI;ALESSANDRO BUDA;FABRIZIO MINERVINI;ELENA MARIA ELLI;ALBERTO FROIO;ANDREA GORI;SERGIO FORESTI","2.08;1.23;1.22;1.2;1.07;1.07;1.07;1.03;0.91;0.91;0.83;0.81;0.79;0.79;0.73;0.71;0.7;0.7;0.68;0.66","ELENA MARIA ELLI;DIEGO CORTINOVIS;ROSSELLA PARINI;MARCO SCARCI;ANDREA GORI;ALESSANDRO BUDA;ATTILIO ROVELLI;ROBERT FRUSCIO;PAOLO BIDOLI;GIACOMO BELLANI;PIETRO PIOLTELLI;LUCA GUERRA;CARLO FERRARESE;CARLO GAMBACORTI‐PASSERINI;FABIO LANDONI;LUCIO TREMOLIZZO;ADRIANA BALDUZZI;RODOLFO RIVERA;CINZIA CRIVELLARO;SILVIA MAITZ","18;12;12;10;10;9;9;9;9;8;8;7;7;6;6;6;6;6;5;5","MARCO SCARCI;FELICE ACHILLI;GIACOMO BELLANI;ROSSELLA PARINI;RODOLFO RIVERA;FRANCESCO FORMICA;STEFANO D’ALESSANDRO;ROBERT FRUSCIO;GIUSEPPE FOTI;RODOLFO MILANI;ATTILIO ROVELLI;ALESSANDRO BUDA;ELENA MARIA ELLI;ALBERTO FROIO;ANDREA GORI;SERGIO FORESTI;CARLO FERRARESE;LUCIO TREMOLIZZO;LUCA GUERRA;ANGELA BENTIVEGNA","2.08;1.23;1.22;1.2;1.07;0.91;0.91;0.83;0.81;0.79;0.79;0.73;0.7;0.7;0.68;0.66;0.65;0.61;0.61;0.58","MADDALENA LETTINO;ABILOVA SAAMAY;ADAM TIMMIS;AGNÈS PASQUET;ALDO P. MAGGIONI;ALEKSANDRA TORBICA;ALEXANDER ALADASHVILI;ALEŠ LINHART;ALIAKSANDR MROCHAK;AMIRAN GAMKRELIDZE;ANDREAS M. ZEIHER;ANDREJS ĒRGLIS;ANTOINE SARKIS;ARIK WOLAK;ARTAN AHMETI;AUREL DEMIRAJ;BARBARA CASADEI;BARBRA DALTON;BERNHARD METZLER;CHRIS P GALE","849;848;848;848;848;848;848;848;848;848;848;848;848;848;848;848;848;848;848;848","MADDALENA LETTINO;PAOLO BIDOLI;DIEGO CORTINOVIS;ELENA MARIA ELLI;ROBERT FRUSCIO;PIETRO PIOLTELLI;ALESSANDRO BUDA;MARIA ROSA POZZI;MARIA GRAZIA STREPPARAVA;GIACOMO BELLANI;SILVIA MAITZ;RAFFAELLA LONGARINI;MARCO SCARCI;CARLO FERRARESE;LORENZA BORIN;FABIO LANDONI;ELISABETTA TERRUZZI;GIOVANNI ROVARIS;ALBERTO LUCCHINI;HERMAN BONDI","849;564;368;308;256;180;177;177;153;148;145;121;120;114;109;107;102;100;98;98","ELENA MARIA ELLI;DIEGO CORTINOVIS;ROSSELLA PARINI;MARCO SCARCI;PAOLO BIDOLI;ALESSANDRO BUDA;GIACOMO BELLANI;PIETRO PIOLTELLI;GIOVANNI ROVARIS;LUCA GUERRA;ATTILIO ROVELLI;CARLO FERRARESE;ELENA DE PONTI;ALESSANDRO SORIA;ELISABETTA TERRUZZI;MONICA FUMAGALLI;SILVIA MAITZ;ADRIANA BALDUZZI;ALESSANDRO GIANI;CINZIA CRIVELLARO","18;12;10;10;9;8;8;8;7;7;6;6;6;5;5;5;5;4;4;4","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;MATHEMATICS;PHILOSOPHY;ECONOMICS;MATERIALS SCIENCE;POLITICAL SCIENCE;GEOLOGY;HISTORY;SOCIOLOGY","269;63;31;18;15;12;11;9;5;3;3;3;2;2;2","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;RADIOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;PEDIATRICS;ANESTHESIA;PSYCHIATRY;OPTICS;NUCLEAR MEDICINE;CANCER RESEARCH;ENDOCRINOLOGY;PHARMACOLOGY","217;81;64;49;38;38;29;27;26;25;25;25;23;21;20;17;16;13;12;10","CANCER;GENE;CHEMOTHERAPY;DISEASE;BONE MARROW;TRANSPLANTATION;POPULATION;COHORT;ADVERSE EFFECT;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;LUNG CANCER;PROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);STEM CELL;LEUKEMIA;ALTERNATIVE MEDICINE;BIOPSY;LUNG;MYELOID LEUKEMIA;RETROSPECTIVE COHORT STUDY","55;33;32;32;24;24;22;21;20;20;19;18;18;17;15;14;12;11;11;11;11;11","HEMATOPOIETIC STEM CELL TRANSPLANTATION;MYELOFIBROSIS;CLINICAL ENDPOINT;COLORECTAL CANCER;HAZARD RATIO;BREAST CANCER;CYCLOPHOSPHAMIDE;HAEMATOPOIESIS;ENDOMETRIAL CANCER;IMMUNOTHERAPY;MYELODYSPLASTIC SYNDROMES;PHENOTYPE;PLACEBO;RITUXIMAB;CERVICAL CANCER;IMATINIB;MUTATION;ACUTE LEUKEMIA;ADENOCARCINOMA;AMYOTROPHIC LATERAL SCLEROSIS;CATHETER ABLATION;CD34;CHROMOSOME;CUMULATIVE INCIDENCE;EJECTION FRACTION;ENZYME REPLACEMENT THERAPY;HEPATITIS C VIRUS;MALIGNANT PLEURAL EFFUSION;MULTICENTER STUDY;NEURORADIOLOGY;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;RANDOMIZATION;TEMOZOLOMIDE","15;14;13;13;12;10;8;8;7;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","RUXOLITINIB;OXALIPLATIN;BUSULFAN;CAPECITABINE;COLONOSCOPY;CRIZOTINIB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;MYELOPROLIFERATIVE NEOPLASM;NIVOLUMAB;SENTINEL LYMPH NODE;ANTIRETROVIRAL THERAPY;COPY-NUMBER VARIATION;DIFFUSING CAPACITY;ERLOTINIB;RIBAVIRIN;ROS1;SENTINEL NODE;ANAPLASTIC LYMPHOMA KINASE;AORTIC RUPTURE;CARBOPLATIN;CASPOFUNGIN;CD3;COLPOSCOPY;DNA METHYLATION;ELTROMBOPAG;EXOME SEQUENCING;GEFITINIB;HEMATOPOIETIC CELL;HEMATOPOIETIC STEM CELL;HPV INFECTION;IMATINIB MESYLATE;KARYOTYPE;KRAS;LATENT TUBERCULOSIS;NILOTINIB;PEMBROLIZUMAB;RIVAROXABAN;THIOTEPA;THROMBOPOIETIN;VATS LOBECTOMY","8;7;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;LUNG NEOPLASMS;AGED, 80 AND OVER;CARCINOMA, NON-SMALL-CELL LUNG;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;YOUNG ADULT;PROSPECTIVE STUDIES;ADOLESCENT;PRIMARY MYELOFIBROSIS;RISK FACTORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ATRIAL FIBRILLATION","153;123;118;108;87;72;71;56;42;38;36;34;31;29;28;26;26;22;20;20","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;HEPATITIS C INFECTION AND TREATMENT;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;ATRIAL FIBRILLATION;GYNECOLOGIC ONCOLOGY;ACUTE MYELOID LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD","18;9;8;8;8;7;7;6;6;5;4;4;4;4;3;3;3;3;3;3","CLINICAL ENDPOINT;TREATMENT;MYELOFIBROSIS;RUXOLITINIB THERAPY;HEMATOPOIETIC CELL TRANSPLANTATION;REGIMEN;RUXOLITINIB;CANCER IMAGING;DISCONTINUATION;INTERQUARTILE RANGE;REFRACTORY (PLANETARY SCIENCE);CARDIOVASCULAR EVALUATION;SENTINEL LYMPH NODE BIOPSY;TREATMENT OUTCOMES;ACUTE MYELOID LEUKEMIA;HEMATOLOGY;POSITIVE END-EXPIRATORY PRESSURE;PROGRESSION-FREE SURVIVAL;ATRIAL FIBRILLATION;BIOMARKER ANALYSIS","13;12;10;9;8;8;8;7;7;7;7;6;6;6;5;5;5;5;4;4","LUNG CANCER;STEM CELL;CELL TRANSPLANTATION;MYELOID LEUKEMIA;PHASE II;ACUTE LYMPHOBLASTIC;ENDOMETRIAL CANCER;LYMPHOBLASTIC LEUKEMIA;OBSERVATIONAL STUDY;ACUTE MYELOID;CELL LUNG;COHORT STUDY;ELDERLY PATIENTS;CHRONIC MYELOID;COLORECTAL CANCER;HEMATOPOIETIC STEM;METASTATIC COLORECTAL;PHASE III;PROSPECTIVE MULTICENTER;REPLACEMENT THERAPY;RETROSPECTIVE STUDY;ADULT PATIENTS;APLASTIC ANEMIA;ATRIAL FIBRILLATION;MULTICENTER STUDY;MULTICENTRE STUDY;NON-SMALL CELL;REAL LIFE;REAL WORLD;THORACIC SURGERY","12;10;9;9;9;7;7;7;7;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;ADVISORY CONSULTANCY;RESEARCH FUNDING;HONORARIA MEMBERSHIP;CONSULTANCY MEMBERSHIP;COMMITTEES SPEAKERS;CONSULTANCY HONORARIA;ADVERSE EVENTS;HR CI;MEDIAN AGE;NOVARTIS HONORARIA;CLINICAL TRIAL;NOVARTIS CONSULTANCY;HONORARIA NOVARTIS;PFIZER HONORARIA;STEM CELL;HONORARIA SPEAKERS;AMGEN HONORARIA;BUREAU EXPERT;EXPERT TESTIMONY;SPEAKER BUREAU;TRAVEL SUPPORT;RESPONSE RATE;RISK FACTORS;SURVIVAL OS;PATIENTS TREATED;CELGENE HONORARIA;CONFIDENCE INTERVAL","202;202;130;109;64;60;49;47;45;41;34;31;29;25;23;22;22;22;21;20;20;20;20;20;19;19;19;18;17;17",122,0.44,8.64,9.75,2,1,0,2,1.75,1,1,10.75,1,1,9.25,0,2,2,3,6,3.25,0,0,55.75,55.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,4.87,469.91,16.3,29,0.64,78.62,2,0,10,2,17,0,0,14,0,31,14,0,0,0,0,0,0,43,2,0,45,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany;Belgium;Japan;Portugal","13;8;3;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;4207 SPORTS SCIENCE AND EXERCISE","43;28;19;5;3;3;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;LUNG;HEMATOLOGY;LUNG CANCER;NEUROSCIENCES;PATIENT SAFETY;BREAST CANCER;ORPHAN DRUG;BRAIN DISORDERS;DIGESTIVE DISEASES;PEDIATRIC;PREVENTION;AGING;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;NEURODEGENERATIVE;TRANSPLANTATION","43;27;21;15;11;8;7;7;7;5;5;4;4;4;4;3;3;3;3;3","CANCER;CARDIOVASCULAR;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;BLOOD;RENAL AND UROGENITAL;RESPIRATORY","19;3;3;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","31;5;4;2;2;1;1;1;1","LUNG CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;LIVER CANCER;OVARIAN CANCER;BLOOD CANCER;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;PROSTATE CANCER","8;5;4;3;2;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.2 SURVEILLANCE","18;6;5;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","10;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;52 PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;48 LAW AND LEGAL STUDIES;5201 APPLIED AND DEVELOPMENTAL PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3202 CLINICAL SCIENCES;4804 LAW IN CONTEXT;3204 IMMUNOLOGY;44 HUMAN SOCIETY","17;6;5;3;3;3;2;2;2;1;1","CLINICAL RESEARCH;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;GENETICS;HEMATOLOGY;MENTAL HEALTH;VIOLENCE RESEARCH;ALS;BASIC BEHAVIORAL AND SOCIAL SCIENCE;CANCER;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;PREVENTION;STEM CELL RESEARCH;YOUTH VIOLENCE","5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;NEUROLOGICAL","1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","2;1;1","BIOMEDICAL;CLINICAL","3;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","6;2","LEUKEMIA / LEUKAEMIA;BLOOD CANCER;NON-HODGKIN'S LYMPHOMA","5;1;1","16 PEACE, JUSTICE AND STRONG INSTITUTIONS","3"
"IRCCS_SANGERARDO",2020,322,21.1614906832298,2.28571428571429,0.229813664596273,0.192546583850932,0.301242236024845,2.03601108033241,1.37037037037037,1.47619047619048,1.24358974358974,0.636645962732919,1,180,88,18,14,0.56,0.27,0.06,0.04,38.53,1.52897389010898,7.2852798053528,0.406832298136646,0.984472049689441,0.489,0.434,0.42,0.432,"DIEGO CORTINOVIS;GIACOMO BELLANI;ALESSANDRO BUDA;PIETRO INVERNIZZI;GIUSEPPE CITERIO;ELENA MARIA ELLI;MATTEO FRIGERIO;DAVIDE PAOLO BERNASCONI;ALESSANDRO RAMBALDI;PAOLO BONFANTI;SILVIA MAITZ;STEFANO MANODORO;MARCO DINELLI;SIMONE FAMULARO;FRANCESCA PALANDRI;SANDRO SIRONI;ALESSANDRA IURLO;LUCA GIANOTTI;GIUSEPPE FOTI;GIANPIERO MANES","19;14;13;13;11;11;10;10;10;10;9;9;9;8;8;8;8;8;8;8","DIEGO CORTINOVIS;MATTEO FRIGERIO;STEFANO MANODORO;MARIA COSTANZA MEAZZINI;MARTA BARBA;ALESSANDRO BUDA;GIACOMO BELLANI;PIETRO INVERNIZZI;LUCA GIANOTTI;MARCO CARBONE;ALESSIO GERUSSI;FABRIZIO MINERVINI;MARCO SCARCI;JAN NOVÝ;ANDREA O. ROSSETTI;GIUSEPPINA BARBELLA;STEFANIA PALMIERI;ALICE COLA;CARLO FERRARESE;RODOLFO MILANI","1.58;1.56;1.42;1.29;1.08;1.05;1.05;1.03;0.88;0.8;0.8;0.8;0.8;0.79;0.79;0.79;0.79;0.79;0.79;0.77","DIEGO CORTINOVIS;GIACOMO BELLANI;ALESSANDRO BUDA;PIETRO INVERNIZZI;GIUSEPPE CITERIO;ELENA MARIA ELLI;MATTEO FRIGERIO;PAOLO BONFANTI;SILVIA MAITZ;MARCO DINELLI;SIMONE FAMULARO;SANDRO SIRONI;LUCA GIANOTTI;GIUSEPPE FOTI;CARLO GAMBACORTI‐PASSERINI;DAVIDE IPPOLITO;ROBERT FRUSCIO;PAOLO BIDOLI;MARTA BARBA;MARCO CARBONE","19;14;13;13;11;11;10;10;9;9;8;8;8;8;8;8;8;8;7;7","DIEGO CORTINOVIS;MATTEO FRIGERIO;MARIA COSTANZA MEAZZINI;MARTA BARBA;ALESSANDRO BUDA;GIACOMO BELLANI;PIETRO INVERNIZZI;LUCA GIANOTTI;MARCO CARBONE;ALESSIO GERUSSI;FABRIZIO MINERVINI;MARCO SCARCI;JAN NOVÝ;ANDREA O. ROSSETTI;GIUSEPPINA BARBELLA;STEFANIA PALMIERI;ALICE COLA;CARLO FERRARESE;RODOLFO MILANI;SANDRO SIRONI","1.58;1.56;1.29;1.08;1.05;1.05;1.03;0.88;0.8;0.8;0.8;0.8;0.79;0.79;0.79;0.79;0.79;0.79;0.77;0.75","MASSIMILIANO GRECO;MAURIZIO CECCONI;GIACOMO BELLANI;ROBERTO FUMAGALLI;GIACOMO GRASSELLI;THOMAS LÄNGER;GIUSEPPE FOTI;ANDREA FORASTIERI MOLINARI;ANTONIO COLUCCELLO;EZIO BONANOMI;FERDINANDO LUCA LORINI;GIANPAOLO CASTELLI;GIORGIO ANTONIO IOTTI;GIOVANNI ALBANO;GIUSEPPE CRESCINI;LUCA CABRINI;NICOLA LATRONICO;SERGIO CATTANEO;SERGIO COLOMBO;GIUSEPPE CITERIO","5618;4789;4467;3643;3642;3594;3565;2930;2930;2930;2930;2930;2930;2930;2930;2930;2930;2930;2930;2922","GIACOMO BELLANI;GIUSEPPE FOTI;PAOLO BONFANTI;PIETRO INVERNIZZI;ERNESTO CONTRO;DIEGO CORTINOVIS;PAOLA FAVERIO;ALESSANDRO SORIA;MATTEO CAIRO;ANNA COPPO;ANNALISA BENINI;DARIO WINTERTON;GRAZIA MESSINESI;MICHELA DI PIERRO;PIETRO VANDONI;SARA MASSIRONI;PATRIZIA VERGANI;MARCO DINELLI;ILARIA BERETTA;MARIANNA ROSSI","2966;2064;900;871;567;549;548;530;483;475;475;475;475;475;430;376;357;354;334;326","DIEGO CORTINOVIS;ALESSANDRO BUDA;GIACOMO BELLANI;PIETRO INVERNIZZI;ELENA MARIA ELLI;MARCO DINELLI;MATTEO FRIGERIO;SILVIA MAITZ;DAVIDE IPPOLITO;GIOVANNI ROVARIS;GIUSEPPE CITERIO;PAOLO BIDOLI;GIUSEPPE FOTI;CARLO GAMBACORTI‐PASSERINI;MADDALENA LETTINO;PAOLO BONFANTI;ALESSIO GERUSSI;MARCO CARBONE;PAOLA FAVERIO;CARLO FERRARESE","19;13;12;12;10;9;9;9;8;8;8;8;8;7;7;7;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;PSYCHOLOGY;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;HISTORY;BUSINESS;MATERIALS SCIENCE;ART","306;82;30;17;14;11;11;11;6;6;5;4;3;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;GENETICS;IMMUNOLOGY;ENVIRONMENTAL HEALTH;CARDIOLOGY;PSYCHIATRY;PEDIATRICS;ANESTHESIA;EMERGENCY MEDICINE;PALEONTOLOGY;OPTICS;RADIOLOGY;CANCER RESEARCH;VIROLOGY;MECHANICAL ENGINEERING;NURSING","253;88;56;50;47;44;39;36;35;30;30;29;26;26;24;20;20;17;17;14;14","DISEASE;CANCER;COHORT;POPULATION;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;GENE;CONFIDENCE INTERVAL;LUNG;ADVERSE EFFECT;CLINICAL TRIAL;INCIDENCE (GEOMETRY);TRANSPLANTATION;BONE MARROW;RANDOMIZED CONTROLLED TRIAL;OUTBREAK;PROSPECTIVE COHORT STUDY;LEUKEMIA;MECHANICAL VENTILATION;PREGNANCY;PROPORTIONAL HAZARDS MODEL;STAGE (STRATIGRAPHY)","75;52;31;31;27;27;26;25;22;21;20;17;17;16;16;15;15;13;13;13;13;13","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;HAZARD RATIO;IMMUNOTHERAPY;2019-20 CORONAVIRUS OUTBREAK;CYCLOPHOSPHAMIDE;ARDS;COLORECTAL CANCER;PHENOTYPE;BREAST CANCER;CERVICAL CANCER;MYELOFIBROSIS;HEPATITIS C VIRUS;UNIVARIATE ANALYSIS;CHROMOSOME;CUMULATIVE INCIDENCE;MUTATION;MYELODYSPLASTIC SYNDROMES;ADENOCARCINOMA;CISPLATIN;GESTATIONAL AGE;GRAFT-VERSUS-HOST DISEASE;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;INFLIXIMAB;MULTICENTER STUDY;OVARIAN CANCER;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;RITUXIMAB;TIDAL VOLUME;TYPE 2 DIABETES;VIRAL LOAD","35;16;16;14;10;10;9;9;9;8;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;NIVOLUMAB;SENTINEL LYMPH NODE;VINCRISTINE;ANTIRETROVIRAL THERAPY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;RADICAL HYSTERECTOMY;RIBAVIRIN;RUXOLITINIB;AUTOSOME;CARDIAC RESYNCHRONIZATION THERAPY;COLECTOMY;COLONOSCOPY;DIFFUSING CAPACITY;DNA METHYLATION;EMPAGLIFLOZIN;ERLOTINIB;FLUDARABINE;GOLIMUMAB;HAPLOINSUFFICIENCY;IN UTERO;LEFT ATRIAL APPENDAGE OCCLUSION;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;MODIFIED RANKIN SCALE;MONOCLONAL;PEMETREXED;PROTEIN PHOSPHATASE 2;RESPIRATORY RATE;SINGLE-NUCLEOTIDE POLYMORPHISM;VAGINAL CANCER;VEDOLIZUMAB","35;7;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;ITALY;AGED;ADULT;COVID-19;RETROSPECTIVE STUDIES;PNEUMONIA, VIRAL;CORONAVIRUS INFECTIONS;TREATMENT OUTCOME;RESPIRATORY DISTRESS SYNDROME;PROSPECTIVE STUDIES;LUNG NEOPLASMS;AGED, 80 AND OVER;RISK FACTORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, NON-SMALL-CELL LUNG","163;156;112;89;74;60;58;57;39;39;38;35;31;30;27;26;23;22;20;20","MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CORONAVIRUS DISEASE 2019;GYNECOLOGIC ONCOLOGY;CANCER IMMUNOTHERAPY;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;HEMATOPOIETIC STEM CELL BIOLOGY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PELVIC FLOOR DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATITIS C INFECTION AND TREATMENT;IMPACT OF COVID-19 INFECTION ON PREGNANCY OUTCOMES;ACUTE MYELOID LEUKEMIA;HEPATOCELLULAR CARCINOMA;IMMUNOGENICITY OF BIOSIMILAR THERAPEUTICS IN DRUG DEVELOPMENT;LYMPHOID NEOPLASMS;MANAGEMENT OF CARDIAC ARREST AND RESUSCITATION","14;12;10;9;9;8;7;7;7;7;7;6;6;5;5;4;4;4;4;4","CLINICAL ENDPOINT;REGIMEN;INTERQUARTILE RANGE;PANDEMIC;DISCONTINUATION;2019-20 CORONAVIRUS OUTBREAK;TREATMENT;CONCOMITANT;POSITIVE END-EXPIRATORY PRESSURE;LIVER DISEASE;TREATMENT OUTCOMES;UNIVARIATE ANALYSIS;ATRIAL FIBRILLATION;CLINICAL CHARACTERISTICS;CUMULATIVE INCIDENCE;IMMUNE CHECKPOINT BLOCKADE;NONINVASIVE VENTILATION;PRIMARY SCLEROSING CHOLANGITIS;STROKE (ENGINE);TREATMENT GUIDELINES","18;12;10;10;9;8;8;7;7;6;6;6;5;5;5;5;5;5;5;5","ACUTE RESPIRATORY;PHASE II;ATRIAL FIBRILLATION;MYELOID LEUKEMIA;NORTHERN ITALY;OBSERVATIONAL STUDY;CERVICAL CANCER;DISTRESS SYNDROME;LUNG CANCER;MULTICENTER EXPERIENCE;PATIENTS TREATED;RESPIRATORY DISTRESS;STEM CELL;ACUTE LYMPHOBLASTIC;BILIARY CHOLANGITIS;BRAIN INJURY;CANCER PATIENTS;CARDIAC ARREST;CARE UNITS;CELL LUNG;CHRONIC MYELOID;COHORT STUDY;COVID- PANDEMIC;COVID- PATIENTS;EMERGENCY DEPARTMENT;LYMPH NODE;LYMPHOBLASTIC LEUKEMIA;MULTICENTER RETROSPECTIVE;MULTICENTER STUDY;PRIMARY BILIARY","8;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;RESEARCH FUNDING;HR CI;HONORARIA MEMBERSHIP;ENDOSCOPY UNITS;ACUTE RESPIRATORY;MM HG;PUBMED SCOPUS;CONSULTANCY HONORARIA;CROSSREF PUBMED;COMMITTEES SPEAKERS;INTENSIVE CARE;MILAN ITALY;CARE UNIT;MECHANICAL VENTILATION;ADVERSE EVENTS;HONORARIA SPEAKERS;SARS-COV- INFECTION;SUSTAINED HYPOCAPNIA;ONLINE PUBLICATION;PUBLICATION DATE;RESPIRATORY DISTRESS;MED -CROSSREF;COVID- PATIENTS;DIGESTIVE ENDOSCOPY;ENDOSCOPY UNIT;HEALTH CARE;PACO MM","133;133;94;72;56;47;46;40;39;38;37;35;33;33;32;29;29;28;27;27;27;26;26;26;25;23;22;22;22;22",178,0.55,10.34,13.75,2,1,0,2,2,1,1,15,1,1,13.5,1,1,3,5.5,9,6,0,0,65.5,66.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,3.29,648.22,17.61,32,0.57,64.21,2,1,3,0,18,0,1,31,0,27,29,0,0,0,0,0,0,50,6,0,55,0,0,1,0,0,0,0,0,0,"Italy;United States;Switzerland;Netherlands;Belgium;France;United Kingdom;Germany;Japan;Sweden;Austria;Czechia;Denmark;Poland;Spain","25;13;6;5;3;3;3;2;2;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3209 NEUROSCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4204 MIDWIFERY;4205 NURSING","55;33;19;5;5;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;LUNG;INFECTIOUS DISEASES;PREVENTION;PATIENT SAFETY;HEMATOLOGY;EMERGING INFECTIOUS DISEASES;LUNG CANCER;LYMPHOMA;NEUROSCIENCES;PNEUMONIA;PNEUMONIA & INFLUENZA;BRAIN DISORDERS;PEDIATRIC;VACCINE RELATED;AGING;BIOTECHNOLOGY","53;27;22;19;17;15;13;12;11;8;6;5;5;5;5;4;4;4;3;3","CANCER;INFECTION;BLOOD;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","16;9;2;2;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION;7.3 MANAGEMENT AND DECISION MAKING;6.4 SURGERY;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.1 INDIVIDUAL CARE NEEDS;8.1 ORGANISATION AND DELIVERY OF SERVICES","27;5;4;3;3;2;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;OVARIAN CANCER;NOT SITE-SPECIFIC CANCER;BRAIN TUMOR;LIVER CANCER","6;6;5;3;3;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","14;2;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,"ZENODO;PUBLIC LIBRARY OF SCIENCE;FRONTIERS;KARGER PUBLISHERS","10;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;44 HUMAN SOCIETY;4403 DEMOGRAPHY;47 LANGUAGE, COMMUNICATION AND CULTURE;49 MATHEMATICAL SCIENCES","27;10;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;HEART DISEASE;RARE DISEASES;BIOTECHNOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;DIGESTIVE DISEASES - (GALLBLADDER);HEART DISEASE - CORONARY HEART DISEASE;LUNG;PATIENT SAFETY;PNEUMONIA & INFLUENZA;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;BRAIN DISORDERS;CANCER;GENETICS;HUMAN GENOME;INFECTIOUS DISEASES;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD)","10;8;6;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","CARDIOVASCULAR;CANCER;RESPIRATORY","6;3;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","3;1","CLINICAL;BIOMEDICAL","8;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","12;2;1","LIVER CANCER;NOT SITE-SPECIFIC CANCER","2;1",NA,NA
"IRCCS_SANGERARDO",2021,331,24.6404833836858,2.54984894259819,0.214501510574018,0.27190332326284,0.332326283987915,2.00475059382423,1.26785714285714,1.60714285714286,1.41025641025641,0.70392749244713,1,161,77,25,12,0.49,0.23,0.08,0.04,18.4,1.19312209333446,8.1543408360129,0.374622356495468,0.987915407854985,0.521,0.436,0.438,0.482,"GIACOMO BELLANI;DAVIDE IPPOLITO;GIUSEPPE CITERIO;PIETRO INVERNIZZI;CARLO FERRARESE;GIUSEPPE FOTI;DIEGO CORTINOVIS;PAOLO BONFANTI;FRANCESCA PALANDRI;MARIA GRAZIA VALSECCHI;MARCO CARBONE;GIUSEPPE BELLELLI;FEDERICO PIERUZZI;GIACOMO GRASSELLI;ELENA MARIA ELLI;ALESSIO GERUSSI;ALESSANDRA IURLO;GIULIA BENEVOLO;FABIO CICERI;NICOLA VIANELLI","22;18;18;16;15;15;13;13;12;12;10;10;10;10;10;9;8;8;8;8","GIACOMO BELLANI;PIETRO INVERNIZZI;MATTEO FRIGERIO;FEDERICO PIERUZZI;CARLO FERRARESE;DAVIDE IPPOLITO;MARTA BARBA;ADRIANA BALDUZZI;GIUSEPPE CITERIO;GIUSEPPE FOTI;DIEGO CORTINOVIS;ALBERTO PIPERNO;STEFANO MANODORO;MARIA GRAZIA VALSECCHI;MARCO CARBONE;RAFFAELLA MARIANI;GIUSEPPE BELLELLI;ROBERTO RONA;CESARE MAINO;RENZO MIGNANI","1.72;1.46;1.46;1.46;1.44;1.42;1.37;1.29;1.08;0.89;0.88;0.88;0.87;0.85;0.83;0.82;0.82;0.78;0.76;0.72","GIACOMO BELLANI;DAVIDE IPPOLITO;GIUSEPPE CITERIO;PIETRO INVERNIZZI;CARLO FERRARESE;GIUSEPPE FOTI;DIEGO CORTINOVIS;PAOLO BONFANTI;MARCO CARBONE;GIUSEPPE BELLELLI;FEDERICO PIERUZZI;ELENA MARIA ELLI;ALESSIO GERUSSI;ANDREA BIONDI;LAURA CRISTOFERI;GIOVANNI ROVARIS;ROBERTO RONA;MATTEO FRIGERIO;MADDALENA LETTINO;SERENA GASPERINI","22;18;18;16;15;15;13;13;10;10;10;10;9;8;8;8;8;7;7;7","GIACOMO BELLANI;PIETRO INVERNIZZI;MATTEO FRIGERIO;FEDERICO PIERUZZI;CARLO FERRARESE;DAVIDE IPPOLITO;MARTA BARBA;ADRIANA BALDUZZI;GIUSEPPE CITERIO;GIUSEPPE FOTI;DIEGO CORTINOVIS;ALBERTO PIPERNO;MARCO CARBONE;RAFFAELLA MARIANI;GIUSEPPE BELLELLI;ROBERTO RONA;CESARE MAINO;GIACOMO MULINACCI;DAVIDE GANDOLA;ROCCO PIAZZA","1.72;1.46;1.46;1.46;1.44;1.42;1.37;1.29;1.08;0.89;0.88;0.88;0.83;0.82;0.82;0.78;0.76;0.69;0.68;0.68","GIUSEPPE FOTI;GIACOMO BELLANI;ROBERTO FUMAGALLI;GIACOMO GRASSELLI;PAOLO BONFANTI;ANTONIO PESENTI;GIUSEPPE CITERIO;ATHANASIOS CHALKIAS;CHRISTINA AGVALD‐ÖHMAN;DAVID BREWSTER;KRISTAPS BOKUMS;PHILIPPE R. BAUER;MARCO RANIERI;MASSIMO ANTONELLI;MASSIMO GIRARDIS;MARIANNA MESCHIARI;TOMMASO TONETTI;AMEDEO GUZZARDELLA;ANDREA FORASTIERI;EMANUELA ROSSI","1281;1177;955;831;771;762;697;682;682;682;682;682;590;585;585;582;545;537;537;532","GIACOMO BELLANI;GIUSEPPE FOTI;GIUSEPPE CITERIO;PAOLO BONFANTI;MADDALENA LETTINO;DANIELA FERLICCA;VINCENZO RUSSOTTO;LUISA VERGA;ROBERTO RONA;MARIANNA ROSSI;DAVIDE IPPOLITO;DIEGO CORTINOVIS;PIETRO INVERNIZZI;GIOVANNI PAOLO MARIA ZAMBROTTA;SILVIA MAITZ;ALESSIO GERUSSI;CARLO GIUSSANI;EMANUELE REZOAGLI;ELENA MARIA ELLI;LORENZA BORIN","758;628;554;451;357;356;355;320;311;309;301;299;250;248;238;206;191;188;186;178","DAVIDE IPPOLITO;GIACOMO BELLANI;PIETRO INVERNIZZI;DIEGO CORTINOVIS;GIUSEPPE CITERIO;CARLO FERRARESE;ELENA MARIA ELLI;GIUSEPPE FOTI;PAOLO BONFANTI;FEDERICO PIERUZZI;GIUSEPPE BELLELLI;ALESSIO GERUSSI;MARCO CARBONE;ROBERTO RONA;GIOVANNI ROVARIS;MADDALENA LETTINO;MATTEO FRIGERIO;LAURA CRISTOFERI;CARLO GIUSSANI;CESARE MAINO","18;18;15;13;13;11;10;10;10;9;9;9;9;8;8;7;7;7;6;6","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;PHILOSOPHY;ART;MATERIALS SCIENCE;BUSINESS","315;92;31;21;21;16;16;13;10;9;8;5;3;3;2","INTERNAL MEDICINE;SURGERY;GENETICS;ONCOLOGY;INTENSIVE CARE MEDICINE;GASTROENTEROLOGY;PATHOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;PEDIATRICS;RADIOLOGY;ANESTHESIA;CARDIOLOGY;EMERGENCY MEDICINE;VIROLOGY;BIOCHEMISTRY;PALEONTOLOGY;CANCER RESEARCH;BIOINFORMATICS;MECHANICAL ENGINEERING;NURSING","257;81;52;52;50;45;42;36;35;34;32;32;29;29;25;23;20;18;17;15;15;15","DISEASE;CANCER;GENE;POPULATION;COHORT;CHEMOTHERAPY;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;OUTBREAK;OBSERVATIONAL STUDY;TRANSPLANTATION;INTENSIVE CARE UNIT;LUNG;LUNG CANCER;STAGE (STRATIGRAPHY);COHORT STUDY;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;INTENSIVE CARE;MULTIVARIATE ANALYSIS;PROPORTIONAL HAZARDS MODEL","93;60;38;35;31;29;29;26;25;20;18;16;14;14;14;13;13;13;12;12;12","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;HAZARD RATIO;IMMUNOTHERAPY;COLORECTAL CANCER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;BREAST CANCER;MUTATION;PHENOTYPE;CLINICAL ENDPOINT;MYELOFIBROSIS;UNIVARIATE ANALYSIS;ENZYME REPLACEMENT THERAPY;PROGRESSION-FREE SURVIVAL;DEMENTIA;EJECTION FRACTION;FABRY DISEASE;GENE EXPRESSION;HAEMATOPOIESIS;CERVICAL CANCER;CYCLOPHOSPHAMIDE;NEURORADIOLOGY;PULMONARY VEIN;RITUXIMAB","48;22;19;14;13;11;10;10;10;9;9;9;8;8;6;6;6;6;6;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;CHIMERIC ANTIGEN RECEPTOR;DNA METHYLATION;MISSENSE MUTATION;RUXOLITINIB;ACUTE LYMPHOCYTIC LEUKEMIA;ANTIRETROVIRAL THERAPY;CORONARY CALCIUM SCORE;ELTROMBOPAG;EXOME SEQUENCING;HEMATOPOIETIC STEM CELL;MUCOPOLYSACCHARIDOSIS TYPE I;VINCRISTINE;ALPHA-SYNUCLEIN;ANAPLASTIC LYMPHOMA KINASE;CARDIAC RESYNCHRONIZATION THERAPY;COLECTOMY;DEMENTIA WITH LEWY BODIES;DIFFUSING CAPACITY;FLUDARABINE;FRONTOTEMPORAL DEMENTIA;GLOBAL DEVELOPMENTAL DELAY;GLOBOTRIAOSYLCERAMIDE;GLYCOGEN STORAGE DISEASE TYPE II;HBSAG;INTERPERSONAL REACTIVITY INDEX;KLEBSIELLA PNEUMONIAE;KRAS;LYMPHOVASCULAR INVASION;METASTATIC BREAST CANCER;MUCOPOLYSACCHARIDOSIS I;MYELOPROLIFERATIVE NEOPLASM;PLATEAU PRESSURE;PRENATAL STRESS;PROBAND;SABR VOLATILITY MODEL;THROMBOPOIETIN;TRANSCRIPTOME;TRANSIENT ELASTOGRAPHY","48;10;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;AGED;MIDDLE AGED;RETROSPECTIVE STUDIES;COVID-19;ADULT;PROSPECTIVE STUDIES;LUNG NEOPLASMS;SARS-COV-2;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;ATRIAL FIBRILLATION;CARCINOMA, NON-SMALL-CELL LUNG;RISK FACTORS;PROGNOSIS;TREATMENT OUTCOME","168;160;88;73;59;58;51;50;34;26;22;22;20;20;20;17;17;17;16;16","LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;CORONAVIRUS DISEASE 2019;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;LYMPHOID NEOPLASMS;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CANCER IMMUNOTHERAPY;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;GYNECOLOGIC ONCOLOGY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PELVIC FLOOR DISORDERS;REGULATION OF IRON METABOLISM AND ANEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","14;12;11;9;9;9;8;7;6;6;5;5;5;5;4;4;4;4;4;4","2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;REGIMEN;UNIVARIATE ANALYSIS;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;STROKE (ENGINE);DISCONTINUATION;FABRY DISEASE;INTRACRANIAL PRESSURE;ATRIAL FIBRILLATION;CLINICAL CHARACTERISTICS;CONCOMITANT;NONINVASIVE VENTILATION;PRIMARY SCLEROSING CHOLANGITIS;RADIOFREQUENCY ABLATION;REFRACTORY (PLANETARY SCIENCE);CANCER IMAGING;CORONAVIRUS INFECTIONS;INTERQUARTILE RANGE","19;18;9;9;8;8;8;7;7;7;6;6;6;6;6;6;6;5;5;5","ATRIAL FIBRILLATION;INTENSIVE CARE;LUNG CANCER;MULTICENTER STUDY;COHORT STUDY;ACUTE LYMPHOBLASTIC;BILIARY CHOLANGITIS;CELL TRANSPLANTATION;COVID- PANDEMIC;COVID- PATIENTS;LYMPHOBLASTIC LEUKEMIA;OBSERVATIONAL STUDY;PRIMARY BILIARY;ADULT PATIENTS;BRAIN INJURY;CANCER PATIENTS;CARE UNIT;CELL LUNG;CRITICALLY ILL;FABRY DISEASE;HEMATOPOIETIC STEM;ILL PATIENTS;IMMUNE THROMBOCYTOPENIA;PHASE II;STEM CELL;COLON CANCER;COMPUTED TOMOGRAPHY;ENDOMETRIAL CANCER;EUROPEAN SOCIETY;ISCHEMIC STROKE","9;9;9;8;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HR CI;HONORARIA MEMBERSHIP;CONSULTANCY HONORARIA;RESEARCH FUNDING;COMMITTEES SPEAKERS;COVID- PATIENTS;MEDIAN AGE;MEDIAN FOLLOW-UP;NOVARTIS HONORARIA;SURVIVAL OS;COHORT STUDY;PATIENTS TREATED;HAZARD RATIO;INTENSIVE CARE;BRAIN INJURY;CONFIDENCE INTERVAL;COVID- PANDEMIC;PFIZER HONORARIA;IN-HOSPITAL MORTALITY;ODDS RATIO;PATIENTS UNDERGOING;BLOOD PRESSURE;TRAVEL SUPPORT;HONORARIA RESEARCH;PB- PB-;AMGEN HONORARIA;DISEASE PROGRESSION","128;128;89;61;52;49;49;28;27;24;22;22;22;21;20;19;19;18;18;18;18;17;17;17;16;16;15;15;14;14",176,0.53,13.69,18.25,2,1,0,2,1.75,1,2,20,1.5,1,17.25,0,1.75,2,6,12,6,0,0,41.25,41.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,3.72,744.58,11.38,23,0.53,84.86,0,1,9,2,17,0,0,14,0,32,11,0,0,0,0,0,0,40,3,0,43,0,0,0,0,0,0,0,0,0,"Italy;United States;Japan;Netherlands;United Kingdom","17;7;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3207 MEDICAL MICROBIOLOGY;31 BIOLOGICAL SCIENCES;3208 MEDICAL PHYSIOLOGY;3213 PAEDIATRICS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","43;22;15;5;5;5;3;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;RARE DISEASES;PATIENT SAFETY;PREVENTION;INFECTIOUS DISEASES;VACCINE RELATED;HEMATOLOGY;BREAST CANCER;AUTOIMMUNE DISEASE;BIODEFENSE;EMERGING INFECTIOUS DISEASES;IMMUNIZATION;CARDIOVASCULAR;DIGESTIVE DISEASES;LUNG CANCER;LYMPHOMA;PNEUMONIA","41;29;15;13;12;10;9;8;7;6;5;4;4;4;4;3;3;3;3;3","CANCER;CARDIOVASCULAR;INFECTION;RESPIRATORY;STROKE;REPRODUCTIVE HEALTH AND CHILDBIRTH","12;6;5;2;2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","31;7;2;1;1;1;1;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LUNG CANCER;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;MELANOMA;MYELOMA;OVARIAN CANCER","5;5;4;4;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;1.4 CANCER PROGRESSION AND METASTASIS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","12;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,"PUBLIC LIBRARY OF SCIENCE;ZENODO;FRONTIERS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;FUTURE SCIENCE GROUP;KARGER PUBLISHERS;SPRINGER NATURE","14;12;5;4;4;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;34 CHEMICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3401 ANALYTICAL CHEMISTRY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;38 ECONOMICS;3801 APPLIED ECONOMICS;4202 EPIDEMIOLOGY;47 LANGUAGE, COMMUNICATION AND CULTURE;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3009 VETERINARY SCIENCES;3103 ECOLOGY;3107 MICROBIOLOGY;3204 IMMUNOLOGY","45;22;11;10;6;6;5;4;3;3;3;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;GENETICS;INFECTIOUS DISEASES;PREVENTION;AUTOIMMUNE DISEASE;CARDIOVASCULAR;EMERGING INFECTIOUS DISEASES;LUNG;BEHAVIORAL AND SOCIAL SCIENCE;DIGESTIVE DISEASES;LIVER DISEASE;NUTRITION;RARE DISEASES;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;HEART DISEASE;HUMAN GENOME;OBESITY;AGING;ARTHRITIS","7;5;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;1;1","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;INFECTION;ORAL AND GASTROINTESTINAL;RESPIRATORY","7;4;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;7.1 INDIVIDUAL CARE NEEDS;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","3;3;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","9;6;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","14;4;3;1","NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;LIVER CANCER;COLON AND RECTAL CANCER;ENDOMETRIAL CANCER;GENITAL SYSTEM, FEMALE;NON-HODGKIN'S LYMPHOMA","7;4;2;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_SANGERARDO",2022,377,22.2758620689655,2.39787798408488,0.175066312997347,0.220159151193634,0.212201591511936,1.97379912663755,1.29411764705882,1.62745098039216,1.33333333333333,0.750663129973475,4,169,73,22,17,0.45,0.19,0.06,0.05,8.97,1.00522766182032,7.12449596774192,0.43501326259947,0.978779840848806,0.559,0.481,0.457,0.475,"ANDREA BIONDI;ELENA MARIA ELLI;PAOLO BONFANTI;CARLO FERRARESE;DIEGO CORTINOVIS;GIACOMO BELLANI;GIUSEPPE FOTI;GIUSEPPE MARINO;FABIO LANDONI;ROBERT FRUSCIO;MARIA GRAZIA VALSECCHI;FRANCESCA PALANDRI;ALESSANDRA IURLO;MATTEO FRIGERIO;ALESSANDRO RAMBALDI;EMANUELE REZOAGLI;MARTA BARBA;DAVIDE IPPOLITO;LAURA ANTOLINI;MADDALENA LETTINO","18;17;16;15;15;14;13;13;13;13;13;12;12;12;12;11;11;11;11;11","GIUSEPPE CITERIO;MATTEO FRIGERIO;MARTA BARBA;PIETRO INVERNIZZI;GIACOMO BELLANI;GIUSEPPE MARINO;ALICE COLA;EMANUELE REZOAGLI;CRISTIANA IACUZZO;DIEGO CORTINOVIS;ANDREA BIONDI;PAOLO BONFANTI;GIUSEPPE FOTI;CARLO FERRARESE;S GUERRASIO;SILVIA VOLONTÈ;DAVIDE IPPOLITO;FABIO LANDONI;ELENA MARIA ELLI;MARIA GRAZIA STREPPARAVA","1.77;1.64;1.57;1.56;1.51;1.48;1.44;1.41;1.34;1.17;1.15;1.13;1.1;1.04;1;0.99;0.88;0.86;0.85;0.84","ANDREA BIONDI;ELENA MARIA ELLI;PAOLO BONFANTI;CARLO FERRARESE;DIEGO CORTINOVIS;GIACOMO BELLANI;GIUSEPPE FOTI;GIUSEPPE MARINO;FABIO LANDONI;ROBERT FRUSCIO;MATTEO FRIGERIO;EMANUELE REZOAGLI;MARTA BARBA;DAVIDE IPPOLITO;MADDALENA LETTINO;PATRIZIA VERGANI;ALICE COLA;SANDRO SIRONI;GIUSEPPE BELLELLI;CARLO GAMBACORTI‐PASSERINI","18;17;16;15;15;14;13;13;13;13;12;11;11;11;11;10;10;9;9;9","GIUSEPPE CITERIO;MATTEO FRIGERIO;MARTA BARBA;PIETRO INVERNIZZI;GIACOMO BELLANI;GIUSEPPE MARINO;ALICE COLA;EMANUELE REZOAGLI;CRISTIANA IACUZZO;DIEGO CORTINOVIS;ANDREA BIONDI;PAOLO BONFANTI;GIUSEPPE FOTI;CARLO FERRARESE;S GUERRASIO;SILVIA VOLONTÈ;DAVIDE IPPOLITO;FABIO LANDONI;ELENA MARIA ELLI;MARIA GRAZIA STREPPARAVA","1.77;1.64;1.57;1.56;1.51;1.48;1.44;1.41;1.34;1.17;1.15;1.13;1.1;1.04;1;0.99;0.88;0.86;0.85;0.84","EMILIO BRIA;GIACOMO BELLANI;ADITYA BARDIA;ALBERTO J. MONTERO;DIRK LAURENT;FLORENCE DALENC;FRANÇOIS‐CLÉMENT BIDARD;FRÉDÉRIC FORGET;HUNG T. KHONG;INES DELEU;JANICE LU;JAVIER CORTÉS;JOOHYUK SOHN;JOSÉ Á. GARCÍA-SÁENZ;JUDIT KOCSIS;KATHLEEN HARNDEN;MARIE‐ANGE MOURET‐REYNIER;MARINA ELENA CAZZANIGA;MAUREEN G. CONLAN;PATRICK M. DILLON","375;359;352;352;352;352;352;352;352;352;352;352;352;352;352;352;352;352;352;352","MARINA ELENA CAZZANIGA;GIACOMO BELLANI;ANDREA BIONDI;DIEGO CORTINOVIS;GIUSEPPE FOTI;PAOLO BONFANTI;GIUSEPPE CITERIO;LUISA VERGA;GIOVANNI PAOLO MARIA ZAMBROTTA;FABIO LANDONI;ELENA MARIA ELLI;GIACOMO MONTI;GIOVANNI ROVARIS;SILVIA MAITZ;MADDALENA LETTINO;RICCARDO GIOVANAZZI;SERENA GASPERINI;CAMELIA CHIFU;ROCCO CORSO;CARLO FERRARESE","352;291;187;158;152;147;128;128;122;120;113;96;96;96;91;82;82;80;76;74","ELENA MARIA ELLI;GIOVANNI ROVARIS;DIEGO CORTINOVIS;PAOLO BONFANTI;MATTEO FRIGERIO;GIUSEPPE FOTI;ANDREA BIONDI;CARLO FERRARESE;MADDALENA LETTINO;DAVIDE IPPOLITO;GIACOMO BELLANI;FABIO LANDONI;EMANUELE REZOAGLI;PIETRO INVERNIZZI;ROBERT FRUSCIO;LUISA VERGA;CARLO GAMBACORTI‐PASSERINI;TOMMASO GRASSI;FEDERICA SINA;CARLO GIUSSANI","17;15;14;12;12;11;11;11;11;10;10;9;8;8;8;8;7;7;7;7","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;SOCIOLOGY;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;ART;GEOLOGY;HISTORY;GEOGRAPHY","356;107;36;31;24;21;16;15;12;9;9;6;4;3;2;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PEDIATRICS;PSYCHIATRY;RADIOLOGY;CARDIOLOGY;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;OPTICS;ANESTHESIA;EMERGENCY MEDICINE;PALEONTOLOGY;GYNECOLOGY;OBSTETRICS","290;97;78;62;59;47;45;44;44;38;38;36;27;26;26;25;24;22;18;17","DISEASE;CANCER;COHORT;GENE;POPULATION;RETROSPECTIVE COHORT STUDY;CHEMOTHERAPY;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;ADVERSE EFFECT;BONE MARROW;PREGNANCY;OBSERVATIONAL STUDY;STAGE (STRATIGRAPHY);ATRIAL FIBRILLATION;LYMPHOMA;TRANSPLANTATION;LEUKEMIA;PROSPECTIVE COHORT STUDY","69;57;51;44;42;38;33;27;26;22;21;20;19;19;17;17;16;16;16;15;15","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;HAZARD RATIO;CLINICAL ENDPOINT;MYELOFIBROSIS;CYCLOPHOSPHAMIDE;CUMULATIVE INCIDENCE;IMMUNOTHERAPY;HEMATOPOIETIC STEM CELL TRANSPLANTATION;2019-20 CORONAVIRUS OUTBREAK;CERVICAL CANCER;NEUTROPENIA;TOLERABILITY;UNIVARIATE ANALYSIS;ARDS;GENE EXPRESSION;HAEMATOPOIESIS;MULTICENTER STUDY;MUTATION;PHENOTYPE","33;17;15;14;14;12;11;11;10;8;8;8;8;8;7;7;7;7;7;7","CORONAVIRUS DISEASE 2019 (COVID-19);RUXOLITINIB;ACUTE LYMPHOCYTIC LEUKEMIA;DNA METHYLATION;FLUDARABINE;NIVOLUMAB;PEMBROLIZUMAB;CARDIAC RESYNCHRONIZATION THERAPY;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;SENTINEL LYMPH NODE;VINCRISTINE;BUSULFAN;CRIZOTINIB;FERTILITY PRESERVATION;MYELOPROLIFERATIVE NEOPLASM;RADICAL HYSTERECTOMY;ABSOLUTE NEUTROPHIL COUNT;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEPRIVATION THERAPY;AXILLA;BRCA MUTATION;CD33;CHA2DS2–VASC SCORE;CHIMERIC ANTIGEN RECEPTOR;CONGENITAL NEUTROPENIA;DIFFUSING CAPACITY;EMPAGLIFLOZIN;ESTROGEN RECEPTOR;GENETIC HETEROGENEITY;GENETIC VARIANTS;GERMLINE MUTATION;HEMATOPOIETIC CELL;MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY;METASTATIC BREAST CANCER;ROS1;THIOTEPA;TRANSIENT ELASTOGRAPHY;VENETOCLAX;VINORELBINE","33;7;5;5;5;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;COVID-19;RETROSPECTIVE STUDIES;MALE;ADULT;AGED;TREATMENT OUTCOME;MIDDLE AGED;ITALY;PROSPECTIVE STUDIES;ATRIAL FIBRILLATION;LEUKEMIA, MYELOID, ACUTE;NEOPLASM RECURRENCE, LOCAL;SARS-COV-2;CHILD;PELVIC ORGAN PROLAPSE;LUNG NEOPLASMS;ALZHEIMER DISEASE","191;181;59;55;54;33;30;26;24;21;20;18;17;16;16;16;15;13;12;11","MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CORONAVIRUS DISEASE 2019;GYNECOLOGIC ONCOLOGY;LYMPHOID NEOPLASMS;PELVIC FLOOR DISORDERS;ATRIAL FIBRILLATION;ACUTE MYELOID LEUKEMIA;CANCER IMMUNOTHERAPY;CORONAVIRUS DISEASE 2019 RESEARCH;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY","15;11;10;10;10;10;9;8;8;8;8;7;6;6;6;5;4;4;4;4","CLINICAL ENDPOINT;PANDEMIC;DISCONTINUATION;CUMULATIVE INCIDENCE;INTERQUARTILE RANGE;REGIMEN;TOLERABILITY;UNIVARIATE ANALYSIS;ATRIAL FIBRILLATION;POSITIVE END-EXPIRATORY PRESSURE;TREATMENT;TREATMENT OUTCOMES;GOLD STANDARD (TEST);MYELOFIBROSIS;RUXOLITINIB;RUXOLITINIB THERAPY;CONCOMITANT;MANTLE CELL LYMPHOMA;NEURORADIOLOGY;PRIMARY SCLEROSING CHOLANGITIS","15;13;12;11;9;9;9;9;8;8;8;8;7;7;7;7;6;6;6;6","ACUTE LYMPHOBLASTIC;OBSERVATIONAL STUDY;ATRIAL FIBRILLATION;LYMPHOBLASTIC LEUKEMIA;STEM CELL;LUNG CANCER;PHASE II;PHASE III;BILIARY CHOLANGITIS;CERVICAL CANCER;MYELOID LEUKEMIA;PATIENTS UNDERGOING;PRIMARY BILIARY;RETROSPECTIVE OBSERVATIONAL;STAGE III;ACUTE MYELOID;ADULT PATIENTS;ALZHEIMERS DISEASE;ARTERIAL HYPERTENSION;BREAST CANCER;CELL LUNG;COHORT STUDY;COVID- PANDEMIC;COVID- PATIENTS;FOLLICULAR LYMPHOMA;FONDAZIONE ITALIANA;HODGKIN LYMPHOMA;MULTICENTER STUDY;MYELODYSPLASTIC SYNDROMES;MYELOPROLIFERATIVE NEOPLASMS","14;14;11;11;9;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","HR CI;MEDIAN AGE;RISK FACTORS;VIEW LARGEDOWNLOAD;MEDIAN FOLLOW-UP;CONFIDENCE INTERVAL;STEM CELL;MEDIAN TIME;PATIENTS RECEIVED;PATIENTS TREATED;SIGNIFICANTLY LOWER;COVID- PATIENTS;ICU ADMISSION;SURVIVAL OS;ADVERSE EVENTS;INTENSIVE CARE;STAGE III;ACUTE RESPIRATORY;SKIN FIBROSIS;CLOSE MODAL;FIGURE VIEW;INCLUDED PATIENTS;LARGEDOWNLOAD PPT;LARGEDOWNLOAD PPTFIGURE;OBSERVATIONAL STUDY;PPT CLOSE;PPTFIGURE VIEW;CLINICAL PRACTICE;COHORT STUDY;PATIENTS UNDERGOING","87;38;36;34;28;24;23;22;22;21;21;20;20;20;19;19;19;18;18;17;17;17;17;17;17;17;17;16;16;16",181,0.48,10.7,11,1,1,0,3,0,1,1,14,1.5,1,12,1,3.25,2,3.5,8,4,0,0,21,21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,4.29,614.19,10.14,17,0.4,95.07,0,3,7,1,16,0,0,15,0,27,15,0,0,0,0,0,0,42,0,0,41,0,0,1,0,0,0,0,0,0,"United States;Italy;Japan;Australia;Finland;Germany;India;Spain","19;16;2;1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4206 PUBLIC HEALTH;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","40;27;14;5;4;3;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;LUNG;DIGESTIVE DISEASES;HEMATOLOGY;NEUROSCIENCES;PATIENT SAFETY;CARDIOVASCULAR;HEART DISEASE;BRAIN DISORDERS;AGING;AUTOIMMUNE DISEASE;INFLAMMATORY BOWEL DISEASE;LUNG CANCER;NEURODEGENERATIVE;PEDIATRIC;TRANSPLANTATION;BIOENGINEERING","38;26;17;13;11;8;8;7;7;6;6;5;4;4;4;4;4;4;4;3","CANCER;ORAL AND GASTROINTESTINAL;CARDIOVASCULAR;NEUROLOGICAL;RESPIRATORY;GENERIC HEALTH RELEVANCE;INFECTION;MENTAL HEALTH;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;STROKE","14;5;4;3;3;2;1;1;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;7.3 MANAGEMENT AND DECISION MAKING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.3 MEDICAL DEVICES;6.4 SURGERY;6.6 PSYCHOLOGICAL AND BEHAVIOURAL","28;3;3;3;3;2;2;2;1;1;1;1","LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;COLON AND RECTAL CANCER;LIVER CANCER;MYELOMA","6;4;3;3;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;2.3 INTERACTIONS OF GENES AND/OR GENETIC POLYMORPHISMS WITH EXOGENOUS AND/OR ENDOGENOUS FACTORS;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","14;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,"FRONTIERS;ZENODO;PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS;FUTURE SCIENCE GROUP;TAYLOR & FRANCIS GROUP;IMMPORT","14;14;5;3;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3208 MEDICAL PHYSIOLOGY;3215 REPRODUCTIVE MEDICINE;38 ECONOMICS;3801 APPLIED ECONOMICS;44 HUMAN SOCIETY;49 MATHEMATICAL SCIENCES","55;16;13;10;7;3;2;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;CANCER;BIOTECHNOLOGY;GENETICS;CARDIOVASCULAR;OVARIAN CANCER;PREVENTION;PATIENT SAFETY;HEART DISEASE;LUNG;NEUROSCIENCES;BRAIN DISORDERS;HEMATOLOGY;AGING;BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN CANCER;GENETIC TESTING;HUMAN GENOME","21;13;12;8;8;6;6;6;5;4;4;4;3;3;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;RESPIRATORY;NEUROLOGICAL","11;6;3;2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING","6;2;2;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","19;6;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","25;3","OVARIAN CANCER;BRAIN TUMOR;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;ENDOMETRIAL CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;NASAL CAVITY AND PARANASAL SINUS CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","6;2;2;2;1;1;1;1;1;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_SANGERARDO",2023,500,18.58,2.79,0.244,0.308,0.29,2.27614379084967,1.29787234042553,1.81176470588235,1.3302752293578,0.776,3,228,97,28,15,0.46,0.19,0.06,0.03,3.79,0.863774298857411,6.31751007613075,0.384,0.984,0.546,0.442,0.432,0.472,"ANDREA BIONDI;MASSIMO CLERICI;CARLO GAMBACORTI‐PASSERINI;MARIA GRAZIA VALSECCHI;FRANCO LOCATELLI;GIUSEPPE FOTI;GIOVANNI CAZZANIGA;GIUSEPPE CITERIO;PIETRO INVERNIZZI;ENRICO CAPUZZI;ROCCO PIAZZA;DIEGO CORTINOVIS;MASSIMILIANO BUOLI;PAOLO BONFANTI;FABRIZIO CAVALCA;CARLO FERRARESE;MATTEO FRIGERIO;GIUSEPPE BELLELLI;ALICE CALDIROLI;ELENA MARIA ELLI","39;22;18;18;15;15;15;15;14;13;13;13;13;13;12;12;12;12;12;12","ANDREA BIONDI;MASSIMO CLERICI;MATTEO FRIGERIO;MARTA BARBA;CARLO GAMBACORTI‐PASSERINI;GIUSEPPE BELLELLI;RENATA NACINOVICH;ALICE COLA;PIETRO INVERNIZZI;GIUSEPPE FOTI;MARCO CARBONE;ENRICO CAPUZZI;MASSIMILIANO BUOLI;ANNA RIVA;GIULIA PURPURA;EMANUELE REZOAGLI;ALICE CALDIROLI;CARMELO RIZZARI;M RIVA;FABRIZIO LUPPI","3.06;2.28;1.92;1.8;1.75;1.6;1.59;1.56;1.56;1.45;1.39;1.37;1.37;1.3;1.3;1.3;1.23;1.19;1.17;1.15","ANDREA BIONDI;MASSIMO CLERICI;CARLO GAMBACORTI‐PASSERINI;MARIA GRAZIA VALSECCHI;GIUSEPPE FOTI;GIOVANNI CAZZANIGA;GIUSEPPE CITERIO;PIETRO INVERNIZZI;ENRICO CAPUZZI;ROCCO PIAZZA;DIEGO CORTINOVIS;PAOLO BONFANTI;FABRIZIO CAVALCA;CARLO FERRARESE;MATTEO FRIGERIO;GIUSEPPE BELLELLI;ALICE CALDIROLI;ELENA MARIA ELLI;MARTA BARBA;FEDERICA COCITO","39;22;18;18;15;15;15;14;13;13;13;13;12;12;12;12;12;12;11;11","ANDREA BIONDI;MASSIMO CLERICI;MATTEO FRIGERIO;MARTA BARBA;CARLO GAMBACORTI‐PASSERINI;GIUSEPPE BELLELLI;RENATA NACINOVICH;ALICE COLA;PIETRO INVERNIZZI;GIUSEPPE FOTI;MARCO CARBONE;ENRICO CAPUZZI;ANNA RIVA;EMANUELE REZOAGLI;ALICE CALDIROLI;CARMELO RIZZARI;M RIVA;FABRIZIO LUPPI;STEFANO ARCANGELI;EMANUELA ZANNIN","3.06;2.28;1.92;1.8;1.75;1.6;1.59;1.56;1.56;1.45;1.39;1.37;1.3;1.3;1.23;1.19;1.17;1.15;1.11;1.09","PIETRO INVERNIZZI;ANDREA BIONDI;DIEGO CORTINOVIS;GIUSEPPE CITERIO;MASSIMO CLERICI;MARCO CARBONE;GIANLUCA PERSEGHIN;MARIA GRAZIA VALSECCHI;GIACOMO D’ANDREA;GIORGIO DI LORENZO;GIOVANNI MARTINOTTI;ILEANA ANDRIOLA;MAURO PETTORRUSO;RAFFAELLA ZANARDI;ROGER S. MCINTYRE;STEFANIA CHIAPPINI;STEFANO L. SENSI;FRANCESCO PASSAMONTI;STEFANO CIARDULLO;MASSIMO BERNARDI","170;129;117;111;110;103;94;93;91;91;91;91;91;91;91;91;91;86;84;82","PIETRO INVERNIZZI;DIEGO CORTINOVIS;MASSIMO CLERICI;GIUSEPPE CITERIO;MARCO CARBONE;ANDREA BIONDI;MATTEO MARCATILI;GIUSEPPE FOTI;LORENZA BORIN;GIOVANNI PAOLO MARIA ZAMBROTTA;MONICA CARPENEDO;ROCCO PIAZZA;GIUSEPPE GAIPA;LUISA VERGA;RAFFAELLA LONGARINI;GIACOMO BELLANI;MADDALENA LETTINO;RENATA NACINOVICH;ELENA MARIA ELLI;MARIA GRAZIA VALSECCHI","170;117;108;104;103;99;77;69;62;53;53;51;49;48;48;46;42;41;39;35","ANDREA BIONDI;MASSIMO CLERICI;CARLO GAMBACORTI‐PASSERINI;PIETRO INVERNIZZI;DIEGO CORTINOVIS;ENRICO CAPUZZI;GIUSEPPE CITERIO;ELENA MARIA ELLI;ALICE CALDIROLI;GIUSEPPE FOTI;FABRIZIO CAVALCA;MATTEO FRIGERIO;FEDERICA COCITO;RENATA NACINOVICH;GIOVANNI CAZZANIGA;MADDALENA LETTINO;ALICE COLA;CARMELO RIZZARI;FABRIZIO LUPPI;FRANCESCA VENDEMINI","29;19;15;14;13;13;13;12;11;11;11;11;10;10;10;10;9;9;9;9","MEDICINE;BIOLOGY;PSYCHOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;ART;HISTORY;PHILOSOPHY;BUSINESS;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE","469;145;49;37;32;28;23;16;12;11;10;4;3;3;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GENETICS;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;PEDIATRICS;PSYCHIATRY;INTENSIVE CARE MEDICINE;CANCER RESEARCH;RADIOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;CARDIOLOGY;ANESTHESIA;PALEONTOLOGY;CLINICAL PSYCHOLOGY;OPTICS;PHARMACOLOGY","363;128;86;81;75;67;66;64;64;50;42;41;40;35;31;28;28;26;25;25","DISEASE;CANCER;COHORT;GENE;CHEMOTHERAPY;POPULATION;RETROSPECTIVE COHORT STUDY;LEUKEMIA;TRANSPLANTATION;ADVERSE EFFECT;BONE MARROW;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;PREGNANCY;PROSPECTIVE COHORT STUDY;CLINICAL TRIAL;INCIDENCE (GEOMETRY);RADIATION THERAPY;ALTERNATIVE MEDICINE;LYMPHOMA","74;65;64;54;46;39;33;32;32;27;27;27;27;25;24;23;22;21;20;20","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HAZARD RATIO;COLORECTAL CANCER;BREAST CANCER;PLACEBO;TOLERABILITY;CHRONIC LYMPHOCYTIC LEUKEMIA;GESTATIONAL AGE;2019-20 CORONAVIRUS OUTBREAK;IMMUNOTHERAPY;PHENOTYPE;MINIMAL RESIDUAL DISEASE;LYMPHOBLASTIC LEUKEMIA;MYELOFIBROSIS;NEUTROPENIA;PROGRESSION-FREE SURVIVAL;CERVICAL CANCER;CUMULATIVE INCIDENCE;GENE EXPRESSION;GENOTYPE;MUTATION;MYELODYSPLASTIC SYNDROMES;T CELL;VIRAL LOAD","29;26;19;17;15;13;12;12;11;11;10;10;10;9;8;8;8;8;7;7;7;7;7;7;7;7","CORONAVIRUS DISEASE 2019 (COVID-19);METASTATIC BREAST CANCER;VENETOCLAX;ANTIRETROVIRAL THERAPY;CHIMERIC ANTIGEN RECEPTOR;RUXOLITINIB;NIVOLUMAB;ACUTE LYMPHOCYTIC LEUKEMIA;CD33;DNA METHYLATION;EMPAGLIFLOZIN;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MISSENSE MUTATION;TREATMENT-RESISTANT DEPRESSION;ASPARAGINASE;AUTOIMMUNE GASTRITIS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY;CYCLIN-DEPENDENT KINASE;DASATINIB;FEBRILE NEUTROPENIA;IBRUTINIB;KRAS;MONOCLONAL;PEMBROLIZUMAB;SENTINEL LYMPH NODE;SINGLE-NUCLEOTIDE POLYMORPHISM;TAMOXIFEN;TOTAL BODY IRRADIATION;VINCRISTINE","29;7;7;6;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;RETROSPECTIVE STUDIES;COVID-19;CHILD;MALE;ADULT;AGED;MIDDLE AGED;PROSPECTIVE STUDIES;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANIMALS;INFANT;SARS-COV-2;INFANT, NEWBORN;ITALY;COLONIC NEOPLASMS;ADOLESCENT","256;234;68;53;42;41;41;35;33;29;27;26;17;16;16;16;15;15;14;13","ACUTE MYELOID LEUKEMIA;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;LYMPHOID NEOPLASMS;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PELVIC FLOOR DISORDERS;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;EATING DISORDERS AND BODY IMAGE CONCERNS;EFFICACY AND RESISTANCE IN CML TREATMENT;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;RADIOTHERAPY PHYSICS AND TECHNOLOGY;COLORECTAL CANCER RESEARCH AND TREATMENT;HEMATOPOIETIC STEM CELL BIOLOGY;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;ADVANCEMENTS IN LUNG CANCER RESEARCH","19;18;12;11;9;9;9;8;6;6;6;6;6;6;5;5;5;5;5;4","CLINICAL ENDPOINT;DISCONTINUATION;PANDEMIC;REGIMEN;TREATMENT OUTCOMES;TOLERABILITY;DEPRESSION (ECONOMICS);INTERQUARTILE RANGE;2019-20 CORONAVIRUS OUTBREAK;CROSS-SECTIONAL STUDY;MINIMAL RESIDUAL DISEASE;POSITIVE END-EXPIRATORY PRESSURE;CAR T CELLS;HEMATOLOGY;PROGRESSION-FREE SURVIVAL;CANCER IMAGING;CUMULATIVE INCIDENCE;MYELOFIBROSIS;STROKE (ENGINE);TREATMENT","26;19;15;13;13;12;10;10;9;9;9;9;8;8;8;7;7;7;7;7","ACUTE LYMPHOBLASTIC;STEM CELL;LYMPHOBLASTIC LEUKEMIA;COHORT STUDY;CELL TRANSPLANTATION;MYELOID LEUKEMIA;BRAIN INJURY;BREAST CANCER;ACUTE MYELOID;HEMATOPOIETIC STEM;RETROSPECTIVE STUDY;LUNG CANCER;OBSERVATIONAL STUDY;TRAUMATIC BRAIN;AUTOLOGOUS STEM;BILIARY CHOLANGITIS;CANCER PATIENTS;CERVICAL CANCER;CROSS-SECTIONAL STUDY;IMMUNE THROMBOCYTOPENIA;INTENSIVE CARE;MESENCHYMAL STROMAL;METASTATIC BREAST;MULTICENTER STUDY;MULTIPLE MYELOMA;PHASE II;PHASE TRIAL;PRECURSOR ACUTE;PRETERM INFANTS;PRIMARY BILIARY","18;17;16;14;11;9;8;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5","MEDIAN AGE;BONE MARROW;STEM CELL;PATIENTS TREATED;ADVERSE EVENTS;RISK FACTORS;PATIENTS RECEIVED;MEDIAN FOLLOW-UP;MEDIAN TIME;LOGISTIC REGRESSION;CELL TRANSPLANTATION;MYELOID LEUKEMIA;SURVIVAL OS;HR CI;ACUTE LYMPHOBLASTIC;COVID- PANDEMIC;DISEASE PROGRESSION;LYMPHOBLASTIC LEUKEMIA;PRIMARY ENDPOINT;SIGNIFICANT DIFFERENCES;CLINICAL PRACTICE;COHORT STUDY;CONFIDENCE INTERVAL;FUNCTIONAL TICS;MEDIAN OS;PATIENTS PTS;HEMATOPOIETIC STEM;MULTIVARIATE ANALYSIS;ODDS RATIO;COMPLETE REMISSION","47;45;39;37;33;33;31;29;28;25;24;24;24;23;22;22;22;22;22;21;20;20;20;20;20;20;19;19;19;18",205,0.41,9.25,11,1,1,0,2,0,1,0,11,1.75,0,11,1,0,2,3,8.25,4,0,0,10,10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,3.29,1123.54,4.26,5,0.21,29.25,0,0,6,1,3,0,0,14,0,13,11,0,0,0,0,0,0,24,0,0,24,0,0,0,0,0,0,0,0,0,"Italy;United States;Austria;Sweden;Switzerland","7;5;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3203 DENTISTRY;3206 MEDICAL BIOTECHNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4205 NURSING","23;12;8;3;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;RARE DISEASES;NEUROSCIENCES;PREVENTION;BRAIN DISORDERS;DIGESTIVE DISEASES;AGING;CHRONIC LIVER DISEASE AND CIRRHOSIS;GENETICS;INFANT MORTALITY;LIVER DISEASE;LUNG CANCER;NEURODEGENERATIVE;PATIENT SAFETY;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS","21;14;9;7;7;6;5;4;4;3;3;3;3;3;3;3;3;3;3;3","CANCER;CARDIOVASCULAR;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RESPIRATORY;REPRODUCTIVE HEALTH AND CHILDBIRTH","9;3;3;3;2;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.2 CELLULAR AND GENE THERAPIES","12;3;2;2;2;1;1;1","LIVER CANCER;BREAST CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;NOT SITE-SPECIFIC CANCER","3;2;2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","8;2;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;ZENODO;KARGER PUBLISHERS","12;9;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;52 PSYCHOLOGY;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;5202 BIOLOGICAL PSYCHOLOGY;3213 PAEDIATRICS;49 MATHEMATICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4206 PUBLIC HEALTH;4207 SPORTS SCIENCE AND EXERCISE;51 PHYSICAL SCIENCES;5107 PARTICLE AND HIGH ENERGY PHYSICS","24;15;10;7;5;5;4;3;3;3;3;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;PREVENTION;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;INFECTIOUS DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;MENTAL HEALTH;NEUROSCIENCES;PEDIATRIC;ACQUIRED COGNITIVE IMPAIRMENT;DEMENTIA;BIODEFENSE;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;LUNG;VACCINE RELATED;CANCER;PNEUMONIA;RARE DISEASES;STEM CELL RESEARCH","13;8;6;6;5;5;5;5;5;4;4;3;3;3;3;3;2;2;2;2","INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;CANCER;REPRODUCTIVE HEALTH AND CHILDBIRTH;NEUROLOGICAL","3;3;2;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;8.1 ORGANISATION AND DELIVERY OF SERVICES","3;1;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","8;3;2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","10;4;2","LEUKEMIA / LEUKAEMIA;HODGKIN'S DISEASE;MYELOMA;NON-HODGKIN'S LYMPHOMA","2;1;1;1","3 GOOD HEALTH AND WELL BEING","2"
"IRCCS_SANGERARDO",2024,426,18.4835680751174,2.81455399061033,0.321596244131455,0.293427230046948,0.354460093896714,2.10175438596491,1.31730769230769,1.52439024390244,1.39814814814815,0.629107981220657,1,195,86,27,18,0.46,0.2,0.06,0.04,0.72,0.751602442767269,4.9551253849538,0.392018779342723,0.995305164319249,0.504,0.419,0.403,0.417,"ANDREA BIONDI;EMANUELE REZOAGLI;GIUSEPPE FOTI;ROBERT FRUSCIO;GIOVANNI B. FORLEO;DIEGO CORTINOVIS;MARCO GIANI;ALESSIO GASPERETTI;MARCO SCHIAVONE;SARA ORNAGHI;CESARE MAINO;GIUSEPPE BELLELLI;DAVIDE IPPOLITO;CLAUDIO TONDO;LAURA ANTOLINI;MAURO BIFFI;MARIA LUISA VENTURA;LUIGI DI BIASE;ROCCO PIAZZA;PIETRO INVERNIZZI","20;19;15;15;14;14;14;13;12;12;11;11;11;11;11;11;11;10;10;10","ANDREA BIONDI;EMANUELE REZOAGLI;PAOLO MAZZOLA;M RIVA;MARCO GIANI;FRANCESCO PETRELLA;ADRIANA BALDUZZI;GIUSEPPE FOTI;LAURA ANTOLINI;ALBERTO LUCCHINI;DIEGO CORTINOVIS;PAOLO BONFANTI;PIETRO INVERNIZZI;MARIA LUISA VENTURA;SARA ORNAGHI;GIUSEPPE BELLELLI;CESARE MAINO;DAVIDE IPPOLITO;ROBERT FRUSCIO;MARCO CASATI","1.88;1.83;1.56;1.48;1.45;1.4;1.35;1.35;1.27;1.22;1.19;1.13;1.09;1.06;1.06;1.06;1.03;1.01;1.01;0.98","ANDREA BIONDI;EMANUELE REZOAGLI;GIUSEPPE FOTI;ROBERT FRUSCIO;DIEGO CORTINOVIS;MARCO GIANI;SARA ORNAGHI;CESARE MAINO;GIUSEPPE BELLELLI;DAVIDE IPPOLITO;MARIA LUISA VENTURA;ROCCO PIAZZA;PIETRO INVERNIZZI;GIOVANNI ROVARIS;PAOLO BONFANTI;ALBERTO LUCCHINI;FABIO PAGNI;SIMONA FUMAGALLI;GIOVANNI CAZZANIGA;GIUSEPPE CITERIO","20;19;15;15;14;14;12;11;11;11;11;10;10;10;10;9;9;9;9;9","ANDREA BIONDI;EMANUELE REZOAGLI;PAOLO MAZZOLA;M RIVA;MARCO GIANI;FRANCESCO PETRELLA;ADRIANA BALDUZZI;GIUSEPPE FOTI;ALBERTO LUCCHINI;DIEGO CORTINOVIS;PAOLO BONFANTI;PIETRO INVERNIZZI;MARIA LUISA VENTURA;SARA ORNAGHI;GIUSEPPE BELLELLI;CESARE MAINO;DAVIDE IPPOLITO;ROBERT FRUSCIO;MARCO CASATI;SAVERIO CERAULO","1.88;1.83;1.56;1.48;1.45;1.4;1.35;1.35;1.22;1.19;1.13;1.09;1.06;1.06;1.06;1.03;1.01;1.01;0.98;0.95","GIUSEPPE CITERIO;EMANUELE REZOAGLI;GIUSEPPE FOTI;CHIARA ROBBA;DAVIDE IPPOLITO;MARCO GIANI;SARA MASSIRONI;CECILIA ÅKERLUND;CARLO GAMBACORTI‐PASSERINI;DENISE BATTAGLINI;EMANUELE RAVANO;GIOVANNI CAZZANIGA;MATTEO POZZI;ANTONIOS DAKANALIS;DIEGO CORTINOVIS;GIACOMO BELLANI;GIOVANNI ROVARIS;ROBERTO CAIROLI;ALESSIO GASPERETTI;ANNA MARIA CAFRO","30;22;20;19;17;16;16;14;13;12;12;12;12;11;11;11;11;11;10;10","EMANUELE REZOAGLI;GIUSEPPE FOTI;SARA MASSIRONI;DAVIDE IPPOLITO;MARCO GIANI;MATTEO POZZI;ANTONIOS DAKANALIS;CARLO GAMBACORTI‐PASSERINI;DIEGO CORTINOVIS;GIOVANNI ROVARIS;GIUSEPPE CITERIO;ARIANNA ZAPPATERRA;CESARE MAINO;IVAN CIVETTINI;MARIA LUISA VENTURA;PAOLO NICCOLÒ FRANCO;ROBERT FRUSCIO;SILVIA PIERINI;ALESSANDRO CATTONI;PIETRO INVERNIZZI","20;17;16;15;15;12;11;11;11;11;11;10;10;10;10;10;10;10;9;9","ANDREA BIONDI;GIOVANNI ROVARIS;EMANUELE REZOAGLI;DIEGO CORTINOVIS;SARA ORNAGHI;ROBERT FRUSCIO;GIUSEPPE BELLELLI;CESARE MAINO;GIUSEPPE FOTI;MARCO GIANI;MARIA LUISA VENTURA;PIETRO INVERNIZZI;FRANCESCO PETRELLA;PAOLO BONFANTI;ADRIANA BALDUZZI;ANTONIOS DAKANALIS;DAVIDE IPPOLITO;MASSIMO CLERICI;PAOLO NICCOLÒ FRANCO;FABIO LANDONI","18;17;14;13;12;12;11;11;10;10;10;10;9;9;8;8;8;8;8;7","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;CHEMISTRY;SOCIOLOGY;ECONOMICS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;ART;HISTORY;BUSINESS;GEOLOGY","405;108;52;40;35;26;25;22;18;14;14;14;7;6;4;4;2;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;ONCOLOGY;PSYCHIATRY;CARDIOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;RADIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;ANESTHESIA;GASTROENTEROLOGY;NURSING;PALEONTOLOGY;PHYSICAL THERAPY;CANCER RESEARCH;CLINICAL PSYCHOLOGY;MECHANICAL ENGINEERING","287;92;67;64;60;53;49;47;45;45;36;34;32;31;25;25;22;21;21;21","DISEASE;CANCER;RETROSPECTIVE COHORT STUDY;GENE;COHORT;POPULATION;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;CHEMOTHERAPY;INCIDENCE (GEOMETRY);MECHANICAL VENTILATION;LUNG;STAGE (STRATIGRAPHY);ALTERNATIVE MEDICINE;BONE MARROW;HEART FAILURE;LEUKEMIA;PSYCHOLOGICAL INTERVENTION","59;53;37;32;31;30;30;29;18;18;17;17;16;15;15;13;13;12;12;12","INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;MULTICENTER STUDY;ENDOMETRIAL CANCER;GESTATIONAL AGE;IMMUNOTHERAPY;INFLAMMATORY BOWEL DISEASE;OVARIAN CANCER;CLINICAL ENDPOINT;DEMENTIA;FETUS;HAEMATOPOIESIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUTATION;2019-20 CORONAVIRUS OUTBREAK;MONOCLONAL ANTIBODY;PROTOCOL (SCIENCE);COLORECTAL CANCER;CYCLOPHOSPHAMIDE;GERMLINE;HAZARD RATIO;LYMPHADENECTOMY;LYMPHOBLASTIC LEUKEMIA;MALIGNANT PLEURAL EFFUSION;MYELOFIBROSIS","17;12;12;9;9;9;9;9;8;8;8;8;8;8;7;6;6;5;5;5;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);INFLAMMATORY BOWEL DISEASES;BRONCHOPULMONARY DYSPLASIA;HERPESVIRIDAE;SENTINEL LYMPH NODE;ANAPLASTIC LYMPHOMA KINASE;BUSULFAN;DNA METHYLATION;EXOME SEQUENCING;GERMLINE MUTATION;RUXOLITINIB;TRIPLE-NEGATIVE BREAST CANCER;ACUTE LYMPHOCYTIC LEUKEMIA;ANTIRETROVIRAL THERAPY;ATROPHIC GASTRITIS;AUTOIMMUNE GASTRITIS;BISPECIFIC ANTIBODY;CARBOPLATIN;CARDIAC INDEX;CHIMERIC ANTIGEN RECEPTOR;COPY-NUMBER VARIATION;CRIZOTINIB;DEBULKING;HBSAG;HEMATOPOIETIC STEM CELL;HISTONE DEACETYLASE;KRAS;LYMPHOVASCULAR INVASION;MEN WHO HAVE SEX WITH MEN;MONOCLONAL;MYELOPROLIFERATIVE NEOPLASM;NEOADJUVANT THERAPY;NIVOLUMAB;PLACENTA;PTEN;RETURN OF SPONTANEOUS CIRCULATION;ROS1;SENTINEL NODE;SERRATIA MARCESCENS;VENETOCLAX","17;6;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;RETROSPECTIVE STUDIES;ITALY;ADOLESCENT;CHILD;TREATMENT OUTCOME;PROSPECTIVE STUDIES;AGED, 80 AND OVER;CHILD, PRESCHOOL;YOUNG ADULT;RISK FACTORS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;FOLLOW-UP STUDIES;INFANT","250;175;112;90;64;60;56;39;37;31;31;29;27;17;17;16;15;12;11;11","MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;GYNECOLOGIC ONCOLOGY;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MANAGEMENT OF DELIRIUM IN CRITICAL CARE PATIENTS;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;MECHANICAL CIRCULATORY SUPPORT SYSTEMS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;EPIDEMIOLOGY AND MANAGEMENT OF CYTOMEGALOVIRUS INFECTION;LYMPHOID NEOPLASMS;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ATRIAL FIBRILLATION;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;EATING DISORDERS AND BODY IMAGE CONCERNS;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS","12;10;8;8;8;7;6;6;6;6;6;6;5;5;5;4;4;4;4;4","POSITIVE END-EXPIRATORY PRESSURE;STROKE (ENGINE);CROSS-SECTIONAL STUDY;CLINICAL ENDPOINT;EXTRACORPOREAL MEMBRANE OXYGENATION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;SINGLE CENTER;2019-20 CORONAVIRUS OUTBREAK;NONINVASIVE VENTILATION;PANDEMIC;BRONCHOPULMONARY DYSPLASIA;CAR T CELLS;DIAGNOSIS;INFLAMMATORY BOWEL DISEASES;NEUROENDOCRINE TUMORS;PANCREATIC NEUROENDOCRINE TUMORS;CENTER (CATEGORY THEORY);DEPRESSION (ECONOMICS);HEMATOLOGY;HEMATOPOIETIC CELL TRANSPLANTATION","12;11;10;8;8;8;8;7;7;7;6;6;6;6;6;6;5;5;5;5","RETROSPECTIVE STUDY;PROSPECTIVE STUDY;COHORT STUDY;OBSERVATIONAL STUDY;ACUTE LYMPHOBLASTIC;CROSS-SECTIONAL STUDY;ENDOMETRIAL CANCER;INFLAMMATORY BOWEL;LUNG CANCER;EXTRACORPOREAL MEMBRANE;LYMPHOBLASTIC LEUKEMIA;MEMBRANE OXYGENATION;RETROSPECTIVE ANALYSIS;CELL TRANSPLANTATION;MULTICENTER STUDY;RETROSPECTIVE COHORT;STEM CELL;SUBCUTANEOUS IMPLANTABLE;ACUTE MYELOID;BOWEL DISEASE;BRAIN INJURY;CERVICAL CANCER;CLINICAL PRACTICE;HEART FAILURE;ISCHEMIC STROKE;ITALIAN ASSOCIATION;ITALIAN SOCIETY;MENTAL HEALTH;MYELOID LEUKEMIA;NORTHERN ITALY","12;11;9;8;7;7;7;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","INTENSIVE CARE;MECHANICAL VENTILATION;PATIENTS TREATED;SIGNIFICANT DIFFERENCES;COHORT STUDY;MEDIAN AGE;PRIMARY OUTCOME;SECONDARY OUTCOMES;CONSECUTIVE PATIENTS;RESPIRATORY FAILURE;RETROSPECTIVE STUDY;V-V ECMO;CARE UNIT;CLINICAL PRACTICE;LDL CHOLESTEROL;MENTAL HEALTH;RISK FACTORS;ADVERSE EVENTS;CLINICAL TRIAL;GN BACTERIA;INCLUDED PATIENTS;INCREASED RISK;LOGISTIC REGRESSION;NURSING CARE;PROGRESSION-FREE SURVIVAL;RESPIRATORY SUPPORT;CLINICAL OUTCOMES;COVID- PATIENTS;CROSS-SECTIONAL STUDY;HR CI","22;21;18;15;14;14;13;13;12;12;12;12;11;11;11;11;11;10;10;10;10;10;10;10;10;10;9;9;9;9",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,6,170,0.38,0,0,43.5,0,0,1,0,1,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Switzerland","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES","2;2;2;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;RARE DISEASES;ORPHAN DRUG;STEM CELL RESEARCH;TRANSPLANTATION","2;2;2;2;2;2;1;1;1","CANCER","2","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","2;1;1","NON-HODGKIN'S LYMPHOMA","2","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
